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Forgetfulness is common in the elderly population, 41% of people between 55 and 
65 and 52% of people over 70 report subjectively experienced memory problems 
(Ponds et al., 1997). Some of them are bothered by their complaints to such an 
extent that they seek professional help. Although these cognitive symptoms can be 
part of the normal ageing process, they could also be very early signs of incipient 
dementia. The following cases serve to illustrate common diagnostic issues in 
these subjects.  
 
 
CASE 1  
A 67-year old man, Mr. X, was referred to the memory clinic because of 
forgetfulness. He reported slowly progressive memory problems that had 
developed over the last 2 to 3 years. Mr. X complained mainly about short-term 
memory problems and word-finding difficulties. He had no problems in 
performing his daily life activities, though his wife stated that Mr. X had become 
less skilful in using for example his mobile phone. She confirmed his complaints 
and added that Mr. X had also become more insecure. The couple stated that Mr. X 
was not depressed, though his mood was negatively influenced by his complaints 
and he feared that he made mistakes. Mr. X wanted to know if he had Alzheimer’s 
disease and what his prognosis would be.  
Mr. X was a friendly, highly educated man, who appeared nervous and uncertain 
during the assessments. He had good insight in his complaints and mentioned his 
worries about possible Alzheimer’s. He retired 5 years ago, but remained active 
through his hobbies. Mr. X reported to withdraw from social situations, because of 
his forgetfulness. Somatic, neurologic, psychiatric and laboratory tests revealed no 
abnormalities. His medical history listed no major diseases. General cognitive 
functioning was normal (MMSE = 28), with very mild clinical dementia symptoms 
(CDR = 0.5) and very mild symptoms of depression (Hamilton Depression Rating 
Scale = 3). Additional diagnostic investigations were performed. The MRI scan 
showed some cortical atrophy and several white matter lesions. 
Neuropsychological assessment showed impairments in mental speed and weak 
memory performance, though the latter was not below the age- and education 
adjusted cut-off. Other cognitive domains, including language, working memory, 
executive functioning and visuoconstruction, showed performances within the 
normal range. Based on all assessments, the conclusion was that Mr. X had no 
dementia, though he did have some cognitive impairment. His symptoms could be 
early signs of dementia, but for now he received a diagnosis of Mild Cognitive 
Impairment (MCI). Mr. X participated in the Clinical Course of Cognition and 
Comorbidity in MCI (4C-MCI) study, for which he received three annual follow-
up assessments.  
PROLOGUE 
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1st follow-up 
Mr. X reported stable memory problems, but increasing word-finding difficulties. 
According to his wife, he had become more slow and clumsy. Further, Mr. X had 
more troubles in solving problems. Emotionally he had become more instable and 
Mr. X admitted that his mood was hindered by the complaints. General cognitive 
functioning was still only mildly impaired (MMSE = 27), though performance in 
daily life functioning decreased. The neuropsychological assessment showed weak 
performances on mental speed and acquiring visual associations, but the latter 
problems were not severe enough to meet criteria for impairment. Scores on the 
other cognitive domains were within the normal range. Compared to the previous 
assessment there was overall stability of performance and even an improvement 
on an episodic memory task. The diagnosis remained MCI.   
 
2nd follow-up 
Mr. X experienced no cognitive decline, though he admitted he had more problems 
in operating electronic devices. His wife reported slow progressive decline in 
multiple domains. There were no obvious problems in daily life functioning, 
though Mrs. X did not feel save anymore when her husband drove in their car. 
General cognitive functioning was still hardly impaired (MMSE = 28) and daily 
functioning was even better than previously. Test performances showed 
impairments in processing speed, but no problems in other cognitive domains. 
Compared to the previous assessment, there was general stability of performance. 
The diagnosis made was again MCI.  
 
3rd follow-up 
Mr. X reported slowly progressive decline in memory, he had more troubles 
remembering names and conversations. There was also mild impairment in 
orientation in time. His wife also reported decline, especially in performing daily 
life activities. Speaking had become harder, because of the word-finding 
difficulties. General cognitive functioning was a bit more impaired (MMSE = 24) 
and also daily life functioning showed decline. The neuropsychological assessment 
showed cognitive impairments in speed, executive functioning and multiple 
memory tests. The diagnosis of Alzheimer type dementia was made.  
 
 
CASE 2 
An 80-year old man, Mr. Y, was referred to the memory clinic because of 
forgetfulness. He reported slowly progressive memory problems over the last 
several years. He said the problems tended to fluctuate over time. Mr. Y’s main 
complaint was a general slowness, which hindered him in processing information. 
He noticed that his complaints increased when he was tired. His wife corroborated 
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the complaints. She thought her husband was slower and less alert than before. 
She further described word-finding difficulties and troubles remembering names. 
They agreed that Mr. Y got angry more easily because of his complaints. In 
addition, he was a bit moody and tended to withdraw from social situations. The 
couple worried about the complaints, especially since they had read an article 
about dementia. There were no obvious impairments in daily life functioning.  
Mr. Y was a friendly man, who adequately described his problems, though he had 
the tendency to trivialize the complaints as normal for his age. Mr. Y had had two 
cerebrovascular accidents (15 and 8 years ago). Further, he suffered from multiple 
vascular problems like hypocholesterolaemia and left ventricle hypertrophy. In 
addition, Mr. Y had experienced multiple depressive episodes in the past, for 
which he never received any treatment. General cognitive functioning was normal 
(MMSE = 28), with very mild clinical dementia symptoms (CDR = 0.5), and some 
depressive symptoms (HDRS = 8). Additional diagnostic investigations were 
performed. The MRI scan showed widespread white matter lesions and endured 
ischemia high in the parietal lobe. There was some global atrophy, but no 
disproportional atrophy of the hippocampus. Laboratory tests revealed no 
abnormalities. Neuropsychological assessment showed impairment in mental 
speed, but also weak performance on memory tasks, which could possibly be 
attributed to the slowing in mental processing and to hearing problems. 
Performance on executive functioning was variable. Other cognitive domains, 
including language, working memory and visuoconstruction showed 
performances within the normal range. Based on all assessments, the conclusion 
was that Mr. Y had no dementia, but he did receive a diagnosis of MCI. Mr. Y also 
participated in  the 4C-MCI study, for which he was followed annually for 3 years.  
 
1st follow-up 
Mr. Y reported decline in short-term memory, but still stated that the complaints 
tended to fluctuate. He also had more problems in planning and performing dual 
tasks. His wife described large day-to-day fluctuations in the problems. She said 
Mr. Y had more trouble finding objects in their house and he had become less 
skilful. Besides, she reported more anxiety and irritation. General cognitive 
functioning showed a slight decline (MMSE = 26) and also daily life functioning 
declined. Test performances showed impairments in mental speed and executive 
functioning, but no problems in other cognitive domains. Compared to the 
previous assessment there was a decline in executive functioning, yet also an 
obvious improvement in memory performance. The diagnosis was again MCI. 
 
2nd follow-up 
Mr. Y reported an improvement in memory and he had become more energetic 
and alert. Furthermore, his mood improved. His wife corroborated his story. Yet, 
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Mr. Y could still be irritated when things did not happen the way he wanted. 
General cognitive functioning improved 3 points (MMSE = 29), and also daily life 
functioning improved. Test performances showed impairment in mental speed, 
but no problems in other cognitive domains. Compared to the previous 
assessment, there were (small) improvements in executive functioning and mental 
speed, though performances on the latter still qualified as cognitively impaired. 
Performance in other cognitive domains remained generally stable. The diagnosis 
remained MCI.  
 
3rd follow-up 
Mr. Y reported obvious improvements in all cognitive domains, which he 
attributed to medication changes made by his cardiologist. He still had some 
minor problems in short term memory, however his mood and quality of life had 
improved. His wife corroborated the positive influence of the medication changes. 
She said there were no problems in daily life functioning, and that the complaints 
were now limited to mild forgetfulness. General cognitive functioning was good 
(MMSE = 30), and there were no impairments in daily life functioning. Tests 
performances were within the normal range for all cognitive domains. Compared 
to the previous assessments, there was an overall improvement in cognitive 
functioning. Since we could not objectify any cognitive impairment, Mr. Y’s 
diagnosis was changed from MCI to subjective cognitive complaints.  
 
Both Mr. X and Mr. Y fulfilled the criteria for MCI when they came to the memory 
clinic, however their course of decline over time and thus their outcome after three 
years differed greatly.  
Questions that arise from these cases are:  
- What is the natural course of cognitive decline in people who present 
themselves at a memory clinic with cognitive complaints and which 
factors influence this course and the risk of developing dementia?  
- What is the impact of these cognitive impairments on the well-being of 
memory clinic visitors?  
In clinical practice, almost 40% of people referred to a memory clinic do not have 
dementia at their initial visit. Yet a part of them has a cognitive disorder 
(Ramakers and Verhey, 2011). These people ask similar questions as described in 
our cases and we see ourselves confronted with the need of patients and caregivers 
to receive more (accurate) information on their prognosis for the forthcoming 
years. These issues formed the basis for the research described in this thesis.  
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GENERAL INTRODUCTION 
Dementia  
Dementia is a growing health problem, especially with the expected ageing of our 
population. The number of people with dementia worldwide was estimated to be 
35.6 million in 2010 and this number is expected to increase to 65.7 million in 2030 
and triple to even 115.4 million in 2050 (World Health Organization, 2012). This 
development poses a major challenge for society, health care systems and has great 
economical impact. Already in 2011, dementia was the second most expensive 
medical disease in the Netherlands, with disease-associated costs of almost 5 
billion euros (Rijksinstituut voor Volksgezondheid en Milieu, 2011). Furthermore, 
dementia is thought to have the highest disease burden of all medical illnesses for 
the patient, but also has a tremendous impact on the caregiver (Ory et al., 1999). 
Although there is currently no pharmacological treatment available to halt disease 
progression, it is important to early identify people at high risk of developing 
dementia. First, because the study of these people and their course of decline allow 
us to identify factors associated with faster decline and/or conversion to dementia 
and to increase insight into underlying pathological brain mechanisms. In 
addition, if pharmacological treatment becomes available in the future, disease-
modifying drugs are likely to be most effective in the early stages of the disease. 
Further, from a clinical point of view, it is important to be able to differentiate 
between individuals with cognitive complaints who are likely to develop dementia 
and individuals who are not, since a reliable prognosis gives us the opportunity to 
initiate timely care and treatment that matches the needs and expectations of 
patients and caregivers. Also, it allows both patients and their caregivers to make 
arrangements for the future. 
 
Mild Cognitive Impairment 
Currently, dementia is often regarded as the end stage at one side of a continuum, 
with normal cognitive functioning at the other end of the spectrum. The 
transitional state between normal cognitive functioning and dementia is now 
usually referred to as Mild Cognitive Impairment (MCI) (Petersen et al., 1999). 
People with MCI are characterized by having cognitive impairments in one or 
multiple cognitive domains, but they do not fulfill the criteria for dementia (yet). 
Although, people with MCI are at an increased risk to develop dementia, a 
substantial proportion of them remains stable or even reverts back to normal 
cognitive functioning after prolonged follow-up (Ganguli et al., 2011, Visser et al., 
2006) (Figure 1).  
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Fig 1 
 
So, it has become clear that MCI denominates a heterogeneous group of people 
with large individual variation in the level and pattern of cognitive impairment, 
the course of decline over time and thus prognosis. This heterogeneity is likely due 
to differences in the underlying cause of the impairment, whereby stability and 
improvement of impairment are unlikely to be caused by dementia pathology but 
may result from psychological factors or medical diseases (Graham et al., 1997, 
Jorm et al., 2004, Olazaran et al., 2011, Sachdev et al., 2013). The observed 
heterogeneity increases the need for a thorough investigation of the profile of 
impairment and the natural course of decline in both people that progress to 
dementia and people that remain only mildly impaired. This may help in the 
identification of, and distinction between those individuals that show a pattern 
and rate of decline that is typical for developing underlying neurodegenerative 
pathology and those that do not.  
 
Multicausality  
Dementia was long thought of as a monocausal disease that resulted from a slowly 
progressive pathological process located in the brain. However, to date dementia is 
increasingly recognized as a multifactorial disease, whereby diseases and factors 
not necessarily located in the brain can enhance underlying neurodegenerative 
pathologies (Olde Rikkert et al., 2006, Olde Rikkert et al., 2005). While age remains 
the most important risk factor for developing dementia (Jorm and Jolley, 1998), 
multiple other factors have been associated with dementia development like 
female gender (Andersen et al., 1999, Fratiglioni et al., 1997), low education (Launer 
et al., 1999, Ott et al., 1995), genetic vulnerability (i.e. Apolipoprotein-E-e4 
genotype) (Farrer et al., 1997), low memory performance (Albert et al., 2001, Chen et 
al., 2000), depression (Jorm, 2001, Palmer et al., 2007) and specific vascular factors 
like mid-life hypertension and diabetes (Lu et al., 2009, Mielke et al., 2007, Qiu et al., 
2005). With increasing age, the combination of and interaction between multiple 
contributing factors may ultimately lead to dementia.  
Unfortunately, an important factor in the elderly population has received little 
attention thus far. The presence of comorbidities has often been an exclusion 
criterion for both diagnostic and therapeutic studies into (early stage) dementia, 
thereby disregarding the increased disease burden of multimorbidity that is 
normal cognitive  
functioning  
Mild Cognitive  
Impairment 
!
Dementia 
       ! !
CHAPTER 1 
 
 
 
 18 
typically associated with advancing age (Uijen and van de Lisdonk, 2008, van den 
Akker et al., 1998).  
Comorbidities are not only related to worse cognitive functioning in the general 
elderly (Comijs et al., 2009, Morrow et al., 2009, Patrick et al., 2002) and demented 
population (Doraiswamy et al., 2002), they can also effect outcomes like quality of 
life, daily life functioning and health service use (Fried et al., 1999, Tooth et al., 
2008). These findings stress the importance of the careful study and clinical 
evaluation of comorbidities in a memory clinic population in order to provide a 
more accurate prognosis and identify additional treatment targets.  
 
Health-related Quality of life 
As so many factors are related to the development of dementia, it is hard to 
pinpoint which aspect should be regarded as the most important target for 
disease-modifying interventions. The absence of curative drug interventions at 
present, and likely also in the near future, signifies the importance of focusing on 
secondary outcomes, like Health-related Quality of Life (HRQoL) in early stage 
cognitive decline. Both people with dementia, their caregivers and health care 
professionals indeed increasingly recognize HRQoL as an important, meaningful 
and desirable outcome throughout the entire course of dementia (Gwyther, 1997, 
Logsdon et al., 2002, Ready and Ott, 2003, Walker et al., 1998, Whitehouse and 
Rabins, 1992). By using HRQoL as an outcome measure, the total impact of disease 
is comprised in a single measure that reflects its multidimensionality. In addition, 
while we are not able to halt or prevent disease progression, HRQoL is a 
potentially modifiable target that can be ameliorated using non-cognitive 
interventions.  
HRQoL is known to be influenced by the presence of chronic medical conditions 
(Fortin et al., 2004), but is also effected by another essential issue in memory clinic 
visitors, that is: subjective cognitive complaints (Mol et al., 2009).  
Therefore, HRQoL of memory clinic visitors and its determinants should be 
studied further in order to evaluate this important outcome and identify potential 
targets for interventions to improve HRQoL.  
 
 
AIM OF THE THESIS 
The general aim of this thesis was to determine the natural course of cognitive 
decline in Mild Cognitive Impairment and investigate the influence of medical 
comorbidity on both cognitive decline and quality of life in memory clinic visitors.   
Our study addressed the following questions: 
 
GENERAL INTRODUCTION 
 
 
 
 19 
1] What is the annual rate of domain-specific cognitive decline in the pre-dementia 
phase? 
2] What is the natural course of cognitive decline in the pre-dementia phase in 
memory clinic visitors? 
3] Which cognitive subtypes exist in memory clinic visitors and what is their 
prognostic value for conversion to dementia? 
4] What is the influence of the severity of comorbidity on cognitive decline and 
conversion to dementia in memory clinic visitors? 
5] Which factors are associated with Health-related Quality of Life (HRQoL) in 
memory clinic visitors? 
 
 
OUTLINE OF THE THESIS 
This thesis consists of two parts. In part A (chapter 2 to 4), we focus on the natural 
course and profile of cognitive decline in Mild Cognitive Impairment. In part B 
(chapter 5 to 7), we describe the impact of comorbidity on cognitive decline and 
conversion to dementia and investigate the impact of comorbidity, cognitive and 
emotional functioning on quality of life in memory clinic visitors.  
The outline is as follows: 
PART A 
Chapter 2 provides a systematic review and meta-analysis of the annual rate of 
domain-specific cognitive decline in the pre-dementia phase. 
In Chapter 3 we compare the pattern, magnitude and temporal sequence of 
cognitive decline between converters to AD dementia in their pre-dementia phase 
and non-converters in a memory-clinic based population.  
 
Chapter 4 assesses the existence of multiple cognitive subtypes in subjects with 
cognitive complaints within a memory-clinic based setting. We determined their 
prognostic value for conversion to dementia.  
 
PART B 
In chapter 5 we describe the general cohort profile of the Clinical Course of 
Cognition and Comorbidity in MCI (4C-MCI) study and the associated Clinical 
Course of Cognition and Comorbidity in Dementia (4C-Dementia) study. Both 
CHAPTER 1 
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studies are prospective, longitudinal multicentre studies into the natural course of 
decline, investigating either persons with MCI or persons with dementia.  
 
Chapter 6 focuses on the influence of the severity of comorbidity on cognitive 
decline and conversion to dementia in memory clinic visitors from the 4C-MCI 
study.  
 
In Chapter 7 we investigate the influence of emotional functioning, cognitive 
functioning and comorbid disease burden on Health-related Quality of Life in 
memory clinic visitors with either MCI or Subjective Cognitive Impairment (SCI) 
from the 4C-MCI study.  
 
Last, Chapter 8 provides a general discussion, summary of the main findings and 
implications for both future research and clinical practice.  
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ABSTRACT 
 
The aim of the present study was to establish and compare the extent of annual 
domain-specific cognitive decline in future dementia subjects for the domains of 
episodic memory, executive functioning, attention/information processing speed, 
verbal ability, visuospatial ability and global cognitive functioning. In addition we 
performed domain wise comparisons to the rates of domain-specific decline in 
non-converters. A systematic literature search was performed into studies of 
cognitive decline in future dementia subjects. We included twenty-one studies, 
representing 2249 pre-dementia subjects and 2439 non-converting controls. The 
effect measure was expressed as Cohen’s delta (d). In an average observation 
period of five years before dementia diagnosis onwards, pre-dementia decline in 
episodic memory (d = -0.35, 95%CI: -0.43; -0.27) and global cognitive functioning  
(d = -0.44, 95%CI: -0.56; -0.32) was significantly larger than decline in the other 
domains, though these domains showed small but significant decline too. Rates of 
domain-specific decline differed significantly between converters and non-
converters for all domains, except attention/information processing speed. We can 
conclude that during a mean observational period of five years prior to dementia 
diagnosis, the strongest indicators of future dementia are accelerated decline in 
episodic memory and global cognitive functioning, while decline in 
attention/information processing speed does not discriminate between future 
converters to dementia and non-converters. 
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INTRODUCTION 
 
In the forthcoming decades, the prevalence of dementia is expected to dramatically 
rise due to the ageing population (World Health Organization, 2012). This poses a 
major challenge for society and health care systems, and therefore creates an 
urgent need for early diagnosis in order to initiate timely care and treatment.  
The most common cause of dementia, Alzheimer’s disease (AD), affects around 60 
to 70 percent of the demented population (World Health Organization, 2012). The 
neurodegenerative changes underlying Alzheimer’s disease dementia, e.g. 
accumulation of amyloid plaques, neurofibrillary tangles and neuronal atrophy, 
start long before clinical dementia diagnosis (Jack et al., 2010, Vos et al., 2013). 
Other dementias are also thought to be preceded by a preclinical phase, during 
which subtle cognitive changes can occur (Backman et al., 2001, Ingles et al., 2002, 
Meyer et al., 2002).  
Alterations in cognition before dementia diagnosis have been described by a 
number of partially overlapping terms such as “cognitive impairment no 
dementia” (CIND), “questionable dementia”, “age-associated cognitive decline” 
(AACD) and others. Currently, cognitive impairment before dementia diagnosis is 
generally referred to as Mild Cognitive Impairment (MCI). MCI was originally 
conceptualized as a primarily amnestic disorder (Petersen et al., 1999), yet broader 
conceptualizations of MCI have been formulated, including amnestic and non-
amnestic forms, and involving single or multiple cognitive domains (Petersen and 
Morris, 2005). 
The current MCI concept corresponds to findings that show cognitive deficits in 
the pre-dementia phase across multiple cognitive domains, like episodic memory 
(Backman et al., 2001, Chen et al., 2000, Rubin et al., 1998), executive functioning 
(Albert et al., 2001, Rapp and Reischies, 2005), verbal fluency (Fabrigoule et al., 
1998, Laukka et al., 2004), attention (Linn et al., 1995, Nielsen et al., 1999) and global 
cognitive functioning (Backman and Small 1998, Fabrigoule et al., 1998). These 
findings are also consistent with evidence from neuroimaging studies indicating 
that multiple brain regions are impaired in prodromal dementia (Jones et al., 2006, 
Burgmans et al., 2009, Jacobs et al., 2011).  
Although we do know that pre-dementia cognitive deficits can occur across 
multiple domains, the longitudinal domain-specific course of cognitive decline 
remains largely undetermined. A better understanding of the magnitude of decline 
in different domains is important to facilitate early diagnosis and thus to increase 
our insight into early pathological brain mechanisms. Therefore, the aim of the 
present study was to systematically review and analyze the evidence on the course 
of cognitive decline in the pre-dementia phase. More specifically, we performed a 
meta-analysis to estimate and compare the annual rate of domain-specific decline 
in episodic memory, executive functioning, attention/information processing 
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speed, verbal ability, visuospatial ability and global cognitive functioning in pre-
dementia subjects. In addition, we performed domain wise comparisons with the 
rates of decline in non-converters to identify the strongest indicators of incipient 
dementia.  
 
 
METHODS 
 
The initial selection of papers was based on the PRISMA guidelines (Moher et al., 
2009) 
 
Search strategy 
We searched the Pubmed, Psychinfo, Embase and Cinahl databases for studies 
published from January 1990 to December 2012. The search terms used were:  
(‘amnestic’ or ‘amnestic syndrome’ or ‘memory impairment’ or ‘mild cognitive 
decline’ or  'mild cognitive impairment' or ‘MCI’ or ‘age-associated cognitive 
decline’ or ‘AACD’ or ‘age-associated memory impairment’ or ‘AAMI’ or 
‘cognitive impairment no dementia’ or ‘CIND’ or ‘alzheimer*’ or ‘memory clinic’ 
or ‘memory disorders clinic’ or ‘dementia clinic’ or ‘prodromal’ or ‘preclinical’) 
and (‘cognitive decline’ or ‘cognitive change’ or ‘course’ or ‘traject*’) and  ('follow-
up study’ or ‘longitudinal’ or ‘prospective’). The search resulted in 2670 hits.  
Titles and abstracts of the retrieved studies were screened for relevance using the 
criteria specified below. Subsequently we searched the references of included 
articles to identify additional studies.   
 
Study selection 
Studies were included in the analyses if they fulfilled the following inclusion 
criteria:  
1) the article was published in English; 2) participants were free of dementia at 
baseline assessment, but over time (minimum follow-up length one year) became 
demented according to any of the following criteria: Diagnostic and Statistical 
Manual of Mental Disorders 4th edition (DSM-IV) (American Psychiatric 
Association, 1994), DSM 3rd Revised Edition (DSM-III-R) (American Psychiatric 
Association, 1987), the International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10) (World Health Organization, 
1993), National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann et al., 1984), or had a clinical dementia diagnosis defined as 
progressive cognitive decline that interfered with activities of daily living together 
with a Clinical Dementia Rating Scale (Morris, 1993) score of 0.5 or higher; 3) the 
article reported data on cognitive functioning at baseline and after a specified 
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follow-up period or reported a slope of cognitive decline during the pre-dementia 
period. 
We retrieved 168 full-text articles that were deemed potentially relevant for our 
study. Of these, 46 were excluded because subjects did not convert to dementia, 45 
reported on cognitive decline but made no distinction between dementia 
converters and non-converters, 17 studies reported no cognitive data at follow-up, 
10 did not report any cognitive data, and another 8 studies reported in a data 
format we could not use for the present analyses (e.g. no standardized slopes). 
In case multiple papers reported on the same cohort, we included the study with 
the largest sample size in our analyses. In case a study from the same cohort 
reported unique information on a specific cognitive domain that was not described 
by the study with the largest sample size, we included the former study for the 
indicated domain. The final selection included 21 studies from 18 independent 
cohorts (see Fig. 1).  
 
Data extraction  
Two raters (RH & WJ) completed the data extraction for each study, any 
discrepancies were resolved by discussions. Studies were classified according to 
setting as; 1) clinical studies that included only patients presenting with cognitive 
complaints at a health care facility; 2) community-based studies that included a 
sample of the general population; 3) other studies that recruited participants from 
both clinical settings and the general population or that did not specify the source 
of participant recruitment. Cognitive status at baseline was classified as 1) normal 
(no objective cognitive impairment); 2) impaired (objectified cognitive impairment, 
but no dementia); 3) unspecified (not reported whether subjects had cognitive 
impairment or not differentiating between subjects with and without 
impairments).  
When the underlying dementia aetiology at time of diagnosis was not specified or 
data were not differentiated according to aetiology, we included all subjects; in 
cases where an AD diagnosis was available for a specific subset of participants we 
included only those subjects. This decision was made since 60 to 70 percent of all 
dementia cases are supposed to have Alzheimer’s disease (World Health 
Organization, 2012), so the majority of the included subjects with dementia 
(aetiology not further specified) will likely have AD. By broadening our inclusion 
criteria, we increased the sample size and thus power of our analyses, and we were 
able to compare rates of decline between the total dementia group and AD 
dementia group. The mean, standard deviation or standard error of the cognitive 
tests at baseline and follow-up (mainly time of diagnosis), or the standardized 
slope/rate of cognitive decline over time were recorded for the pre-dementia 
group and, if available, for the non-converter group. 
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Figure 1 Flow diagram of study selection 
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Cognitive outcome measures 
The outcome measure was the average annual rate of decline in cognitive 
performance in the time period before dementia diagnosis. The authors organized 
the individual neuropsychological tests into five specific cognitive domains and  
one global cognitive functioning domain, based on well-known 
neuropsychological literature (Lezak et al., 2004). The specific domains identified 
were: episodic memory, executive functioning, attention/information processing 
speed (IPS), verbal ability and visuospatial ability. Nine studies provided cognitive 
domain scores themselves, which were consistent with our categories. Each 
domain score was a weighted/average score of all measurements used in that 
domain. Four of these studies provided a global cognition/global composite score 
too, which was based on the weighted/average scores of all neuropsychological 
tests in the respective study. Supplementary table 1 provides the specific domains 
and their associated tests as identified by the authors, please note that tests from 
the nine studies that provided cognitive domain scores themselves are not 
reported in this table.  
 
Data analysis 
Effect sizes (ES) for future dementia cases and non-converters were calculated 
using Cohen’s delta (d), which is the difference between the mean score at baseline 
and follow-up divided by the pooled standard deviation (Cohen, 1988). ES were 
calculated such that a negative ES indicated decline in cognitive performance. If 
studies used more than one measure for a cognitive domain (e.g. multiple episodic 
memory tests) we averaged the ES of these tests, which is in accordance with the 
procedures used by the studies reporting cognitive domain scores.  
For studies presenting only slopes as an outcome, we followed the procedure 
described by Peterson and Brown (Peterson and Brown, 2005) and calculated an r-
statistic first, which we then transformed into a Cohen’s d (Friedman, 1968). For 
studies that used a change-point model to model decline over time, we used only 
the reported decline after the change-point for calculating the ES in the pre-
dementia group, since the slope before the change-point is thought to represent 
age-related cognitive decline and does not differ from the slope of non-converters. 
For studies that reported baseline and follow-up data, we divided the ES by the 
mean follow-up time in years of the respective study, since slopes and their ES 
represent decline over a one-year time period. By this means, all ES can be 
considered as a measure of annual decline. Effect sizes between 0.2 and 0.5 were 
classified as small, between 0.5 and 0.8 as medium and 0.8 and over as large 
(Cohen, 1988).  
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Assessment of risk of bias 
Two authors (RH & WJ) rated the risk of bias of each study using items in the 
categories: subject sampling, reference diagnosis, test description and longitudinal 
design, selected from rating scales for methodological quality of diagnostic and 
prognostic studies (Altman, 2001; Deeks, 2001) and based on the procedure used 
by Elias-Sonnenschein (Elias-Sonnenschein et al., 2011) (see supplementary table 2). 
Studies that did not fulfill the criteria of an item or that did not provide enough 
information for rating an item, received a negative assessment on that item. In case 
of discrepancies between the reviewers, a consensus meeting with a third reviewer 
was held. The total number of items to rate was fifteen. This number was divided 
into tertiles, and studies that scored within the highest tertile (11 – 15) were 
classified as ‘low risk of bias’, studies that scored within the second tertile (6 – 10) 
were classified as ‘intermediate risk of bias’ and studies that scored within the 
lowest tertile (0 – 5) were classified as ‘high risk of bias’. Risk of bias assessments 
were used in a subsequent meta-regression to identify whether studies with a high 
risk of bias differed in outcome from studies with an intermediate or low risk of 
bias.  
 
Statistical analysis 
Analyses were performed using STATA version 12 for Mac OS X (StataCorp, 
Texas). Significance was set at p < 0.05 in two-sided tests. 
We used random effects models to calculate the pooled Cohen’s d. Basic 
assumption of the random effects model is that the effects being estimated in the 
different studies are not identical, but vary randomly around the population 
average. Hence, the between-study variance is estimated and included in the 
weighting of the effect sizes. We used t-tests to calculate differences in ES between 
specific domains in the converter group, and to calculate differences in domain-
specific ES between groups (converters vs. non-converters).  
Furthermore, we assessed heterogeneity of each outcome measure with Cochrane’s 
Q, which is calculated as the weighted sum of squared differences between 
individual study effects and the pooled effect across studies (Gavaghan et al., 
2000). A significant Q-value indicates heterogeneity of results, which may be due 
to potential moderating variables. We performed meta-regression to identify 
possible explanations for heterogeneity. We tested for the effect of baseline 
participant age, sampling method (population based, clinic based, other), initial 
cognitive status of participants (impaired, normal, unspecified), dementia outcome 
(AD vs. dementia) and risk of bias (high, intermediate, low). We tested for 
publication bias by visual inspection of asymmetry in funnel plots, which assess 
the relationship between sample size and effect size. In addition, we performed 
Egger’s regression test (Egger et al., 1997), which statistically assesses funnel plot 
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asymmetry. An asymmetrical funnel plot and a significant p-value on Egger’s 
regression test indicate possible publication bias.  
 
 
RESULTS 
 
We included two clinical studies, fifteen population-based studies and four other 
studies (one study that was both clinical and population-based and three studies in 
which the source of participants was unspecified). In these studies 2249 subjects 
converted to dementia at follow-up. At baseline most subjects (n=1942, 86%) were  
classified as cognitive impairment unspecified. Of the remaining cases, 104 (5%) 
were classified as cognitively impaired at baseline and 203 (9%) subjects were 
cognitively normal. Twelve studies provided information on decline in subjects 
that did not convert to dementia and formed the non-converting control group. 
This group included 2439 subjects, who were classified as cognitively normal 
(n=776, 32%), unspecified (n=1509, 61%) or impaired (n=154, 7%) at baseline and 
by definition remained non-demented during follow-up. At baseline, the mean age 
of the pre-dementia group was 80.0 years, compared to 76.5 years in the non-
converter group. Characteristics of the included studies are provided in table 1.  
In the converter group data for the global cognitive functioning domain was 
available from 13 studies (n = 1323), for episodic memory from 13 studies  
(n = 1698), for executive functioning from 4 studies (n = 420), for attention/IPS 
from 7 studies (n = 873), for verbal ability from 12 studies (n = 1563) and for 
visuospatial ability from 10 studies (n = 1613). In the non-converter group data for 
global cognitive functioning was available from 7 studies (n= 1392), for episodic 
memory from 9 studies (n = 1182), for attention/IPS from 5 studies (n = 513), for 
verbal ability from 6 studies (n = 669) and for visuospatial ability from 6 studies (n 
= 815). The number of studies for executive functioning was considered too limited 
to perform meta-analysis in the non-converter group (3 studies, n = 302) (table 2). 
The weighted mean follow-up time in the converter group ranged from 3.6 years 
for executive functioning to 5.9 years for attention/IPS, grand mean 5.2 years, and 
in the non-converter group from 3.2 years (executive functioning) to 4.7 years 
(visuospatial ability), grand mean 3.9 years (table 2).  
 
Meta-analysis 
ES were significant for all cognitive domains in the converter group (table 2; 
supplementary figures 1 – 6). ES for average annual decline were all small (range  
d = -0.16, 95% CI: -0.30; -0.03 to d = -0.44, 95% CI: -0.56; -0.32). The largest ES were 
observed for episodic memory (d = -0.35, 95% CI: -0.43; -0.27) and global cognitive 
functioning (d = -0.44, 95% CI: -0.56; -0.32).  
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When we repeated our analysis for global cognitive functioning using only studies 
that reported MMSE scores (6 studies), the ES did not significantly change  
(d = -0.48, 95% CI: -0.58; -0.37). This ES corresponds to a biannual decline on 
MMSE of approximately 1 point. When comparing the magnitude of decline 
between different domains in the converter group, ES of global cognitive 
functioning and episodic memory were significantly larger than ES in the other 
cognitive domains.  
When we repeated our analyses using only data of subjects who converted to AD 
dementia, results did not essentially change, except for the attention/IPS domain 
where the ES was no longer significant (d = -0.26, 95% CI: -0.53; 0.01). Furthermore, 
there was not enough data available to calculate an ES for the executive 
functioning domain (see supplementary table 3).   
ES in the non-converter group were only significant for global cognitive 
functioning (d=-0.08, 95% CI: -0.16; -0.01) (table 2), and the magnitude of decline 
did not differ significantly between domains. When comparing the domain-
specific 
ES between the converter and non-converter group, the ES for attention/IPS did 
not differ between groups (p = 0.17). For all other domains, future dementia 
subjects showed larger decline than non-converters (p < 0.05).  
When we excluded studies with subjects that were reported to be already 
cognitively impaired at baseline, results in all groups did not essentially change 
(results not shown).  
 
Heterogeneity and meta-regression 
The ES for attention/IPS showed a significant level of heterogeneity across studies 
in the converter group (Q= 14.16, p = 0.03) (table 2), but meta-regression showed 
no significant associations between study characteristics (baseline age, initial 
cognitive status, sampling method and dementia outcome) and ES. In the non-
converter group there was no notable heterogeneity across studies (table 2).  
 
Publication bias 
Egger’s regression test and visual inspection of the funnel plots revealed no 
convincing evidence for publication bias (or, more correctly, small study bias) in 
both groups (table 2). However, many funnel plots contained only few studies, so 
there might be a lack of power to detect small-study bias (supplementary figure 7 
and 8). 
 
Methodological quality  
29% of the studies were classified as ‘low risk of bias’ and the remaining studies as 
‘intermediate risk of bias’. The study with the lowest risk of bias was assessed 
positive on 80% of all items, most studies scored positive on 60 to 67% of all items.  
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Meta-regression results showed that studies with an intermediate risk of bias did 
not differ in any cognitive domain outcome measure from studies with a low risk 
of bias. The same result was found when we repeated meta-regression using the 
raw risk of bias scores.  
 
 
DISCUSSION 
 
The aim of the present study was to estimate and compare the annual rate of 
domain-specific decline of six cognitive domains in subjects in the pre-dementia 
phase by means of meta-analysis. In addition, a comparison with the domain-
specific rate of decline in non-converters was made. During a mean observational 
period of five years prior to dementia diagnosis onwards, decline in episodic 
memory and global cognitive functioning was significantly larger than decline in 
other cognitive domains, though there was modest decline in all domains. Further,  
attention/information processing speed was the only cognitive domain where the 
extent of decline did not differ between converters and non-converters. 
Our established relatively large ES of episodic memory corresponds with the 
observation that the earliest pathological changes in AD usually occur in the 
medial temporal lobe regions, which are known to be critical for episodic memory 
functioning (Ridha et al., 2006, Sluimer et al., 2009). Conform expectations, global 
cognitive functioning and other cognitive domains showed pre-dementia decline 
too. This is consistent with findings of pathology spread in prodromal AD, 
indicating that multiple brain structures, like the cingulum (Jones et al., 2006), 
parietal (Jacobs et al., 2011) and frontal cortex (Burgmans et al., 2009), may be 
affected before dementia diagnosis. The relatively large ES of global cognitive 
functioning might reflect the pre-dementia decline of all other domains. 
Nonetheless, it is probably the episodic memory deficit that contributes most to 
this large effect size, since memory tests are an important component of measures 
of global cognitive functioning and of the MMSE in particular.  
Decline in most domains differed significantly between converters and non-
converters, except for attention/IPS. This lack of discriminative power might be 
due to the fact that attention/IPS is known to be affected by normal ageing 
processes (Finkel et al., 2007, Hoogendam et al., 2014). Interestingly, when we 
repeated our analyses using only data from subjects who converted to AD 
dementia, the decline in attention/information processing speed was no longer 
significant. This seems to indicate that decline in attention/IPS might not be a 
good predictor for conversion to AD dementia, which is in accordance with a 
previous study (Albert et al., 2001), however it could be an indicator of developing 
other forms of dementia.  
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Clinical implications 
Our findings may have implications for constructing optimal neuropsychological 
test batteries aimed at detecting dementia in an early phase. Since the magnitude 
of decline in episodic memory and global cognitive functioning was significantly 
larger (ES almost twofold) than decline in the other domains, measures for 
episodic memory and global cognitive functioning seem to be the most promising 
tools for early detection of dementia. In clinical practice, a decline of 0.35 SD units 
per year in episodic memory and a decline of 0.44 SD units per year in global 
cognitive functioning (or a biannual decline of one point on the MMSE) seems 
indicative of future dementia. In this way, it might be possible to detect cognitive 
decline at an even earlier stage 
 
Limitations 
The present study has several limitations. First, there is the potential problem of 
circularity in our arguments, since the clinical definition of dementia is partially 
based on cognitive impairment and decline. Therefore, it seems obvious that  
converters decline before dementia diagnosis. Nonetheless, since the aim of our 
study was not to demonstrate the presence of cognitive decline before dementia 
diagnosis, but rather to compare the magnitude of decline between domains, this 
has not influenced our results. Another possible limitation could be that our 
analyses on attention/IPS and executive functioning were based on relatively few 
studies. This limited power of the analyses could introduce heterogeneity by 
enlarging the effect of a single study on the ES. We indeed observed heterogeneity 
of the ES in attention/IPS in the converter group. Furthermore, we grouped the 
neuropsychological tests into broad cognitive domains, yet for some domains, in 
particular attention/IPS, there is still considerable debate about the precise 
definition of these functions. This might be reflected in the existence and use of a 
lot of different tests that intend to measure these functions. Episodic memory, for 
example, showed no notable heterogeneity, but there is a lot less controversy about 
the definition of this domain. Besides, the classification of neuropsychological tests 
into cognitive domains is also not straightforward. For certain tasks (e.g. word list 
recall learning tasks) the corresponding cognitive domain is obvious, but for others 
(e.g. Trail Making Test) grouping is more ambiguous (Lezak et al., 2004). Further, 
since different studies used different neuropsychological tests, it could be that 
differences in ES between studies resulted from differences in the accuracy of the 
used test. 
Also, for the majority of subjects we did not know cognitive status at baseline. As a 
result we do not know the differences in rate of decline between those with normal 
cognition and those with mild cognitive impairment. In addition, this might have 
lead to an overestimation of decline in the non-converter group, since potentially 
impaired subjects are probably more likely to develop further cognitive decline 
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and progress to dementia over time. This probably has increased the chance of 
type I error, and hence even stronger differences in the rate of decline between 
converters and “true” non-converters likely exist in nature. For both groups we 
included a small number of subjects with known cognitive impairment at baseline, 
but when repeating analyses without this group results did not essentially change 
(results not shown).   
Next, our results may have been affected by the quality of the studies. However, 
the assessments of risk of bias were good to moderate, with no studies being 
classified as high risk of bias, although we have been lenient in our overall 
classifications. We may have even underestimated these assessments, because 
rating was only based on information that was provided in the article. In addition, 
our meta-regression showed that risk of bias classification had no significant effect 
on results. Our outcome could have been influenced also by publication bias and 
by the fact that not all identified studies provided standardized slopes or means 
and standard deviations and were therefore excluded. Despite the fact that Egger’s 
test was not significant in both groups, many funnel plots only had a limited 
number of studies, meaning these assessments lacked power. However, the results 
of the studies not included in the present analyses because of unusable data 
formats do not appear to oppose our findings.  
 
Conclusions  
The present meta-analysis showed that during a mean observational period of five 
years prior to dementia diagnosis, the strongest indicators of future dementia were 
accelerated decline in episodic memory and global cognitive functioning, while 
decline in attention/IPS does not discriminate between future dementia converters 
and non-converters.   
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SUPPLEMENTARY DATA 
 
Supplementary table 1 Classification of cognitive tests into cognitive domains 
for studies not specifying domains 
Cognitive Domain Neuropsychological Tests 
Global Cognitive Functioning Mini Mental State Examination (Folstein et al., 1975); 
Blessed Information Memory and Concentration Test 
(Blessed et al., 1968); Alzheimer’s Disease Assessment 
Scale – Cognitive Subscale [ADAS-COG] (Rosen et al., 
1984); Cambridge Cognitive Examination (Derix et 
al., 1992; Roth et al., 1986) 
Episodic Memory The Recognition Memory Test (Warrington, 1984); 
Free and Cued Selective Reminding Test (Grober and 
Buschke, 1987); Word Recall and recognition 
(Bäckman and Forsell, 1994); Buschke Cued Recall 
paradigm for memory assessment (Buschke, 1984); 
Rey Auditory Verbal Learning Test (Rey, 1964); 
Benton Visual Retention Test Multiple Choice version 
(Benton, 1974); Benton Visual Retention Test Form C 
(Benton, 1974); Wechsler Memory Scale Logical 
Memory subtest (Wechsler, 1975); Wechsler Memory 
Scale Paired Associated Learning subtest (Wechsler, 
1975); Buschke Selective Reminding Test (Buschke 
and Fuld ,1974); Russell’s adaptation of the Visual 
Reproduction Test: Recall (Russell, 1975) 
Executive Functioning Trail Making Test AB, part B (Reitan, 1958); 
Adaptation of the Trail Making Test: Trailmaking 
Test ABC, part C (Koivisto et al., 1992)  
Attention/ Information Processing  
Speed 
Psychomotor Speed Tests (Willison and Warrington, 
1992); Trail Making Test part A (Reitan 1958); WAIS 
Digit Symbol (Wechsler, 1981); Wechsler Memory 
Scale Mental Control subtest (Wechsler, 1945); Figure 
Identification (Dureman et al., 1971) 
Verbal Ability Letter Fluency Task (F, A, S, P); Category Fluency 
Task (animals, supermarket, food); Isaacs Set Test 
(Isaacs and Kennie, 1973); Graded Naming Test 
(McKenna and Warrington, 1983); Boston Naming 
Test (Mack et al., 1992); Synonym Test (Dureman et 
al., 1971) 
Visuopatial Ability (modified version of ) WAIS-R Block Design 
(Wechsler, 1981); Visual Object & Spatial Perception 
Test (Warrington and James, 1991); Benton Visual 
Retention Test: Form D-Copy (Benton, 1974); 
Russell’s adaptation of the Visual Reproduction Test: 
Copying (Russell, 1975) 
DOMAIN-SPECIFIC DECLINE BEFORE DEMENTIA 
 
 
 
 49 
Supplementary table 2 Methodological quality rating 
Item Criterion 
1. Sampling of subjects  
1.1 Random or consecutive selection Indication that consecutive subjects or randomly 
selected subjects were included 
1.2 Recruited as single cohort with 
specified disease state 
Indication that all subjects were included as a 
single cohort at a specified (usually early) point in 
the course of disease. 
1.3 Selection and referral processes 
fully described 
Description of sampling method and the inclusion 
and exclusion criteria; and (for clinical studies 
only), full description of referral pattern 
1.4 Clinical and demographic 
characteristics fully described 
Data presented on age, gender, educational level, 
and score for the MMSE or equivalent cognitive 
screening test 
1.5 Complete 
 
 
This item was scored present if it was indicated 
that all eligible patients had undergone the 
diagnostic test or if it was mentioned how many 
of the eligible patients had not undergone the 
diagnostic test and that the baseline characteristics 
of these patients were compared with the 
characteristics of the patients who had undergone 
the diagnostic test  
1.6 Large sample size Baseline sample of at least 50 subjects 
  
2. Reference diagnosis  
2.1 Methods and tests described in 
detail 
Description of person who made the diagnosis 
and of data used for diagnosis 
2.2 Positive and negative diagnoses 
clearly described  
Description of dementia criteria used 
2.3 Available for a high proportion of 
subjects 
Follow-up rate of at least 85% 
2.5 Blinding procedures used to 
prevent knowledge of result of 
diagnostic test influencing the reference 
diagnosis (i.e. verification bias) 
 
 
This item was scored positive if it was explicitly 
mentioned that the person who made the 
diagnosis of dementia at follow-up was blinded 
for all results of the baseline diagnostic assessment 
(i.e. neuropsychological assessment) except for 
age, sex, and educational level (since these 
variables are not part of the diagnostic criteria). 
 
3. Experimental test 
 
3.1 Description of test described in 
detail 
Description of measurements used to assess 
cognitive functioning such that it could be 
reproduced 
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Supplementary table 2 (continued) 
Item Criterion 
3.2 All baseline results described Description of the baseline results of the 
cognitive assessments for at least the future 
demented subjects 
 
4. Longitudinal design 
4.1 Sufficient length of follow-up 
 
4.2 Low variability in follow-up length 
 
 
This item was scored present if the length of 
follow-up was at least 3 years 
This item was scored present if the variability in 
the follow-up length between subjects was 2 
years or less.  
aItems were selected and adapted from rating scales of methodological quality of diagnostic and 
prognostic studies as described in Altman DG, Systematic reviews of evaluations of prognostic 
variables, BMJ 2001;323:224–8; and Deeks JJ, Systematic reviews in health care: Systematic reviews of 
evaluations of diagnostic and screening tests. BMJ 2001;323:157–62 
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ABSTRACT 
 
Background 
We investigated the course of decline in multiple cognitive domains in non-
demented subjects from a memory clinic setting, and compared pattern, onset and 
magnitude of decline between subjects who progressed to AD dementia at follow-
up and subjects who did not progress.  
 
Methods 
In this retrospective cohort study 819 consecutive non-demented patients who 
visited the memory clinics in Maastricht or Amsterdam between 1987 and 2010 
were followed until they became demented or for a maximum of ten years  
(range 0.5 – 10). Differences in trajectories of episodic memory, executive 
functioning, verbal fluency, and information processing speed/attention between 
converters to AD dementia and subjects remaining non-demented were compared 
by means of random effects modeling.  
 
Results 
The cognitive performance of converters and non-converters could be 
differentiated already seven (episodic memory) to three (verbal fluency and 
executive functioning) years prior to dementia diagnosis. Converters declined in 
these three domains, while non-converters remained stable on episodic memory 
and executive functioning and showed modest decline in verbal fluency. There 
was no evidence of decline in information processing speed/attention in both 
groups. 
 
Conclusions 
Differences in cognitive performance between converters to AD dementia and 
subjects remaining non-demented can be established already seven years prior to 
diagnosis for episodic memory, with verbal fluency and executive functioning 
following several years later. So, in addition to early episodic memory decline, also 
decline in executive functions may flag incident dementia. In contrast, change in 
information processing speed/attention seems less informative.  
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INTRODUCTION 
 
The neurodegenerative changes underlying Alzheimer’s disease (AD) start long 
before the disease becomes clinically manifest (Jack et al., 2010), gradually leading 
to subtle cognitive changes several years before the diagnosis of AD-type dementia 
can be made. This transitional stage between normal cognitive functioning and 
dementia is often referred to as Mild Cognitive Impairment (MCI) (Petersen et al., 
1999).  
Consistent with the observation that neuropathological changes start in brain 
circuits subserving memory formation and consolidation, many studies identified 
memory deficits as an early predictor of conversion to AD dementia (Albert et al., 
2001, Silva et al., 2013, Tabert et al., 2006). Further, population-based studies also 
reported subtle deficits in non-memory domains in individuals with prodromal 
AD, such as insufficiencies in executive functioning (Albert et al., 2001, Rapp & 
Reischies, 2005), verbal fluency (Fabrigoule et al., 1998, Laukka et al., 2004), 
attention (Linn et al., 1995, Nielsen et al., 1999), and global cognitive functioning 
(Backman & Small, 1998, Fabrigoule et al., 1998). In addition, longitudinal studies 
comparing the rate of cognitive decline in those who later develop AD dementia 
and those who do not, indicate a sudden steep decline in episodic memory in 
converters in the prodromal AD phase (Johnson et al., 2009, Laukka et al., 2012). 
These and other studies also demonstrate that multiple cognitive functions, like 
verbal fluency and executive functioning show a steeper decline in AD converters 
compared to non-converters several years prior to dementia diagnosis (Amieva et 
al., 2005, Grober et al., 2008, Johnson et al., 2009, Laukka et al., 2012, Mungas et al., 
2010, Thorvaldsson et al., 2011). Unfortunately, current outcomes are largely based 
on non-clinical samples from healthy volunteer populations, which are not directly 
comparable to the help-seeking memory clinic visitors who already experience 
some cognitive problems.  
A better understanding of the pattern, magnitude and temporal sequence of these 
cognitive deficits in clinical populations is important to facilitate early diagnosis 
and increase insight into early pathological brain mechanisms. 
Therefore, the aim of the present study was to compare the pattern, onset and rate 
of cognitive decline between AD dementia converters and non-converters in a 
large sample of memory clinic visitors not demented at baseline. We hypothesized 
that a) differences in decline between groups can be established for all cognitive 
domains (episodic memory, information processing speed/attention, verbal 
fluency and executive functioning), yet converters show a pattern of most 
pronounced decline in memory and executive functioning, and b) that these 
differences become manifest many years before dementia diagnosis is made.  
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METHODS 
 
Subjects 
This study is part of the Clinical Course of Cognition and Comorbidity in MCI (4C-
MCI) study, a longitudinal study on cognitive decline in initially non-demented 
memory clinic visitors. Participants for the present study were retrospectively 
selected from the cumulative clinical and research registration systems of the 
memory clinic at the Alzheimer Centre Limburg at Maastricht University Medical 
Centre (MUMC) and the memory clinic based Amsterdam Dementia Cohort from 
the Alzheimer Centre at the VU Medical Centre (VUmc) (van der Flier et al., 2014).  
Inclusion criteria were: age ≥ 55 years, subjective or objective cognitive 
impairment, no dementia, Clinical Dementia Rating scale (CDR) score ≤ 0.5 or 
Global Deterioration Scale (GDS) score ≤ 3. Exclusion criteria were neurological 
diseases that could have caused cognitive impairment such as Parkinson’s or 
Huntington’s disease, acute stroke, Normal Pressure Hydrocephalus, Korsakoff’s 
syndrome, a medical history of brain tumor or encephalitis. Participants having 
any other comorbidities, including cerebrovascular or psychiatric disorders were 
not excluded in this study. For the present study we selected patients who visited 
the memory clinics between 1987 and 2010 and had at least one follow-up 
assessment, yielding a sample size of N = 819. Both site contributed equally 
(Maastricht n = 393; Amsterdam n = 426). Maastricht patients tended to be 
younger and less educated.  
 
Assessment at baseline  
At baseline, all patients underwent a standardized clinical assessment, which 
included a detailed history of the patient, a psychiatric, neurologic and physical 
examination, appropriate laboratory tests, an extensive neuropsychological 
assessment (see below) and a magnetic resonance imaging (MRI) or a 
computerized tomography (CT) scan. 
All neuropsychological test scores were converted to z-scores adjusted for age, sex 
and education, based on norms for the healthy population (Schmand et al., 2003, 
Van der Elst et al., 2005, 2006a, 2006b). Subjects with a z-score lower than -1.5 SD 
on any neuropsychological test were classified as having MCI, all other subjects 
were classified as having SCI. Participants referred with a psychiatric, neurologic 
or other medical disorder (not meeting exclusion criteria) that could have caused 
cognitive impairment were recorded as MCI or SCI with suspected underlying 
psychiatric comorbidity, suspected underlying neurologic comorbidity or 
suspected underlying other comorbidity respectively. All remaining patients were 
classified as MCI or SCI without relevant comorbidities. From the database we 
extracted data on age, gender, level of education and neuropsychological test 
scores. 
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Neuropsychological assessment  
Both centers used a standard test battery for diagnostic and research purposes. 
Episodic Memory was assessed by means of the Dutch adaptation of the 15-Word 
Verbal Learning Task (VLT) (Lezak et al., 2004, Van der Elst et al., 2005). The score 
at the delayed recall trial was used to measure episodic memory. Information 
processing speed/attention was measured using the average of the Stroop Color 
Word Test (SCWT) (Hammes, 1973) cards 1 and 2 (SCWT 1 – 2) and Trail Making 
Test (Lezak et al., 2004, Schmand et al., 2003) part A (TMT-A). An interference 
index from the SCWT, calculated as Card 3 – [(Card 1 + Card 2) / 2] (Van der Elst 
et al., 2006b), as well as TMT part B were used to measure executive functioning, 
more specifically two components of executive functioning: concept shifting and 
sensitivity to inference. For assessing verbal fluency, a one-minute animal fluency 
test was used (Luteijn & Barelds, 2004).  
 
Follow-up assessment 
The follow-up assessment included a neurologic and medical examination and a 
neuropsychological assessment comparable to baseline. The diagnosis of dementia 
and AD dementia at follow-up was made by a neurologist or neuropsychiatrist 
according to the DSM-IV and NINCDS-ADRDA criteria (American Psychiatric 
Association, 1994, McKhann et al., 1984) after multidisciplinary consensus using all 
available information. Frontotemporal dementia (FTD) was diagnosed according 
to the Neary criteria (Neary et al., 1998). The diagnosis of vascular dementia was 
made according to the NINDS-AIREN criteria (Roman et al., 1993). Dementia with 
Lewy bodies (DLB) was diagnosed following the guideline of the international 
DLB consensus group (McKeith et al., 2005). Other rare forms of dementia (e.g. 
HIV-dementia complex, Creutzfeldt-Jakob disease etc.) were summarized under 
‘other dementia’. Non-demented subjects were classified as MCI or SCI conform 
classification procedures at baseline assessment.  
For the present study we used information on dementia status at follow-up, date 
of dementia diagnosis and dementia type. Mean follow-up time was 2.7 years  
(median = 2.0) with a range from 0.5 to 10.0 years. Throughout follow-up patients 
had on average three neuropsychological assessments (median = 2; range = 2 – 11; 
total number = 2200). During this period 183 (21.3%) incident dementia cases were 
established, of which 143 (78.1%) subjects developed AD dementia. For the present 
study we excluded the 40 subjects who converted to other forms of dementia.  
 
Informed consent 
In the Netherlands, the use of anonymized routine data does not require ethical 
approval or written informed consent. In the Amsterdam Dementia Cohort all 
patients provided informed consent for the use of their routine clinical practice 
data for research purposes.  
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Statistical analyses 
Statistical analyses were performed using STATA version 12 for Mac OS X 
(StataCorp, Texas). Significance was set at p < 0.05 in two-sided tests. For 
neuropsychological test scores we used z-scores to allow comparison across 
domains. Baseline differences between groups were analyzed using t tests for 
continuous variables and χ2 tests for categorical variables. Cognitive decline over 
time was assessed using random-effects (linear mixed) models, thereby accounting 
for the fact that repeated measurements are correlated within individuals. In 
addition, the use of mixed models makes the preprocessing of data by (multiple) 
imputation methods unnecessary, since the model handles missing data effectively 
by using all available data at a given time point and by integrating missing values 
for cognition slopes with maximum likelihood.  
Follow-up time was inverted and thus ranged from -10 years to zero, where zero 
(T0) is the time of diagnosis for incident dementia cases or last available 
assessment for non-converters. Thus, only converters’ information from 
assessments prior to dementia diagnosis was included in order to restrict analyses 
to the pre-dementia phase. First, models with random intercepts were specified, 
where the random intercept is the difference between converters and non-
converters at T0.  Random slopes were included if likelihood ratio testing (LRT) 
suggested that this gave better fit compared to the model with only a random 
intercept. To study differences in rate of decline over time between the groups (1= 
AD dementia converters, 0 = non-converters), a group-by-time interaction term 
was added. In case of statistically significant differences between groups in rate of 
decline (i.e. a significant group-by-time interaction), we computed model-based 
estimates for each one-year time-point in order to find the point of first-time 
deviation in cognitive performance between the two groups. The random-effects 
models were adjusted for age, sex, study centre and education (low, middle, high).  
 
 
RESULTS 
 
Baseline differences 
Characteristics of the patients at study entry, according to dementia status at 
follow-up and for the total group, are listed in Table 1. Subjects who developed 
AD dementia were about 3.5 years older at their first visit to the memory clinic and 
had significantly lower scores on the VLT and verbal fluency compared to subjects 
who did not convert to AD dementia. The baseline diagnosis of the converter 
group was mainly MCI (n = 113; 79%), while baseline diagnosis in the non-
converters was more equally divided between MCI and SCI (MCI: n = 399; 59%; 
SCI: n = 277, 41%). 
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Table 1 Characteristics of patients at first visit to the memory clinic  
Variable Overall AD converters Non-converters 
n 819 143 676 
Age, y 67.2 (7.65) 70.1 (6.28)** 66.6 (7.77) 
Sex (% male) 
Education 
  % Low 
  % Middle 
  % High 
Baseline diagnosis, n (%) 
  MCI 
  SCI   
54.6 % 
 
20.1 % 
43.5 % 
36.4 % 
 
512 (62.5) 
307 (37.5) 
46.2 %* 
 
22.9 % 
48.6 % 
28.5 % 
 
113 (79.0)* 
30 (21.0)* 
56.4% 
 
19.5 % 
42.4 % 
38.1 % 
 
399 (59.0) 
277 (41.0)  
VLT (delayed recall) 
Fluency 
TMT-A 
TMT-B 
SCWT 1 - 2 
SCWT interference  
Follow-up length, y 
Number of repeated 
measurement occasions, n (%) 
  2 
  3 
  4 
  5 or more 
-1.1 (1.36) 
-0.6 (0.97) 
-0.3 (1.26) 
0.1 (1.24) 
-0.8 (1.70) 
-0.7 (1.84) 
2.7 (2.16) 
 
 
482 (58.9) 
184 (22.5) 
113 (13.8) 
40 (4.9) 
-2.2 (0.99)**  
-0.8 (0.79)** 
-0.5 (1.16) 
-0.1 (1.20) 
-0.7 (1.25) 
-0.9 (1.84) 
2.2 (1.53)** 
 
 
93 (65.0) 
27 (18.9) 
16 (11.2) 
7 (4.9) 
-0.9 (1.33) 
-0.5 (1.00) 
-0.2 (1.28) 
0.1 (1.25) 
-0.9 (1.78) 
-0.7 (1.84) 
2.8 (2.26) 
 
 
389 (57.5) 
157 (23.3) 
97 (14.4) 
33 (4.9) 
Data are mean (SD), unless otherwise specified. All cognitive test scores are presented as z-scores. 
Group size is different for cognitive tests. VLT = Verbal Learning Test; TMT-A = Trailmaking Test  
part-A; TMT-B = Trailmaking Test part-B; SCWT 1 - 2 = average of Stroop Color Word Test 1 + 2;  
SCWT interference = Stroop Color Word Test interference index. 
* p < 0.05 compared with non-converters 
** p < 0.01 compared with non-converters 
 
 
For the non-converters, the suspected underlying cause of the cognitive complaints 
was classified as follows: 91 subjects (13.5%) were classified as “suspected 
underlying psychiatric comorbidity”, 27 subjects (4.0%) were classified as 
“suspected underlying neurological comorbidity” and 39 subjects (5.8 %) were 
classified as “suspected underlying other comorbidity”. The remaining 519 (76.8%) 
subjects had no relevant comorbidity. Of the subjects with suspected underlying 
psychiatric comorbidity only 11 patients (10.8%) converted to AD dementia at 
follow-up, and of the subjects with suspected underlying neurologic comorbidity 
of the complaints only 2 (6.9%) converted to AD dementia at follow-up. Further, 
for the groups with suspected underlying other comorbidity or no relevant 
comorbidity respectively 8 (17%) and 122 (19%) patients converted to AD 
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dementia. More extensive information on baseline diagnosis and suspected 
underlying aetiology for the two groups can be found in Table 2. 
 
 
Table 2 Groups at final assessment stratified by baseline diagnosis and 
suspected baseline aetiology 
                                                                                                     Diagnosis at last assessment 
  NNon-converter group Converter group 
Baseline diagnosis  MCI SCI AD 
MCI Suspected underlying psychiatric 
comorbidity 
35 (59.3%) 17 (28.8%) 7 (11.9%) 
 Suspected underlying neurologic 
comorbidity 
16 (80.0%) 3 (15.0%) 1 (5.0%) 
 Suspected underlying other 
comorbidity 
20 (57.1%) 7 (20.0%) 8 (22.9%) 
 No relevant comorbidity 231 (58.0%) 70 (17.6%) 97 (24.4%) 
 Total 302 97 113 
SCI Suspected underlying psychiatric 
comorbidity 
8 (18.6%) 31 (72.1%) 4 (9.3%) 
 Suspected underlying neurologic 
comorbidity 
2 (22.2%) 6 (66.7%) 1  (11.1%) 
 Suspected underlying other 
comorbidity 
5 (41.7%) 7 (58.3%) 0 (0%) 
 No relevant comorbidity 60 (24.7%) 158 (65.0%) 25 (10.3%) 
 Total 75 202 30 
MCI = Mild Cognitive Impairment; SCI = Subjective Cognitive Impairment; AD = Alzheimer’s Disease 
dementia. 
 
 
Table 3 Mean annual rate of change per neuropsychological test for Alzheimer 
dementia (AD) converters and non-converters, and the corresponding values for 
a group-by-time interaction effect  
Neuropsychological  AD Converters Non-converters Interaction effect 
test  Mean 
change 
p-value Mean     
 change 
p-value χ2  p-value 
VLT  
Fluency 
TMT-A 
TMT-B 
SCWT 1 + 2 
SCWT interference  
-0.15 
-0.17 
-0.03 
-0.15 
-0.10 
-0.25 
<.01 
<.01 
 .39 
<.01 
 .05 
<.01 
0.01 
-0.10 
0.02 
-0.01 
-0.04 
-0.04 
.56 
<.01 
.08 
.59 
<.01 
.17 
16.11 
6.37 
1.08 
17.30 
2.01 
6.74 
<.01 
.01 
.30 
<.01 
.16 
.01 
VLT = 15-Word Verbal Learning Test; TMT-A = Trail Making Test part-A; TMT-B = Trail Making Test  
part-B; SCWT 1 - 2 = average of Stroop Color Word Test 1 + 2; SCWT interference = Stroop Color Word  
Test interference index.  
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Rate and pattern of cognitive decline 
Random effects models compared the slope of cognitive decline between non-
converters and converters to AD dementia. A significant group-by-time interaction 
effect suggested that the mean annual rates of decline of the two groups differed 
significantly for the Verbal Learning Test, Trail Making Test-B, Stroop interference 
index and verbal fluency, but not for Trail Making Test-A and the averaged Stroop 
1 + 2 (see Table 3). AD converters declined significantly on most tests (e.g. Verbal 
Learning Test, Trail Making Test-B, Stroop interference index and verbal fluency), 
but showed no change over time on Trail Making Test-A and the averaged Stroop 
1 + 2 (see Table 3). In contrast, non-converters remained generally stable in all 
domains, except for a modest decline on verbal fluency and a marginal decline on 
the averaged Stroop 1 + 2. 
 
Next, we studied potential deviations from a linear trend over time by including 
the quadratic term for time in above analyses. A quadratic curvature best 
described the trajectory in verbal fluency (beta of time as a quadratic term = -.01, p 
= .001). For the other domains adding a quadratic term did not improve the model.  
The trajectories for the different cognitive domains were plotted using model-
based estimates and are shown in Figure 1. 
 
Onset of decline  
We then computed at which time point during the pre-dementia phase, significant 
differences in cognitive performance of AD converters and non-converters could 
be established for the first time looking backwards from the point of diagnosis. 
Segmenting follow-up time by one-year time bands and calculating model-based 
estimates per year, this distinction could be made already seven years prior to 
diagnosis for the Verbal Learning Test. For non-memory tests, the point of 
differentiation occurred several years later, three years before diagnosis for the 
Trail Making Test-B and verbal fluency and two years prior to diagnosis for the 
Stroop interference index. Before these time points, the cognitive performances of 
the two groups were not distinguishable, which is also indicated in Figure 1 by the 
curves (representing cognition slopes) showing overlapping 95% confidence 
intervals (see fig. 1). Since the plotted curves are based on linear prediction 
models, for some tests (e.g. Stroop interference, Trail Making Test-B) index curves 
seem to start to differ between groups again, several years before the point of 
differentiation, but this is purely due to the linear prediction and does not 
represent the actual data (see fig. 1).  
When we repeated our analyses using only data from patients who were followed 
for 3 years or more, results did not essentially change.  Yet, for the TMT-B, the 
point of differentiation could be established even earlier in time (i.e. 6 years prior 
to AD dementia diagnosis). 
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Figure 1 Average cognitive decline with 95% CI for converters to Alzheimer 
dementia (AD, black diamonds) and non-converters (gray circles) per cognitive 
test. Time axis is inverted and shows years before end of study (i.e. date of 
dementia diagnosis for converters or last follow-up assessment for non-
converters) 
 
VLT = Verbal Learning Test; TMT-A = Trail Making Test part-A; TMT-B = Trail Making Test part-B; 
SCWT 1 - 2 = average of Stroop Color Word Test 1 + 2; SCWT interference = Stroop Color Word Test 
interference index; * = point of first differentiation between groups.  
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DISCUSSION 
 
To the best of our knowledge, the present study is the first large multicenter 
longitudinal study that explicitly aimed at describing the trajectories of various 
cognitive functions in converters to AD dementia and non-converters in a memory 
clinic setting. Our main finding is that differences in cognitive performance 
between converters to AD dementia and non-converters already exist seven 
(episodic memory) to three (executive functioning and verbal fluency) years prior 
to diagnosis. Furthermore, we found profound differences in cognitive trajectories 
between the two groups for these domains, with pre-demented subjects showing 
marked decline while non-converters remained generally stable. For information 
processing speed/attention both groups did not decline substantially and hence 
there was no difference between groups.  
 
Our established differences in cognitive performance between converters and non-
converters several years before dementia diagnosis corroborate findings of 
population-based studies, although follow-up of these studies was generally 
shorter (1.5 to 3.6 years). As in our memory-clinic based study, the differences 
were found for the domains of episodic memory (Albert et al., 2001, Amieva et al., 
2005, Chen et al., 2000), executive functioning (Albert et al., 2001, Chen et al., 2000, 
Hanninen et al., 1995) and verbal fluency (Chen et al., 2000, Clark et al., 2009, Raoux 
et al., 2008). Studies with longer follow-up reported differences in episodic 
memory, verbal fluency and abstract thinking (a part of executive functioning) 
already nine (Amieva et al., 2005) to five (only verbal fluency reported) (Clark et al., 
2009) years prior to AD dementia diagnosis. This is roughly comparable to our 
established points of distinction, although differences in verbal fluency and 
abstract thinking in one study are reported even several years earlier than we 
found. Yet, when we repeated our analyses for a subgroup of our population, 
including only patients who were followed for three years or more, our point of 
differentiation for concept shifting (a part of executive functioning) proved to be 
six years prior to AD dementia diagnosis, which matches previous findings even 
better. The differences between our main results and the results of these previous 
studies are likely to be affected by study population, which consisted of healthy 
subjects from the general population, while we investigate subjects who presented 
with cognitive complaints at a memory clinic and thus also our non-converters are 
likely to perform on a lower level than healthy population-based control subjects.  
 
We observed differences between groups in the rate of decline, which was most 
profound for the domains of episodic memory and executive functioning, 
mirroring findings in non-clinical samples (Chen et al., 2001, Grober et al., 2008, 
Johnson et al., 2009, Mungas et al., 2010) and a clinical sample (van Harten et al., 
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2013). Although one population-based study found differences only for decline in 
episodic memory but not in executive functioning (Albert et al., 2007), (although 
differences in executive functioning almost reached significance) and one negative 
study reported similar rates of decline for the two groups in episodic memory 
(Backman et al., 2001). However, it must be noted that this last study was restricted 
to decline from six to three years prior to diagnosis, which does not correspond to 
the timeframe used in most studies (i.e. immediately preceding diagnosis). Our 
results further correspond with the observation that the earliest pathologic 
changes in AD usually occur in the medial temporal lobe regions, which are 
known to be critical for episodic memory functioning (Ridha et al., 2006, Sluimer et 
al., 2009).  Moreover, our established multi-domain decline in pre-demented 
subjects also match findings of spread pathology before AD diagnosis, indicating 
that multiple brains structures, like the parietal (Jacobs et al., 2011) and frontal 
cortex (Burgmans et al., 2009) are affected. 
 
Our findings further indicated decline in verbal fluency for both groups, which is 
also reported by a population-based study (Clark et al., 2009). Moreover, 
significant decline on fluency measures prior to AD dementia diagnosis is reported 
by multiple population-based studies (Grober et al., 2008, Laukka et al., 2012, 
Raoux et al., 2008). Our established decline for non-converters might be due to an 
underlying ageing process, which is reported for verbal fluency by other studies 
(Auriacombe et al., 2001, Crossley et al., 1997).  
 
For information processing speed/attention we did not find differences between 
groups. While our findings are supported by several previous population-based 
studies (Cerhan et al., 2007, Fox et al., 1998), others have reported significant 
differences between groups in this domain (Chen et al., 2000, Galvin et al., 2005). 
Differences in study design, study sample and definition of this cognitive domain 
might explain part of these inconsistencies. For instance the study by Galvin et al. 
(2005) followed subjects that converted to both AD and non-AD dementias, with 
the latter being more likely to exhibit attention/speed deficits early in the course of 
decline, e.g. due to evolving vascular cognitive impairment (O'Brien et al., 2003). 
Another population-based study reported significant decline for speed/attention 
measures in both converters and non-converters (Wilson et al., 2011). This seems to 
be in accordance with our (borderline) significant decline on the SCWT 1 – 2 for 
both groups. Since the decline is found for both groups, at least part of it might be 
due to a common underlying ageing process. Indeed attention seems to be a poor 
discriminator between converters to AD dementia and non-converters (Albert et 
al., 2001) Interestingly, when we repeated our analyses including data that were 
gathered after the dementia diagnosis was made, information processing 
speed/attention did show significant cognitive decline for the converters (results 
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not shown). This implies that decline in attention is still subtle in the pre-dementia 
phase and starts widening as underlying pathology progresses. More importantly, 
since pathological decline in information processing speed/attention is absent in 
the pre-dementia phase of AD, the determined decline in executive functioning 
can be considered as a pure executive problem, because no underlying attention or 
speed problems are found. 
 
In the present study, non-converters remained stable in general. The absence of 
cognitive decline in subjects remaining cognitively healthy is well established in 
other studies (Chen et al., 2001, Galvin et al., 2005, Rubin et al., 1998, Wilson et al., 
1999). The absence of decline over time in this ageing population might be due to 
learning and habituation effects, which are well documented in healthy elderly 
populations (Ferrer et al., 2004, Machulda et al., 2013, Mitrushina & Satz, 1991). An 
alternative explanation for the absence of decline in non-converters might be that 
subjects experiencing subjective cognitive complaints feel reassured after their visit 
to the memory clinic. The relieve of feelings of stress, anxiety or worrying could 
lead to improvement in their performance over time, since it is known that feelings 
of depression and anxiety are associated with poorer cognitive performance 
(Bunce et al., 2012). 
 
Our findings might have implications for designing optimal neuropsychological 
test batteries aiming at detecting dementia at an early stage. Episodic memory and 
executive functioning showed the largest differences in decline between groups, 
and hence the trajectories on these measures might be the most indicative of future 
dementia. The stated decline in executive functioning, urges the need to focus not 
solely on episodic memory tests in the current neuropsychological assessment, but 
give equal importance to executive functioning measures. 
 
The present study has its own strengths and limitations. Major strengths of this 
study include the large sample size and a relatively long follow-up period of up to 
ten years. This allowed for the inclusion of a considerable number of dementia 
converters with several assessment points, leading to stable estimates in well-
powered random-effect analyses. Furthermore, we tried to maximize 
generalizability by a) using data that were not locally restricted to a single center, 
and b) applying broad inclusion criteria in which most comorbidities were 
included. In addition, the statistical analyses made maximal use of all available 
data from the repeated measures design. However, the use of routine clinical data 
might have impact on data quality and lead to missing observations on several 
relevant neuropsychological tests. Though, a considerable number of patients also 
participate in ongoing research, in which the standard assessment protocol 
contains all cognitive tests specified here. Hence, most patients had full 
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information on these measures. Also, some neuropsychological domains were not 
routinely assessed, like visuospatial functions. However, these functions are often 
regarded as less discriminative between future AD converters and non-converters 
(Albert et al., 2001, Rubin et al., 1998). Next, some non-converters might have been 
misclassified at their latest follow-up assessment because they will convert to 
dementia in the future, thereby diluting the effect. However, when we compare 
our conversion rate (21.3% over a mean period of 2.7 years) with the established 
conversion estimates in a systematic review (6.5%/year) (Mitchell and Shiri-
Feshki, 2009) our ratio corresponds to the established estimates. In addition, it 
should be noted that conversion rates are known to diminish over time, with 
cumulative numbers averaging 22.9% in studies with long-term follow-up.   
Further, some non-converters did not return for further follow-up assessment, 
leading to selection bias. Unfortunately, we do not have information about specific 
reasons of attrition due to the naturalistic setting of this cohort. However, again, 
this selection bias most likely would have led to an underestimation of the 
differences between groups, as non-converters with intact cognition might be 
inclined to get lost to follow-up in this clinical setting.  
 
In conclusion, the present study shows that differences in cognitive performance 
between converters to AD dementia and non-converters can be established already 
seven years prior to diagnosis for episodic memory, with verbal fluency and 
executive functioning following several years later. Additionally, we found 
profound differences between the two groups in the cognitive trajectories of these 
domains, however not for information processing speed/attention. Next to 
accelerated decline in episodic memory, decline in executive functions may flag 
future dementia converters and should be given equal weight as memory decline 
in the diagnostic process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
COGNITIVE DELINE IN THE PRE-DEMENTIA PHASE 
 
 
 
 77 
REFERENCES 
 
Albert, M., Blacker, D., Moss, M.B., Tanzi, R., & McArdle, J.J. (2007). Longitudinal change in 
cognitive performance among individuals with mild cognitive impairment. 
Neuropsychology, 21, 158-169. 
Albert, M.S., Moss, M.B., Tanzi, R., & Jones, K. (2001). Preclinical prediction of AD using 
neuropsychological tests. Journal of the International Neuropsychological Society, 7, 
631-639. 
Amieva, H., Jacqmin-Gadda, H., Orgogozo, J.M., Le Carret, N., Helmer, C., Letenneur, L., 
Barberger-Gateau, P., Fabrigoule, C., & Dartigues, J.F. (2005). The 9 year cognitive 
decline before dementia of the Alzheimer type: a prospective population-based 
study. Brain, 128, 1093-1101. 
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition. Washington DC: American Psychiatric Association. 
Auriacombe, S., Fabrigoule, C., Lafont, S., Jacqmin-Gadda, H., & Dartigues, J.F. (2001). 
Letter and Cateogry Fluency in Normal Elderly Participants: a Population-Based 
Study. Aging, Neuropsychology and Cognition, 8, 98-108. 
Backman, L., & Small, B.J. (1998). Influences of cognitive support on episodic remembering: 
tracing the process of loss from normal aging to Alzheimer's disease. Psychology 
and Aging, 13, 267-276. 
Blessed, G., Tomlinson, B.E., & Roth, M. (1968). The association between quantitative 
measures of dementia and of senile change in the cerebral grey matter of elderly 
subjects. British Journal of Psychiatry, 114, 797-811. 
Bruscoli, M., & Lovestone, S. (2004). Is MCI really just early dementia? A systematic review 
of conversion studies. International Psychogeriatrics, 16, 129-140. 
Bunce, D., Batterham, P.J., Mackinnon, A.J., & Christensen, H. (2012). Depression, anxiety 
and cognition in community-dwelling adults aged 70 years and over. Journal of 
Psychiatric Research, 46, 1662-1666. 
Burgmans, S., van Boxtel, M.P., Smeets, F., Vuurman, E.F., Gronenschild, E.H., Verhey, F.R., 
Uylings, H.B., & Jolles, J. (2009). Prefrontal cortex atrophy predicts dementia over a 
six-year period. Neurobiology of Aging, 30, 1413-1419. 
Cerhan, J.H., Ivnik, R.J., Smith, G.E., Machulda, M.M., Boeve, B.F., Knopman, D.S., Petersen, 
R.C., & Tangalos, E.G. (2007). Alzheimer's disease patients' cognitive status and 
course years prior to symptom recognition. Aging, Neuropsychology, and Cognition: 
A Journal on Normal and Dysfunctional Development, 14, 227-235. 
Chen, P., Ratcliff, G., Belle, S.H., Cauley, J.A., DeKosky, S.T., & Ganguli, M. (2000). 
Cognitive tests that best discriminate between presymptomatic AD and those who 
remain nondemented. Neurology, 55, 1847-1853. 
Chen, P., Ratcliff, G., Belle, S.H., Cauley, J.A., DeKosky, S.T., & Ganguli, M. (2001). Patterns 
of cognitive decline in presymptomatic Alzheimer disease: a prospective 
community study. Archives of General Psychiatry, 58, 853-858. 
Clark, L.J., Gatz, M., Zheng, L., Chen, Y.L., McCleary, C., & Mack, W.J. (2009). Longitudinal 
verbal fluency in normal aging, preclinical, and prevalent Alzheimer's disease. 
American Journal of Alzheimer's Disease and Other Dementias, 24, 461-468. 
 
CHAPTER 3 
 
 
 
 78 
Crossley, M., D'Arcy, C., & Rawson, N.S. (1997). Letter and category fluency in community-
dwelling Canadian seniors: a comparison of normal participants to those with 
dementia of the Alzheimer or vascular type. Journal of Clinical and Experimental 
Neuropsychology, 19, 52-62. 
Fabrigoule, C., Rouch, I., Taberly, A., Letenneur, L., Commenges, D., Mazaux, J.M., 
Orgogozo, J.M., & Dartigues, J.F. (1998). Cognitive process in preclinical phase of 
dementia. Brain, 121, 135-141. 
Ferrer, E., Salthouse, T.A., Stewart, W.F., & Schwartz, B.S. (2004). Modeling age and retest 
processes in longitudinal studies of cognitive abilities. Psychology and Aging, 19, 
243-259. 
Fox, N.C., Warrington, E.K., Seiffer, A.L., Agnew, S.K., & Rossor, M.N. (1998). 
Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's 
disease. A longitudinal prospective study. Brain, 121, 1631-1639. 
Galvin, J.E., Powlishta, K.K., Wilkins, K., McKeel, D.W., Jr., Xiong, C., Grant, E., Storandt, 
M., & Morris, J.C. (2005). Predictors of preclinical Alzheimer disease and dementia: 
a clinicopathologic study. Archives of Neurology, 62, 758-765. 
Gelinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999). Development of a functional 
measure for persons with Alzheimer's disease: the disability assessment for 
dementia. American Journal of Occupational Therapy, 53, 471-481. 
Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., & Kawas, C. (2008). 
Memory impairment, executive dysfunction, and intellectual decline in preclinical 
Alzheimer's disease. Journal of the International Neuropsychological Society, 14, 266-
278. 
Hammes, J. (1973). De Stroop Kleur-Woord Test: Handleiding [The Stroop Color-Word Test: 
Manual]. Amsterdam: Swets & Zeitlinger. 
Hanninen, T., Hallikainen, M., Koivisto, K., Helkala, E.L., Reinikainen, K.J., Soininen, H., 
Mykkanen, L., Laakso, M., Pyorala, K., & Riekkinen, P.J., Sr. (1995). A follow-up 
study of age-associated memory impairment: neuropsychological predictors of 
dementia. Journal of the American Geriatrics Society, 43, 1007-1015. 
Jack, C.R., Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, 
R.C., & Trojanowski, J.Q. (2010). Hypothetical model of dynamic biomarkers of the 
Alzheimer's pathological cascade. Lancet Neurology, 9, 119-128. 
Jacobs, H.I., Van Boxtel, M.P., Uylings, H.B., Gronenschild, E.H., Verhey, F.R., & Jolles, J. 
(2011). Atrophy of the parietal lobe in preclinical dementia. Brain and Cognition, 75, 
154-163. 
Johnson, D.K., Storandt, M., Morris, J.C., & Galvin, J.E. (2009). Longitudinal study of the 
transition from healthy aging to Alzheimer disease. Archives of Neurology, 66, 1254-
1259. 
Laukka, E.J., Jones, S., Small, B.J., Fratiglioni, L., & Backman, L. (2004). Similar patterns of 
cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's 
disease. Journal of the International Neuropsychological Society, 10, 382-391. 
Laukka, E.J., Macdonald, S.W., Fratiglioni, L., & Backman, L. (2012). Preclinical cognitive 
trajectories differ for Alzheimer's disease and vascular dementia. Journal of the 
International Neuropsychological Society, 18, 191-199. 
Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). Neuropsychological Assessment, 4th 
Edition (4th Edition ed.). Oxford, UK: Oxford University Press. 
COGNITIVE DELINE IN THE PRE-DEMENTIA PHASE 
 
 
 
 79 
Linn, R.T., Wolf, P.A., Bachman, D.L., Knoefel, J.E., Cobb, J.L., Belanger, A.J., Kaplan, E.F., &  
D'Agostino, R.B. (1995). The 'preclinical phase' of probable Alzheimer's disease. A 
13-year prospective study of the Framingham cohort. Archives of Neurology, 52, 485-
490. 
Luteijn, F., & Barelds, D.P.H. (2004). Groninger Intelligentie Test 2 Handleiding [Groninger 
Intelligence Test 2 Manual]. Amsterdam: Harcourt Assessment BV. 
Machulda, M.M., Pankratz, V.S., Christianson, T.J., Ivnik, R.J., Mielke, M.M., Roberts, R.O., 
Knopman, D.S., Boeve, B.F., & Petersen, R.C. (2013). Practice effects and 
longitudinal cognitive change in normal aging vs. incident mild cognitive 
impairment and dementia in the Mayo Clinic Study of Aging. The Clinical 
Neuropsychologist, 27, 1247-1264. 
McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., 
Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., 
Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., 
Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, 
R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, 
I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-
Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q., & Yamada, 
M. (2005). Diagnosis and management of dementia with Lewy bodies: third report 
of the DLB Consortium. Neurology, 65, 1863-1872. 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E.M. (1984). 
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work 
Group under the auspices of Department of Health and Human Services Task 
Force on Alzheimer's Disease. Neurology, 34, 939-944. 
Mitchell, A. J. & Shiri-Feshki, M. (2009). Rate of progression of mild cognitive  
 impairment to dementia--meta-analysis of 41 robust inception cohort  
 studies. Acta Psychiatrica Scandinavica, 119, 252-65. 
Mitrushina, M., & Satz, P. (1991). Effect of repeated administration of a neuropsychological 
battery in the elderly. Journal of Clinical Psychology, 47, 790-801. 
Mungas, D., Beckett, L., Harvey, D., Farias, S.T., Reed, B., Carmichael, O., Olichney, J., 
Miller, J., & DeCarli, C. (2010). Heterogeneity of cognitive trajectories in diverse 
older persons. Psychology and Aging, 25, 606-619. 
Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., 
Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., & 
Benson, D.F. (1998). Frontotemporal lobar degeneration: a consensus on clinical 
diagnostic criteria. Neurology, 51, 1546-1554. 
Nielsen, H., Lolk, A., Andersen, K., Andersen, J., & Kragh-Sorensen, P. (1999). 
Characteristics of elderly who develop Alzheimer's disease during the next two 
years-a neuropsychological study using CAMCOG. The Odense Study. 
International Journal of Geriatric Psychiatry, 14, 957-963. 
O'Brien, J.T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J.V., 
Ballard, C., DeCarli, C., Gorelick, P.B., Rockwood, K., Burns, A., Gauthier, S., & 
DeKosky, S.T. (2003). Vascular cognitive impairment. Lancet Neurology, 2, 89-98. 
Petersen, R.C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal 
Medicine, 256, 183-194. 
CHAPTER 3 
 
 
 
 80 
Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., & Kokmen, E. (1999). 
Mild cognitive impairment: clinical characterization and outcome. Archives of 
Neurology, 56, 303-308. 
Raoux, N., Amieva, H., Le Goff, M., Auriacombe, S., Carcaillon, L., Letenneur, L., & 
Dartigues, J.F. (2008). Clustering and switching processes in semantic verbal 
fluency in the course of Alzheimer's disease subjects: results from the PAQUID 
longitudinal study. Cortex, 44, 1188-1196. 
Rapp, M.A., & Reischies, F.M. (2005). Attention and executive control predict Alzheimer 
disease in late life: results from the Berlin Aging Study (BASE). American Journal of 
Geriatric Psychiatry, 13, 134-141. 
Ridha, B.H., Barnes, J., Bartlett, J.W., Godbolt, A., Pepple, T., Rossor, M.N., & Fox, N.C. 
(2006). Tracking atrophy progression in familial Alzheimer's disease: a serial MRI 
study. Lancet Neurology, 5, 828-834. 
Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., 
Amaducci, L., Orgogozo, J.M., Brun, A., Hofman, A., & et al. (1993). Vascular 
dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN 
International Workshop. Neurology, 43, 250-260. 
Rubin, E.H., Storandt, M., Miller, J.P., Kinscherf, D.A., Grant, E.A., Morris, J.C., & Berg, L. 
(1998). A prospective study of cognitive function and onset of dementia in 
cognitively healthy elders. Archives of Neurology, 55, 395-401. 
Schmand, B., Houx, P., & de Koning, I. (2003). Normen voor Stroop kleur-woord tests, Trail 
Making test en Story Recall van de Rivermead Behavioural Memory Test. [Norms for 
Stroop color-word tests, Trail Making Test and Story Recall of the Rivermead Behavioural 
Memory Test]. Amsterdam: Nederlands Instituut van Psychologen, Sectie 
Neuropsychologie. 
Silva, D., Guerreiro, M., Santana, I., Rodrigues, A., Cardoso, S., Maroco, J., & de Mendonca, 
A. (2013). Prediction of long-term (5 years) conversion to dementia using 
neuropsychological tests in a memory clinic setting. Journal of Alzheimer's Disease, 
34, 681-689. 
Sluimer, J.D., van der Flier, W.M., Karas, G.B., van Schijndel, R., Barnes, J., Boyes, R.G., 
Cover, K.S., Olabarriaga, S.D., Fox, N.C., Scheltens, P., Vrenken, H., & Barkhof, F. 
(2009). Accelerating regional atrophy rates in the progression from normal aging to 
Alzheimer's disease. European Radiology, 19, 2826-2833. 
Tabert, M.H., Manly, J.J., Liu, X., Pelton, G.H., Rosenblum, S., Jacobs, M., Zamora, D., 
Goodkind, M., Bell, K., Stern, Y., & Devanand, D.P. (2006). Neuropsychological 
prediction of conversion to Alzheimer disease in patients with mild cognitive 
impairment. Archives of General Psychiatry, 63, 916-924. 
Thorvaldsson, V., Macdonald, S.W., Fratiglioni, L., Winblad, B., Kivipelto, M., Laukka, E.J., 
Skoog, I., Sacuiu, S., Guo, X., Ostling, S., Borjesson-Hanson, A., Gustafson, D., 
Johansson, B., & Backman, L. (2011). Onset and rate of cognitive change before 
dementia diagnosis: findings from two Swedish population-based longitudinal 
studies. Journal of the International Neuropsychological Society, 17, 154-162. 
Van der Elst, W., van Boxtel, M.P., van Breukelen, G.J., & Jolles, J. (2005). Rey's verbal 
learning test: normative data for 1855 healthy participants aged 24-81 years and the 
influence of age, sex, education, and mode of presentation. Journal of the 
International Neuropsychological Society, 11, 290-302. 
COGNITIVE DELINE IN THE PRE-DEMENTIA PHASE 
 
 
 
 81 
Van der Elst, W., Van Boxtel, M.P., Van Breukelen, G.J., & Jolles, J. (2006a). Normative data 
for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch 
speaking participants and the effects of age, education, and sex. Journal of the 
International Neuropsychological Society, 12, 80-89. 
Van der Elst, W., Van Boxtel, M.P., Van Breukelen, G.J., & Jolles, J. (2006b). The Stroop color-
word test: influence of age, sex, and education; and normative data for a large 
sample across the adult age range. Assessment, 13, 62-79. 
van der Flier, W.M., Pijnenburg, Y.A., Prins, N., Lemstra, A.W., Bouwman, F.H., Teunissen, 
C.E., van Berckel, B.N., Stam, C.J., Barkhof, F., Visser, P.J., van Egmond, E., & 
Scheltens, P. (2014). Optimizing patient care and research: the amsterdam 
dementia cohort. Journal of Alzheimer's Disease, 41, 313-327. 
van Harten, A.C., Smits, L.L., Teunissen, C.E., Visser, P.J., Koene, T., Blankenstein, M.A., 
Scheltens, P., & van der Flier, W.M. (2013). Preclinical AD predicts decline in 
memory and executive functions in subjective complaints. Neurology, 81, 1409-1416. 
Wilson, R.S., Beckett, L.A., Bennett, D.A., Albert, M.S., & Evans, D.A. (1999). Change in 
cognitive function in older persons from a community population: relation to age 
and Alzheimer disease. Archives of Neurology, 56, 1274-1279. 
Wilson, R.S., Leurgans, S.E., Boyle, P.A., & Bennett, D.A. (2011). Cognitive decline in 
prodromal Alzheimer disease and mild cognitive impairment. Archives of 
Neurology, 68, 351-356.

 
 
 
 
83 
 
 
 
CHAPTER 4 
 
 
 
 
 
PROGRESSION TO DEMENTIA IN MEMORY  
CLINIC PATIENTS WITHOUT DEMENTIA: 
A LATENT PROFILE ANALYSIS 
 
 
 
 
 
Sebastian Köhler, Renske Hamel, Nicole Sistermans, Ted Koene, Yolande A.L. 
Pijnenburg, Wiesje M. van der Flier, Philip Scheltens, Pieter Jelle Visser, Pauline 
Aalten, Frans R.J. Verhey, Inez Ramakers 
 
 
 
 
 
 
Neurology 2013; 81(15), 1342-1349 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 
 
84 
ABSTRACT 
 
Objective 
To identify the existence of discrete cognitive subtypes among memory clinic 
patients without dementia and test their prognostic values. 
 
Methods 
In a retrospective cohort study of 635 patients without dementia visiting the 
Alzheimer centers in Maastricht or Amsterdam, latent profile analysis identified 
cognitive subtypes based on immediate and delayed memory recall, delayed 
recognition, information-processing speed, attention, verbal fluency, and executive 
functions. Time to dementia was tested in weighted Cox proportional hazard 
models adjusted for confounders. 
 
Results 
Five latent classes represented participants with high-normal cognition (15%), low-
normal cognition (37%), primary memory impairment in recall (MI) (36%), 
memory impairment in recall and recognition (MI+) (5%), and primary non-
memory impairment (NMI) (6%). Compared with low-normal cognition, 
participants with NMI had the highest risk of dementia (hazard ratio [HR] 5 5.94, 
95% confidence interval [CI] 5 3.46–10.18) followed by MI (HR 5 3.05, 95% CI 5 
2.09–4.46) and MI+ (HR 5 3.26, 95% CI 5 1.72–6.17), while participants with high-
normal cognition had the lowest risk (HR 5 0.24, 95% CI 5 0.07–0.80). Subtypes 
further showed differential relationships with dementia types, with MI and MI+ 
most often converting to Alzheimer-type dementia and NMI to other forms of 
dementia. 
 
Conclusions 
Cognitive subtypes can be empirically identified in otherwise heterogeneous 
samples of memory clinic patients and largely confirm current strategies to 
distinguish between amnestic and nonamnestic impairment. Studying more 
homogeneous cognitive subtypes may improve understanding of disease 
mechanisms and outcomes. 
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INTRODUCTION 
 
A major pursuit in current dementia research is finding early diagnostic markers 
flagging individuals at risk of dementia. Several cognitive high-risk groups have 
been defined by imposing different cut-offs on neuropsychological tests such as in 
age-associated cognitive decline (AACD), cognitive impairment no dementia 
(CIND) or mild cognitive impairment (MCI) (Gauthier et al., 2006). These high-risk 
groups have higher conversion rates to dementia than cognitively healthy 
individuals (Visser et al., 2006). For MCI, several subtypes have been proposed to 
account for differences in clinical presentation, with the most common distinction 
being made on two axes: single-domain versus multi-domain impairment, and 
amnestic versus non-amnestic impairment (Petersen and Morris, 2005). 
While the definition of MCI and related concepts has been guided by theoretical 
and clinical insight, an alternative approach to understand cognitive heterogeneity 
is to statistically test the existence of distinct but in themselves homogeneous 
subpopulations. A few studies have used cluster analysis (Delano-Wood et al., 
2009, Libon et al., 2010, McKinlay et al., 2009, Ylikoski et al., 1999) or latent profile 
analysis (LPA) (Hanfelt et al., 2011) in non-demented memory clinic patients, and 
found three (Delano-Wood et al., 2009, Libon et al., 2010, McKinlay et al., 2009), five 
(Ylikoski et al., 1999), or seven different patient subgroups (Hanfelt et al., 2011). 
Most of these studies had a small sample size (≤ 120 patients), with the exception 
of one study (Hanfelt et al., 2011). In addition, the predictive validity of these 
subtypes for the dementia outcome remains opaque. 
Therefore, the aim of the present study was to 1) explore the existence of one or 
more cognitive subtypes in a large sample of non-demented memory-clinic 
patients, and 2) to study their prognostic value for predicting dementia. 
 
 
METHODS 
 
Study population 
The Clinical Course of Cognition and Comorbidity in MCI (4C-MCI) study 
examines the prognosis of memory clinic patients. For the retrospective study arm, 
data were pooled from the clinical and research record systems of the Alzheimer 
Centre Limburg at Maastricht University Medical Centre and the Amsterdam 
Dementia Cohort from the Alzheimer Centre at the VU University Medical Centre 
in the Netherlands. Inclusion criteria were: age ≥ 55 years, subjective or objective 
cognitive impairment based on neuropsychological assessment, no dementia, 
Clinical Dementia Rating scale score ≤ 0.5 or Global Deterioration Scale score ≤ 3. 
Exclusion criteria were: current diagnosis of normal pressure hydrocephalus, 
Huntington’s disease, Parkinson’s disease, Korsakoff’s syndrome, brain tumor, 
encephalitis or recent cerebrovascular accident. Participants were allowed to take 
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any medication. For the present study we excluded 325 participants with 
incomplete neuropsychological information on relevant tests (see below), yielding 
a sample size of N = 635. Those included tended to be younger, male, better 
educated, to have a baseline diagnosis of SCI instead of MCI, and better 
neuropsychological test performance than those excluded. Both sites contributed 
equally (Maastricht: n=321, Amsterdam: n=314). Maastricht participants tended to 
be younger and less educated. 
 
Clinical assessment at baseline 
At baseline, all participants underwent a standardized assessment: detailed history 
of the subject; psychiatric, neurological, and physical examination; appropriate 
laboratory tests; neuropsychological assessment; computerized tomography or 
magnetic resonance imaging (for differential diagnosis). A clinical consensus 
diagnosis of MCI was made according to standard criteria, i.e. presence of 
significant cognitive impairment on neuropsychological tests, and absence of 
interference with instrumental activities of daily living (using the Blessed 
Dementia Rating Scale (Blessed et al., 1968) Disability Assessment for Dementia 
(Gelinas et al., 1999)) and dementia (Petersen, 2004). Participants referred with a 
psychiatric or neurological disorder (not meeting exclusion criteria) for suspicion 
of primary cognitive deficits were recorded as “psychiatric disorder” or 
“neurological disorder”. In the absence of cognitive impairment and major 
psychiatric or neurological disorders, a diagnosis of subjective cognitive 
impairment (SCI) was made. From the databases, we extracted information on age, 
gender, level of education, baseline diagnosis, and neuropsychological test scores. 
 
Neuropsychological assessment 
Both centers use a standard test battery for diagnostic and research purposes 
(appendix). Episodic memory was assessed with the Rey Verbal Learning Task 
(Lezak et al., 2004, van der Elst et al., 2005). The scores for immediate recall, 
delayed recall (after 20 minutes) and delayed recognition were recorded. 
Information processing speed and executive functions were measured with the 
Trail Making Test (TMT) (Lezak et al., 2004, Schmand et al., 2003) and the Stroop 
Color Word Test (SCWT) (Hammes, 1973). For the latter, an interference index was 
calculated as Card 3 - [(Card 1 + Card 2) / 2] (van der Elst et al., 2006b). The TMT-
A and the average of SCWT cards 1 and 2 were used as measures of information-
processing speed. The difference between TMT-B and TMT-A as well as the SCWT 
interference index were used as a measure of executive functions/inhibitory 
control. For verbal fluency, participants had to name as many animals as possible 
within 60 seconds (Lezak et al., 2004, van Der Elst et al., 2006a). 
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Dementia outcome at follow-up 
The follow-up assessment included a neurological and medical examination and a 
neuropsychological assessment. A diagnosis of dementia and Alzheimer’s disease 
(AD) was made after multidisciplinary consensus using all available information 
by a neurologist or neuropsychiatrist according to the DSM-IV and NINCDS-
ADRDA criteria (APA, 1994; McKhann, Drachman et al. 1984). Frontotemporal 
dementia (FTD) was diagnosed according to the Neary criteria, without further 
distinction between FTD variants (Neary et al., 1998). A diagnosis of vascular 
dementia (VaD) was made according to the NINDS-AIREN criteria (Roman et al., 
1993). A diagnosis of dementia with Lewy-bodies (DLB) followed the guidelines of 
the international DLB consensus group (McKeith et al., 2005). Other, rare forms of 
dementia (e.g. HIV-dementia complex, Creutzfeldt-Jakob disease) were 
summarized under “other dementia”. For the present study, we used information 
on dementia status at last follow-up, date of dementia diagnosis, dementia type, 
and date of death (if available). The mean follow-up time was 3.4 years (median = 
2.4 years), with a range from 0.2 to 14.6 years. During a total of 2187.18 person-
years, 155 incident dementia cases were recorded (annual incidence rate = 7.1%). 
 
Statistical analyses 
LPA (Garrett et al., 2002) was run in Mplus 7 (Múthen & Múthen, Los Angeles). For 
easy comparisons, neuropsychological test scores were centered using the sample’s 
grand mean. Models with increasing numbers of classes were run. Model fit and 
parsimony were compared by adjusted Bayesian Information Criterion (Nylund et 
al., 2007) (BIC; lower is better) and comparing the model with k classes to the 
model with k-1 classes using the Lo-Mendell-Rubin likelihood ratio test (Nylund et 
al., 2007) (LMR LRT). Amount of ambiguity in class allocation was assessed by 
standardized entropy score (scores ≥ .80 are acceptable) (Ramaswamy et al., 1993). 
Cox proportional hazard regression were then run in Stata 12.1 (StataCorp, Texas) 
to test differences in hazard ratios (HR) and their 95% confidence intervals (CI) 
between cognitive classes, adjusted for current age, gender, level of education 
(binned into low, middle high), and study site. Survival time was entered as years 
since birth (in order to adjust for current age (Thiébaut and Bénichou, 2004)), and 
entry into the study (start of risk period) as date of first neuropsychological 
assessment. Observations were censored at date of dementia diagnosis, date of last 
record of neuropsychological assessment or date of death, whatever came first. 
Cox regressions were weighted using the inverse of an individual’s posterior class 
probability. Similarly, comparisons of means and proportions across classes were 
inverse-probability weighted, yielding a design-based F statistic. All tests were 
two-sided with an alpha-level of p < .05. For more details see the appendix.  
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Standard protocol approvals, registrations, and patient consents 
In the Netherlands, the use of anonymized routine data does not require ethical 
approval or written informed consent. 
 
 
RESULTS 
 
The sample characteristics of the 635 participants are shown in Table 1. 
 
 
Table 1 Baseline characteristics of the sample 
 N % 
Total 635 100 
Females 266 41.9 
Education   
   Low 91 14.8 
   Middle 287 46.6 
   High 238 38.6 
   
 Mean SD 
Age, y 67.1 7.2 
Immediate recall, no of words 35.1 9.9 
Delayed recall, no of words 6.0 3.6 
Recognition memory, no of words 13.2 2.3 
Trail Making A, sec 49.5 19.7 
SCWT average cards 1+2, sec 58.7 12.9 
Verbal fluency, no of words 20.1 6.0 
Trail Making B – A, sec 62.0 57.1 
SCWT interference, sec 68.9 38.5 
SCWT = Stroop Color-Word Test. 
 
 
Cognitive profiles 
Model fit and substantive interpretation suggested that five classes represented the 
most parsimonious solution (appendix). Figure 1 and Table 2 show their cognitive 
profiles. Quantitative (i.e. differences in severity of impairment) and qualitative 
differences (i.e. differences in affected domains) between participants became 
apparent. We then compared the mean scores of each class to Dutch norm scores 
(for the mean age and education of that class), and used this and the standardized 
scores (Figure 1) to identify the cognitive domains that differentiated subtypes 
most saliently. Classes 1 (N = 99, 15% of the sample) and 2 (N = 238, 38%) 
consisted of participants with normal cognitive functioning, with the former 
performing superior in terms of immediate and delayed memory recall. In 
contrast, classes 3 (N = 232, 36%), 4 (N = 30, 4%) and 5 (N = 38, 5%) presented with 
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cognitive impairments, albeit with differences in their underlying profile. Classes 3 
and 4 were characterized by prominent impairment in memory recall, but only 
class 4 showed additional deficits in delayed recognition. Participants in class 5 
showed marked deficits in non-memory functions, while memory functioning was 
in between the other classes.  
Based on these profiles, we labeled classes as follows: class 1 = high normal 
cognition (HNC), class 2 = low normal cognition (LNC), class 3 = primary memory 
impairment in recall (MI), class 4 = memory impairment in recall + impairment in 
delayed recognition (MI+), and class 5 = primary non-memory impairment (NMI). 
Table 2 gives the raw cognitive test scores for the latent classes and their 
distribution of baseline diagnoses. HNC mostly consisted of participants 
diagnosed with subjective cognitive impairment. MI and MI+ included relatively 
more participants with MCI, while the LNC class was in-between. In NMI, half 
had a diagnosis of MCI, while the remainders were scattered over the other 
diagnostic groups. 
Dementia risk 
Of the 155 incident dementia cases, only 3 were in HNC (weighted cumulative 
incidence = 2.7%), 37 in LNC (15.1%), 86 in MI (38.8%), 12 in MI+ (39.6%), and 17 in 
NMI (44.9%). We then tested differences in dementia risk using weighted Cox 
proportional hazard regression adjusted for age, gender, level of education and 
study site. Compared to LNC (being the largest class), HNC had a lower risk for 
dementia (HR = 0.24, 95%CI = 0.07 to 0.80, p = .020). In contrast, increased risks 
were observed for MI (HR = 3.05, 95%CI = 2.09 to 4.46, p < .001), MI+ (HR = 3.26, 
95%CI = 1.72 to 6.17, p < .001) and NMI (HR = 5.94, 95%CI = 3.46 to 10.18, p < 
.001). The cumulative hazard function is plotted in Figure 2 and shows largely 
similar curves for MI and MI+. 
Type of dementia 
The distribution of dementia subtypes among classes (Figure 3) further suggested 
aetiological heterogeneity (design-based F = 3.25, d.f. = 17.82, 2744.57, p < .001). 
While all three cases in HNC developed AD dementia, LNC showed a more 
diverse outcome pattern, including a relatively high risk of FTD (proportion 
weighted for participants’ class probability = 26% of cases). MI and MI+ most often 
developed AD dementia (82% versus 73%, respectively), whereas most cases in 
NMI (53%) were diagnosed with non-AD dementia. 
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Figure 1 Neuropsychological profiles of the five latent classes. For easy 
comparisons, raw scores were standardized using the total sample’s grand mean 
(= score of ‘0’) 
 
HNC = High-normal cognition, LNC = Low-normal cognition, MI = Memory impairment in recall,  
MI+ = Memory impairment in recall + recognition, NMI = Non-memory impairment. 
 
 
Figure 2 Cumulative hazard plot of differential associations with dementia risk 
across cognitive subtypes (note that curves for MI and MI+ largely overlap)
HNC = High-normal cognition, LNC = Low-normal cognition, MI = Memory impairment in recall, MI+ 
= Memory impairment in recall + recognition, NMI = Non-memory impairment.  
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Figure 3 Distribution of dementia types within cognitive subgroups. Individual 
bars sum up to the number of total cases within a group, and numbers within 
bars show absolute numbers of cases per dementia type 
 
AD = Alzheimer’s disease, VaD = Vascular dementia, FTD = Frontotemporal dementia, DLB = 
Dementia with Lewy bodies; HNC = High-normal cognition, LNC = Low-normal cognition, MI = 
Memory impairment in recall, MI+ = Memory impairment in recall + recognition, NMI = Non-memory 
impairment. 
 
 
DISCUSSION 
 
This study found five cognitive subtypes among a naturalistic sample of 
consecutive memory clinic patients. Subtypes represented participants with low 
and high normal cognition, participants with primary amnestic deficits with or 
without impairment in long-term memory consolidation, and participants with 
primary non-amnestic impairment. Subtypes displayed differential associations 
with overall dementia risk and types of dementia. Findings show that it is 
inefficient to treat patients’ data as if coming from a single population (e.g. MCI), 
and that failure to take variability into account may dilute associations that exist 
between subpopulations. 
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The cognitive subtypes are largely congruent with an earlier study in a similar 
population (Hanfelt et al., 2011). This study found seven classes among 1,655 MCI 
patients, representing minimal impairment, functional and neuropsychiatric 
features, amnestic impairment with or without functional and neuropsychiatric 
features, amnestic multi-domain with or without functional and neuropsychiatric 
features, and executive dysfunctions with language disorder. The study was 
restricted to participants with MCI, and hence did not include subjective cognitive 
impairment. Another study found four cognitive subtypes among patients with 
AD dementia: mild global impairment, severe global impairment, impairment in 
memory and orientation, and non-memory impairment (Davidson et al., 2010). 
Empirical evidence thus lends support for differentiating between subjective, 
amnestic and non-amnestic impairment. 
The assessed neuropsychological domains that differentiated patient groups with 
low/high dementia risk were memory recall (immediate and delayed), attention 
and executive functions, which is consistent with previous studies (Gauthier et al., 
2006, Tabert et al., 2006). The Alzheimer Disease Neuroimaging Initiative showed 
that the predictive power for dementia conversion increased after adding memory 
recall and TMT B scores to a model that already included measures of structural 
brain changes (Ewers et al., 2012). Another study from that group compared 
cognitive, brain volumetric and cerebrospinal biomarkers, and concluded that 
delayed recall, TMT A and a construction test were strong predictors of dementia 
risk, with scores in delayed recall explaining more variance in the dementia 
outcome than any biomarker (Gomar et al., 2011). 
We observed the highest risk in participants with prominent non-amnestic 
impairment, though this subtype made up a relatively small proportion of all 
participants (6%). It seems unlikely that this group merely represents a more 
advanced disease stage, because memory functions were relatively spared. It 
instead suggests aetiological differences with other subtypes. Indeed, fewer 
participants in the NMI group had a baseline diagnosis of MCI compared to MI 
and MI+. More importantly, more than half of cases were diagnosed with non-AD 
dementia at follow-up, supporting the idea that non-amnestic impairment more 
often evolves into non-AD dementia (Petersen and Morris, 2005). The higher risk 
in NMI compared to MI and MI+ is consistent with the finding that non-memory 
functions predict short-term dementia conversion, whereas memory functions 
predict dementia only in the long run (Sacuiu et al., 2009). Executive dysfunctions 
have been related to small vessel disease and VaD (O'Brien et al., 2003). In patients 
with subcortical VaD, deficits in executive functions are predictive of the severity 
of white matter abnormalities (Price et al., 2005). Hence, one might speculate that 
NMI may display more severe cerebrovascular abnormalities that make them 
convert to non-AD dementia more rapidly than people with memory deficits 
develop AD dementia. 
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In contrast, impairment in recognition memory did not impress as a major taxon 
for differentiating between participants with varying dementia risk, as indicated 
by very similar conversion rates for MI and MI+. Impaired delayed recognition is 
often considered to arise from damage to the hippocampus and entorhinal cortex, 
which in turn predicts MCI-to-dementia conversion (deToledo-Morrell et al., 2004, 
Visser et al., 2002). Yet, delayed recall might relate as strongly to hippocampal 
changes as delayed recognition scores, or even more so (Dos Santos et al., 2011, 
Kerchner et al., 2012). It seems unlikely that the MI and MI+ subtypes represent 
different disease stages as their time-to-dementia would be expected differ. As 
shown in Figure 2, their risk is identical at all time points during the follow-up, 
with neither group consuming their risk more rapidly. Yet, small class sizes led to 
relatively wide confidence intervals, and larger samples would be needed to get 
more precise estimates. 
Another interesting aspect was that differentiation between high and low normal 
cognition, and the higher dementia risk in the latter. We explored potential 
differences post-hoc. There were no differences in education (p = .275), but the 
LNC group was 4.7 years older on average (P < .001) and more often male (p = 
.003, but these aspects did not explain the differences in dementia risk. The LNC 
group performed worse on all cognitive tests compared to the HNC group (all 
p<.001). Since they did not differ on educational level, the groups could represent 
different disease stages with similar premorbid functioning. Alternatively, the 
LNC might represent pathological decline while HNC represents the ‘worried 
well’ without a neuropathological substrate. Intriguingly, the LNC subtype 
comprised a relatively high proportion of FTD cases. This fits with the observation 
that non-cognitive symptoms are more prominent in prodromal FTD than 
cognitive impairment, especially in the behavioral FTD variant (Seelaar et al., 2011). 
We explored whether a diagnosis of FTD in LNC was predicted by baseline 
diagnosis, but there was no case with a referral diagnosis of psychiatric or 
neurological disorder in this subtype. Of the 9 FTD cases, 1 (11%) had a diagnosis 
of SCI, 2 (22%) a diagnosis of MCI, while 6 (67%) had a postponed diagnosis. The 
latter category reflects diagnostic uncertainty. No other major patterns were 
identified by cross-tabulation of referral diagnosis at baseline against dementia 
type at follow-up for each of the remaining latent classes. 
Our findings have implications for designing neuropsychological batteries for 
differentiating cognitive subtypes (e.g. within the MCI construct), and maximizing 
predictive power for dementia conversion. Measures of immediate and delayed 
recall, processing speed and executive functions (TMT B-A, SCWT interference 
index) appear most informative. LPA and related multivariate statistics might help 
finding cognitive endophenotypes for studying disease mechanisms, relations with 
structural and functional brain changes and dementia disease loci and risk alleles 
in genetic association studies. This approach may reveal more informative patterns 
of associations than studying isolated cognitive domains. 
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This study has its own strengths and weaknesses. We used a relatively large 
sample size that allowed for stable solutions in a multivariate framework. We 
included a naturalistic sample of consecutive memory clinic admissions with 
minimal selection criteria. The sample was not restricted to MCI, but included 
subjective impairment and psychiatric/ neurological patients with a (suspected) 
primary cognitive impairment. This follows recent recommendations to include 
these patients in clinical research of cognitive disorders in order to maximize 
generalizability (Steffens et al., 2006). Yet, the reliance on routine data might have 
impacted on data quality. Some neuropsychological domains were not routinely 
assessed including visuospatial functions and language. Whether their inclusion 
would have led to additional subtypes with prognostic value is unclear. We also 
excluded participants with incomplete neuropsychological data. The remaining 
sample showed a relatively high proportion of cognitively normal individuals, and 
therefore they might not mirror the true population prevalence of these subtypes. 
This might have affect precision (95%CIs) of the estimates for a given class. A 
larger sample size would have increased the power of statistical tests. In addition, 
the routine data did not include neuropathological confirmation or collection of 
potential diagnostic biomarkers for dementia diagnosis. 
Finally, fit criteria for the LPA solution were not entirely consistent. The decision 
for five classes was based on the LMR LRT, although the adjusted BIC suggested 
six or even seven classes. The LMR LRT serves as an upper limit in latent 
class/profile analysis as it is more likely to overestimate rather than to 
underestimate the number of classes (Nylund et al., 2007). Solutions with more 
than five classes further tended to result in less meaningful/interpretable 
solutions, and the five-class model was considered to be more parsimonious. 
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SUPPLEMENTARY DATA 
 
Details on neuropsychological assessment 
Both centers use a standard test battery for diagnostic and research purposes. 
Episodic memory was assessed with the Rey Verbal Learning Task (Lezak et al., 
2004, van der Elst et al., 2005). In the Dutch version of this test, participants have to 
reproduce a list of 15 non-related monosyllabic words in five subsequent trials 
(immediate recall). Delayed recall after 20 minutes measures active memory 
retrieval, while delayed recognition measures long-term memory retention. 
Information processing speed and executive functions were measured with the 
Trail Making Test (TMT) and the Stroop Color Word Test (SCWT). The TMT 
consists of two parts. Part A requires participants to connect circles numbered 1 to 
25 in ascending order. In part B, participants have to connect circles by alternating 
between numbers (1 to 13) and letters (A to L), i.e. they go from 1 to A, to 2, to B 
etc. (Lezak et al., 2004, Schmand et al., 2003). The SCWT (Hammes, 1973) had a 10 
rows by 10 columns format with four colors (red, blue, green, yellow) and 
consisted of three conditions: card 1 requires participants to read as fast as possible 
a series of 100 color-names; card 2 requires them to name the colors of the ink in 
which a series of 100 colored bars is printed; card 3 requires them to name the 
colors in which a series of 100 color-names is printed, with there being an 
incongruence between the color and the color-name (e.g. the word “red” printed in 
green color). An interference index was calculated as Card 3 - [(Card 1 + Card 2) / 
2] (van der Elst et al., 2006b). The TMT-A and the average of SCWT cards 1 and 2 
were used as measures of information-processing speed. The difference between 
TMT-B and TMT-A as well as the SCWT interference index were used as a 
measure of executive functions/inhibitory control. For verbal fluency, participants 
had to name as many animals as possible within 60 seconds (Lezak et al., 2004, van 
der Elst et al., 2006a). 
 
Details on statistical analysis 
LPA tests whether the observed distribution of parameters can be described more 
parsimoniously as a mixture of two or more unobserved (i.e. latent) 
subpopulations (Garrett et al., 2002). In contrast to cluster analysis, informative 
model fit indices assist in judging model parsimony, number of classes, and 
uncertainty in class allocation. Different models with increasing numbers of classes 
were run, and model fit and parsimony were compared using the sample size 
adjusted Bayesian Information Criterion (BIC; lower is better) (Nylund et al., 2007). 
In addition, we compared the model with k classes to the model with k-1 classes 
using the Lo-Mendell-Rubin likelihood ratio test (LMR LRT) (Nylund et al., 2007). 
After deciding on the number of latent classes, individuals were allocated to the 
class for which they had the highest posterior probability of belonging. The 
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ambiguity in class allocation is captured by the standardized entropy score, which 
ranges from 0 to 1, with scores ≥ .80 being acceptable (Ramaswamy et al., 1993). 
Data were then exported to Stata 12.1 (StataCorp, Texas). Cox proportional hazard 
regression was used to study differences in hazard ratios (HR) and their 95% 
confidence intervals (CI) across cognitive classes, adjusted for current age, gender, 
level of education (binned into low, middle high), and study site. Survival time 
was entered as years since birth (in order to adjust for current age as opposed to 
baseline age), and entry into the study (start of risk period) as date of first 
neuropsychological assessment (Thiébaut and Bénichou, 2004). All observations 
were censored at date of diagnosis, date of last record of neuropsychological 
assessment or date of death. The proportional hazard assumption was assessed by 
Schoenfeld residuals and inspection of Nelson-Aalen plot. To adequately reflect 
the probabilistic nature of the cognitive subtypes, Cox regressions were weighted 
using the inverse of an individual’s posterior class probability, thereby giving 
relatively more weight to participants with higher certainty of class allocation 
when estimating hazards. For the same reason, comparisons of means and 
proportions across classes were inverse-probability weighted using procedures for 
complex surveys (i.e. Rao-Scott second-order corrections of χ2, yielding a design-
based F statistic and adjusted degrees of freedom). All tests were two-sided with 
an alpha-level of p < .05. 
 
Results from latent profile analysis 
Model fit for the LPA, suggested that five classes fit the data better than four 
classes when judged by the LMR LRT (see supplementary table 1). The adjusted 
BIC suggested further improvement by adding more classes to the model, but 
comparing the 5- and the 6-class solution suggested that the latter model 
essentially broke one of the smaller classes down into two even smaller classes 
(<3% of the sample). We hence decided to accept the more parsimonious 5-class 
solution. The entropy score of 0.86 suggested good certainty in class allocation for 
individual participants. 
 
 
 
 
 
 
 
 
 
PROGRESSION TO DEMENTIA: LATENT PROFILE ANALYSIS 
 
 
 
101 
Supplementary table1 Fit indices for models with different numbers of latent 
classes 
No. of classes adj. BIC LMR LRT Entropy 
1 39399 - - 
2 38464 <0.0001 0.803 
3 38011 0.0112 0.873 
4 37799 0.0290 0.884 
5 37629 0.0013 0.857 
6 37496 0.8075 0.863 
7 37368 0.1025 0.876 
LMR LRT = Lo-Mendell-Rubin likelihood ratio test for comparing non-nested models; adj. BIC = 
sample-size adjusted Bayesian Information Criterion. 
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ABSTRACT  
 
Heterogeneous disease trajectories of mild cognitive impairment (MCI) and 
dementia are frequently encountered in clinical practice but there is still 
insufficient knowledge to understand the reasons and mechanisms causing this 
heterogeneity. In addition to correlates of the disorder (e.g. dementia subtype), 
patient characteristics such as their health status, comorbidities and frailty may 
contribute to heterogeneous trajectories over time. Therefore, two complementary 
longitudinal cohort studies called the Clinical Course of Cognition and Comorbidity in 
Mild Cognitive Impairment (4C-MCI study, n=315) and Dementia (4C-Dementia study, 
n=327) began enrolment in 2009. Participants were prospectively recruited from 
three collaborating Dutch Alzheimer Centers, with three annual follow-up 
assessments after baseline. Extensive neuropsychological assessments, reliable 
diagnoses of the cognitive disorder present and detailed profiling of comorbidities, 
health and frailty at each follow up are the key features of the 4C studies. As such, 
the 4C studies studied the hypothesis that patients’ comorbidities and frailty are 
associated with the course of MCI and dementia measured with a comprehensive 
and multidimensional set of outcomes including cognition, daily functioning, 
quality of life, behavioral disturbances, caregiver burden, institutionalization and 
death. 
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WHY WERE THE COHORTS SET UP? 
 
Dementia is a syndrome of impaired cognitive functioning that interferes with 
living independently. It is a global public health issue with numbers of people 
suffering from dementia estimated to increase from 35.6 million in 2010 to 65.7 
million in 2030, and to 115.4 million in 2050 worldwide (World Health 
Organization, 2012). Mild cognitive impairment (MCI) is a state of impaired 
cognitive performance, which does not significantly interfere with living 
independently. Yet, MCI is a risk factor for developing dementia. Both in MCI and 
dementia, progression over time varies tremendously among patients. Some 
patients with MCI progress precipitately after the diagnosis, whereas a substantial 
proportion of patients do not develop dementia even after a prolonged period of 
up to 10 years (Visser et al. 2006). In the stage of a clinically manifest dementia 
syndrome, studies have shown huge differences in speed of decline over time, 
even within a well-characterized cohort of persons with dementia of the Alzheimer 
type (Leoutsakos et al., 2014). Understanding the causes leading to heterogeneous 
trajectories is essential for healthcare professionals to deliver personalized care and 
to maximally delay the progression of the condition. However, current knowledge 
cannot fully explain the phenotypical heterogeneity present in patients. Part of the 
heterogeneity can be attributed to different aetiological diagnoses, such as 
Alzheimer’s Disease (AD), Vascular Dementia (VaD), Dementia with Lewy Bodies 
(DLB) and Frontotemporal Dementia (FTD). To further increase our understanding 
of the observed heterogeneity, it was hypothesized that dementia may be a multi-
causal, complex and dynamic disorder with involvement of many body 
systems/organs at different levels, rather than a disease with a single pathology 
(Fotuhi et al., 2009). Therefore, the phenotypes may be highly influenced by patient 
profile factors such as the health status of an individual patient (Boyle et al., 2009, 
Buchman et al., 2008, Melis et al., 2013, Leoutsakos et al. 2012), in addition to 
disease characteristics such as the nosological subtype. The majority of patients 
with MCI and dementia are aged, experience different levels of frailty and suffer 
from a considerable number of comorbidities (Marengoni et al., 2009). 
Unfortunately, how these patient characteristics influence the development and 
prognosis of the disorder is largely unknown. Two complementary multicenter 
longitudinal cohorts were launched in the Netherlands in 2009, named the Clinical 
Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia, the 
‘4C-MCI’ and ‘4C-Dementia’ for short, with the following research objectives:  
1. explore heterogeneity in trajectories of progression in multiple outcomes, 
survival and institutionalization in persons with newly diagnosed MCI 
and dementia, for MCI this includes conversion to dementia; 
2. investigate whether comorbidity (number and severity of chronic 
comorbidities and presence of certain comorbidities) and physical frailty 
influence the course and outcome of MCI and dementia; 
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3. develop prediction rules for individual decline in cognition, behavior, and 
daily functioning, institutionalization and death.  
 
 
WHO IS IN THE COHORT? 
 
Included were patients with subjective and/or objective cognitive complaints 
referred to three memory clinics: Alzheimer Center, VU University Medical Center 
Amsterdam (West of the Netherlands), Alzheimer Centre Limburg, Maastricht 
University Medical Center (South of the Netherlands) and Radboud Alzheimer 
Centre, Radboud university medical center (East of the Netherlands). The three 
local ethical committees of the respective centers approved the studies. Patients 
had to be fluent in Dutch, and otherwise meet the inclusion and exclusion criteria 
of the 4C-MCI or 4C-Dementia study to be included. Written informed consent 
was obtained from all the participants and their informal caregivers.  
 
In essence, the 4C–MCI and the 4C–Dementia studies were similar in study design 
and implementation, but were conducted in different disease stages. People with a 
new diagnosis of dementia were included in the 4C-Dementia cohort. Patients who 
had subjective cognitive complaints or objective cognitive impairments based on 
neuropsychological test results but did not fulfill the diagnostic criteria for 
dementia were included in the MCI cohort. As such the inclusion was broader 
than in previous studies on MCI and dementia since comorbidities were allowed, 
thus resulting in a patient sample that was more representative for regular patient 
groups. The eligibility criteria for the 4C–MCI and the 4C–Dementia cohorts are 
shown in table 1. 
 
 
Table 1 Inclusion criteria for the 4C-MCI and 4C-Dementia studies 
 The 4C–MCI cohort The 4C–Dementia cohort 
Cognitive performance subjective and/or objective 
cognitive impairments 
objective cognitive 
impairments 
Fulfil the DSM-IV diagnostic 
criteria for dementia  (American 
Psychiatric Association, 1994) 
No Yes 
Clinical Dementia Rating (CDR) 
Scale (Morris, 1993) 
0–0.5 0.5 – 2 
Mini Mental State Examination 
(MMSE) score (Folstein, Folstein 
& McHugh, 1975) 
Not specified ≥ 10 
Age ≥ 55 years Not specified 
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The exclusion criteria for both cohorts were similar: 
1) The absence of a reliable informant (defined as someone who had contact 
with the participant for at least once a week); 
2) If the participant was expected to be unable to have at least one follow-up 
assessment; 
3) The presence of other neurological disorders that could cause cognitive 
impairment or affect cognitive performance, such as, Parkinson's Disease, 
Huntington’s Disease, Normal Pressure Hydrocephalus (NPH), 
Korsakov’s syndrome, and a medical history of brain tumour, encephalitis 
or epilepsy.  
 
How often have the subjects been followed up? 
The 4C–MCI and 4C–Dementia cohort studies were carried out simultaneously. 
Both cohorts aimed to enrol over 300 participants at baseline, equally from three 
centres. This goal was accomplished in May 2011 for both studies. The participants 
were scheduled to have three annual follow-ups (12, 24, 36 months) after the 
baseline measurement. The flowcharts for both cohorts are shown in Figures 1 and 
2. 
 
What has been measured and how has this changed? 
A multidisciplinary team, consisting of physicians, neuropsychologists and 
research assistants collaborated in the standardized collection of the baseline and 
follow-up data. Data were collected on demographics, syndromal  and aetiological 
diagnosis, cognitive functioning, health conditions, functional abilities, 
neuropsychiatric symptoms, quality of life, and care resource use. An overview of 
the collected data per measurement is presented in table 2. 
 
1. Syndromal diagnosis of MCI and dementia 
Syndromal diagnoses were made at baseline and reviewed and updated at every 
follow-up visit. The diagnosis of MCI was based on Petersen criteria (Petersen et 
al., 1999) and was operationalized as a z-score lower than -1.5 SD (compared to 
Dutch norms) on any of the cognitive tests (see below). Subjects with cognitive 
complaints without verified impairment on cognitive tests were categorized as 
subjective cognitive decline (SCD). The diagnosis of dementia was based on DSM-
IV criteria (American Psychiatric Association, 1994). Aetiological dementia 
diagnoses were made according to standardized clinical criteria for AD (NINCDS-
ADRDA criteria,(McKhann et al., 1984)), vascular dementia (NINDS-AIREN 
criteria, (Roman et al., 1993)), frontotemporal dementia (Neary et al., 1998), and 
Lewy body dementia (McKeith et al., 1996).  
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Figure 1 Flowchart of the 4C–MCI cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMS = Amsterdam; MAA = Maastricht; Nij = Nijmegen; CRF = case record form. 
 
 
 
 
 
 
3-Year follow-up 
Mar 2013 – Sep 2014 
211 complete CRF  
AMS 70, MAA 81, 
NIJ 60  
 
32 No 3-year follow-up 
- 9 refusal 
- 8 deceased 
- 1 institutionalized 
- 0 too ill 
- 3 untraceable 
- 11 other reasons 
 
25 telephone interviews 
(Minimal but essential 
info) 
AMS 7, MAA 10, NIJ 8 
37 No 1-year follow-up 
-  10 refusal 
-  8 deceased 
-  1 institutionalized 
-  5 too ill 
-  1 untraceable  
-  12 other reasons 
 
1-Year follow-up 
Jan 2011 – Sep 2012 
248 complete CRF  
AMS 91, MAA 87, 
NIJ 70  
30 telephone interviews 
(Minimal but essential 
info) 
AMS 5, MAA 19, NIJ 6 
33 No 2-year follow-up 
- 8 refusal 
- 0 deceased 
- 12 institutionalized 
- 3 too ill 
- 0 untraceable  
- 10 other reasons 
 
2-Year follow-up 
Feb 2012 – Sep 2013 
225 complete CRF  
AMS 82, MAA 72, 
NIJ 71  
 
35 telephone interviews 
(Minimal but essential 
info) 
AMS 9, MAA 25, NIJ 1 
Baseline recruitment (4C-MCI) 
Dec 2009 – May 2011 
N=315, MAA 118, AMS 99, NIJ 98 
15 Back  !
8 Back 
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Figure 2 Flowchart of the 4C–Dementia cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMS = Amsterdam; MAA = Maastricht; Nij = Nijmegen, CRF = case record form.  
 
 
 
 
 
55 No 1-year follow-up 
-  13 refusal 
-  22 deceased 
-  2 institutionalized 
-  5 too ill 
-  5 untraceable  
-  8 other reasons 
 
52 No 2-year follow-up 
- 9 refusal 
- 29 deceased 
- 5 institutionalized 
- 1 too ill 
- 1 untraceable  
- 7 other reasons 
 
2-Year follow-up 
Mar 2012 – Sep 2013 
155 complete CRF  
AMS 71, MAA 31, 
NIJ 53  
 
60 telephone interviews 
(Minimal but essential 
info) 
AMS 23, MAA 37, NIJ 0 
3-Year follow-up 
Mar 2013 – Sep 2014 
140 complete CRF  
AMS 55, MAA 48, 
NIJ 37  
 
37 No 3-year follow-up 
- 9 refusal 
- 21 deceased 
- 3 institutionalized 
- 0 too ill 
- 1 untraceable 
- 3 other reasons 
 
27 telephone interviews 
(Minimal but essential 
info) 
AMS 11, MAA 11, NIJ 5 
48 Back  
 
49 Back  
 
Baseline recruitment (4C-Dementia) 
Feb 2010 – May 2011 
N=327, AMS 112, MAA 112, NIJ 103 
1-Year follow-up 
Feb 2011 – Dec 2012 
219 complete CRF  
AMS 99, MAA 60, 
NIJ 60  
53 telephone interviews 
(Minimal but essential 
info) 
AMS 11, MAA 30, NIJ 12 
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Table 2 Contents of data collection in the 4C studies 
 Baseline 12 
months 
24 
months 
36 
months 
Informed consent √    
Demographics √ √ √ √ 
Subjective cognitive functions √ √ √ √ 
MMSE √ √ √ √ 
CDR √ √ √ √ 
Subjective cognitive functioning √ √ √ √ 
Neuropsychological assessment √ √ √ √ 
Physical examination & structural 
medical review 
√ √ √ √ 
Medications (prescribed & taken) √ √ √ √ 
Hospitalization (if any)  √ √ √ 
Syndromal diagnoses √ √ √ √ 
Comorbidities (CIRS-G) √ √ √ √ 
Frailty (Fried criteria + Frailty index) √ √ √ √ 
DAD (disability assessment) √ √ √ √ 
GDS-15 (depression, self-reported) √ √ √ √ 
NPI (neuropsychiatric symptoms) √ √ √ √ 
Euroqol 5D √ √ √ √ 
Care resource use √ √ √ √ 
Refusal or withdrawal data  √ √ √ 
Institutionalization (outcome & date)  √ √ √ 
Death (outcome & date)  √ √ √ 
MMSE = Mini Mental State Examination; CDR = Clinical Dementia Rating scale; CIRS-G= 
Cumulative Illness Rating Scale for Geriatrics; DAD = Disability Assessment for Dementia;   
GDS-15 = Geriatric Depression Scale; NPI = Neuropsychiatric Inventory.  
 
 
2. Cognitive performance and neuropsychological assessment 
Cognitive performance in the 4C studies was evaluated by subjective rating and an 
extensive neuropsychological assessment.   
 
2.1 Subjective cognitive symptoms  
Data about the self-reported start (gradual or sudden), course (stable, fluctuated or 
progressively deteriorated) and duration of the cognitive complaints were 
collected. In addition, patients were asked whether they had noticed a change in 
four cognitive functions (memory, concentration, mental capacity, and vitality) 
during the last year (Aalten et al., 2014). Change in each function was scored on a 
7-point Likert scale ranging from -3 (very strong decline) to +3 (very strong 
improvement). If the participant was unable to answer by himself, the caregiver 
rated the changes based on daily contact and observation.  
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2.2 Objective cognitive assessment 
The neuropsychological assessment consisted of the same standardized battery of 
cognitive tests as used in the Dutch Parelsnoer Institute study (www.string-of-
pearls.org), covering the following domains: global cognition, episodic memory, 
implicit visual learning, working memory, word fluency, information processing 
speed, attention, executive functioning and visual perception (table 3).  
 
 
Table 3 Standardized cognitive tests and the corresponding domains 
Neuropsychological tests Cognitive domain(s) 
Mini Mental State Examination (MMSE) 
(Folstein et al., 1975, Kok and Verhey, 2002)  
 
Global cognition 
15-Word Verbal Learning Test (VLT) 
(Brand and Jolles, 1985, Van der Elst et al., 
2005) immediate recall (5 trails), delayed 
recall and delayed recognition 
 
Episodic memory 
Visual Association Test (VAT), short 
version (Lindeboom et al., 2002) 
 
Implicit associative visual learning 
Digit Span subtest (forwards and 
backwards) of the Wechsler Adult 
Intelligence Test (3rd Edition) (Wechsler, 
1997)  
 
Working memory 
60 seconds animal fluency (Lezak, 2004) 
 
Verbal word fluency / semantic memory 
Letter Digit Substitution Test (LDST) (van 
der Elst et al., 2006a) 
 
Information processing speed 
Stroop Color Word Test (SCWT, 3 subtasks) 
(Hammes, 1973, Stroop, 1992, Van der Elst 
et al., 2006b) 
 
Information processing speed, attention 
and executive functioning / response 
inhibition 
Trail Making Test (TMT) parts A & B 
(Reitan, 1958, Tombaugh, 2004)  
 
Information processing speed, attention 
and executive functioning / concept 
shifting 
Visual Object and Space Perception battery 
(VOSP, Optional) (Warrington and James, 
1991)..  Dot counting and incomplete letters 
subtests 
Visual perception 
 
Foltein et al., 1975) (Ko 
k and Verhey, 2002) (Brand and Jolles, 1985)  
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3.Health conditions & functional abilities  
3.1 Physical examination and structural medical review  
Height, weight, waist circumference, averaged systolic and diastolic blood 
pressure of the participants were recorded. Smoking and drinking status, the type, 
quantity and frequency of tobacco and alcohol consumption were asked. The 
physician structurally reviewed the patient’s personal medical history at baseline, 
and particularly queried extrapyramidal symptoms, gait disturbances, and family 
history of dementia and Parkinson’s disease. Newly diagnosed diseases were 
updated at every follow-up visit, also recording any taken medication and each 
hospitalization (supplementary table 1).  
 
3.2 Comorbidity  
The presence of the chronic conditions hypertension, heart failure, obesity, 
delirium, COPD, and renal failure was checked and, if present, the disease 
duration and the stages of heart failure (NYHA) (Dolgin, 1994) COPD (GOLD) 
(Global Initiative for Chronic Obstructive Lung Disease, 2014) and renal failure 
(K/DOQI) (National Kidney Foundation, 2002) were recorded.  
 
The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) (Miller et al., 1992) was 
used to quantitatively measure the disease burden and reflects the number and 
severity of the diseases. Using the CIRS-G, all diseases were classified into 14 
organ systems: cardiac (heart only), vascular, hematologic, respiratory, 
ophthalmologic and otorhinolaryngologic, upper gastrointestinal, lower 
gastrointestinal, hepatic and pancreatic, renal, genitourinary, musculoskeletal and 
tegumental, neurologic, endocrine/metabolic and breast, and psychiatric. If a 
patient had multiple diseases in a single category, the most severe one was 
appraised. The severity of impairment was rated with a 0–4 grading scale from no 
problem to extremely severe problems  (e.g. organ failure) resulting in a total score 
ranging from 0 – 56. The CIRS-G can be adapted as a measure of pure physical 
functioning in the 4C studies by excluding the psychiatric category, since this 
category includes cognition related comorbidities. The total score than runs from 0 
to 52.  
 
3.3 Frailty 
Frailty was operationalized using the widely accepted five physical criteria 
developed by Fried et al. (2001): A frailty index based on accumulated deficits can 
be operationalized from the 4C data (Searle et al., 2008).  
 
4. Functional abilities 
The Disability Assessment for Dementia (DAD) scale (Gelinas et al., 1999), 
measuring both basic and instrumental activities of daily living (ADL, IADL), was 
used to evaluate the severity of impairment in everyday functioning through a 
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structured interview with the caregiver. The participant’s abilities to perform ten 
different (I)ADL activities in the 2 weeks prior to the visit were rated. The final 
DAD score was converted to a percentage from 0 to 100, in which a higher 
percentage indicates a higher level of daily functioning.   
 
5. Neuropsychiatric symptoms 
Neuropsychiatric symptoms are common in MCI and dementia and may cause 
emotional burden and distress to the caregiver. Further, they are one of the 
principal determinants of institutionalization. The 4C studies used the Geriatric 
Depression Scale (GDS-15) (Sheikh and Yesavage, 1986) to assess the presence and 
severity of depressive symptom in older patients. The Neuropsychiatric Inventory 
(NPI) (Cummings, 1997) was used to characterize the psychopathology of the 
patient through a structured interview with the caregiver, assessing 12 common 
neuropsychiatric symptoms. A screening question for each neuropsychiatric 
symptom was asked to confirm the presence of the symptom before rating the 
frequency (1–4, rarely–very often) and severity (1–3, mild–severe) and caregiver 
burden (0–5, not at all–very severely/extremely). The total NPI score ranged from 
1 to 144.  
 
6.Quality of life 
The EQ-5D (EuroQol-group, 1990), was used to measure health-related quality of 
life and results in a score from 0 – 100, where higher scores indicate better 
functioning. The EQ-5D was rated by the patient and by the caregiver: for the 
situation of the patient and for the caregiver him-/herself.  
 
7.Care resource use  
Besides patient and disease related data, also data about the patient’s care resource 
use was investigated by assessing the number of visits to the general practitioner, 
home care, day care, institutionalized care, hospital in- and outpatient, emergency 
care, other professionals, informal care, medical goods, and out-of-pocket 
expenditures. 
 
8.Refusal or withdrawal, minimum but essential data collected for research  
The reasons for dropout were collected and categorized. The attrition is shown in 
the flowchart of Figures 1–2.  With their consent, the study investigators made 
efforts to collect minimal but essential data for research through a telephone 
interview with the participant (or caregiver) who wanted to discontinue their full 
participation. Researchers asked about the course of cognitive symptoms, 
functional abilities in (i)ADLs (any help or assistance needed in certain activities), 
and global severity of dementia (CDR). If the participant had received a diagnosis 
of MCI or dementia from another physician, the syndromal diagnosis was 
documented. Despite refusal to participate in a particular follow-up, some patients 
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agreed to be approached at the next follow-up and did return to fully participate in 
the studies, as shown in Figures 1–2.  
 
9.Changes of study protocol and implementation 
Some changes to the original research protocol were made for better 
implementation and completion of the studies. Based on the experiences during 
the baseline interview, an evaluation of the reliability of information provided by 
the participant and the caregiver was added to the follow-up assessments.  
 
By default, the assessments were carried out in the memory clinics. However, for 
some participants, it was inconvenient to visit the memory clinic due to immobility 
or other physical conditions. Where possible, home visits (to the patient’s house or 
nursing home) were implemented in the follow-ups, carried out by a well-trained 
researcher, to limit attrition.  
 
 
WHAT HAS BEEN FOUND? KEY FINDINGS AND PUBLICATIONS 
 
Sample characteristics and differences 
In the MCI and dementia cohort, 315 and 327 participants were included 
respectively. Noticeably, more men than women were recruited in the MCI cohort, 
consistently across the three centers, whereas more women were recruited in the 
Dementia cohort, except in Amsterdam (table 4). Participants in the MCI cohort 
were on average 5.2 years younger, had better cognitive performance, functional 
abilities, physical condition and quality of life. However, they also had higher 
depression scores than those in the Dementia cohort at baseline (Table 5). Due to 
different geographical locations and the different medical specialty (neurology, 
psychiatry and geriatrics) of the departments hosting the three memory clinics, 
there may be a center effect within each cohort, which will be accommodated in 
the analyses.  
 
Cognition  
The majority of the participants experienced a progressive cognitive decline in the 
phase before the baseline diagnosis, namely 67.6% in the MCI cohort, and 85.9% in 
the Dementia cohort, starting at about 3–3.5 years on average before entering in 
either cohort. Episodic memory was the most severely impaired cognitive domain 
among MCI patients, whereas among dementia patients, multiple cognitive 
functions were severely impaired (with a 4C dementia cohort average of less than  
-1.5 SD worse than the Dutch norm), especially executive functioning, attention 
and information processing speed.  
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Table 4 Baseline demographic characteristics of the participants in the 4C–MCI 
and 4C–Dementia cohorts 
 4C-MCI cohort 4C-Dementia 
cohort 
N 315 327 
Age at baseline (years, mean ± SD) 69.8 ± 8.7 75.0 ± 10.1 
Female sex 111 (35.2) 179 (54.7) 
Caucasian 311 (98.7) 323(98.8) 
Education  9 (2.8) unreported 
    Low (lower than middle school) 126 (40.0) 140 (42.8) 
    Middle (high school / vocational education) 78 (24.8) 88 (26.9) 
    High (university) 111 (35.2) 90 (27.5) 
BMI (mean ± SD) 26.2 ± 3.9 25.9 ± 4.2 
Marital Status   
    Married/registered partnership, cohabiting 244 (77.5) 199 (60.9) 
    Widow/widower 42 (13.3) 92 (28.1) 
    Single, divorced 29 (9.2) 31 (9.5) 
    Others 0  5 (1.5) 
Living situation  1 (0.3) unreported 
    Alone, independently 59 (18.7) 87 (26.6) 
    With partner and/or children 242 (76.8) 202 (61.8) 
    In nursing home (institutionalized) 9 (2.9) 21 (6.4) 
    Others 5 (1.6) 16 (4.9) 
Caregiver’s relation with the participant 1 (0.3) unreported 2 (0.6) unreported 
Partner 224 (71.1) 168 (51.4) 
Son/daughter 60 (19.5) 110 (33.6) 
Brother/sister 7 (2.2) 10 (3.1) 
Other relatives or acquaintance 23 (7.3) 37 (10.3) 
All the data represent N (%), unless otherwise specified. BMI = Body Mass Index.  
 
 
Comorbidities and physical conditions 
Hypertension was highly prevalent in dementia patients (50.5%) at baseline. The 
prevalences of other comorbidities were similar in both cohorts: diabetes mellitus 
(17%), COPD (8%), and kidney problems (8%). By quantitative measures of disease 
burden (CIRS-G), vascular diseases were the most frequently  and severely 
affected comorbid category in both cohorts. For the AD patients in the dementia 
cohort, it was found that comorbidities were associated with cognitive 
performance; frailty was associated with functional abilities at baseline 
(Oosterveld et al., 2014).   
 
Neuropsychiatric symptoms 
The most prevalent neuropsychiatric symptoms reported by the caregivers in the 
MCI cohort were irritability (50.5%, average score 5.4 out of 12 in NPI), 
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apathy/indifference (42.5%, 5.3) and depression/dysphoria (40.6%, 4.7). These 
neuropsychiatric symptoms were also the most common in the dementia cohort, 
with different rankings: apathy/indifference (50.5%, 6.5), depression/dysphoria 
(37.6%, 5.3), irritability (35.5%, 5.3).  
 
 
Table 5 Baseline cognitive, physical and functional characteristics and quality of 
life of the participants in the 4C studies 
 The 4C-MCI 
cohort 
The 4C-Dementia 
cohort 
Duration of cognitive problems (range) 3.3 ± 3.8 (0~32) 3.1 ± 2.6 (0~18) 
Course of cognitive problems, N (%)   
   Unreported     
Progressive 
29 (9.2) 
213 (67.6) 
18 (5.5) 
281 (85.9) 
Stable 40 (12.7) 14 (4.3) 
   Fluctuated 33 (10.5) 14 (4.3) 
MMSE  26.9 ± 2.6 21.9 ± 3.7 
Cognitive tests (Z-score)*    
    VLT immediate -1.1 ± 1.2 -2.3 ± 1.1 
    VLT delayed -1.2 ± 1.3 -2.4 ± 0.9 
    Animal fluency -0.7 ± 0.8 -1.7 ± 0.9 
    TMT-A -0.3 ± 1.4 -1.7 ± 1.9 
    TMT-B -0.4 ± 1.3 -1.5 ± 1.7 
    Stroop card 1 + 2 (mean) -1.2 ± 1.7 -2.8 ± 2.5 
    Stroop card 3 -1.2 ± 2.4 -3.8 ± 3.8 
GDS-15   3.6 ± 2.8 3.2 ± 2.7 
NPI total score 14.5 ± 15.0 16.4 ± 16.4 
CIRS-G total score (range)  7.09 ± 4.87 (0~23) 9.07 ± 4.68 (1~25) 
CIRS-G severity index 0.55 ± 0.37 0.58 ± 0.38 
CIRS-G comorbidity index (range) 2.25 ± 1.93 (0~8) 3.08 ± 1.84 (0~9) 
DAD  86.74 ± 15.70 70.36 ± 24.65 
Frailty, N (%)    
    insufficient information 22 (7.0) 17 (5.2) 
    Not frail (≤1) 219 (69.5) 215 (65.7) 
    Pre-frail (2) 44 (14.0) 49 (15.0) 
    Frail (≥3) 30 (9.5) 46 (14.1) 
EQ-5D VAS  69.35 ± 15.63 67.26 ± 17.79 
All the data are presented as mean (SD) unless otherwise specified. MMSE = Mini Mental State 
Examination; VLT = Verbal Learning Test; TMT-A = Trailmaking Test part A; TMT-B = Trailmaking 
Test part B; SCWT = Stroop Colour Word Test; GDS-15 = Geriatric Depression Scale; NPI = 
Neuropsychiatric Inventory; CIRS-G = Cumulative Illness Rating Scale for Geriatrics; DAD = Disability 
Assessment for Dementia;  EQ-5D = Euroqol 5D;  
* Despite the application of the Petersen criteria for definition of MCI, mean cognitive scores on the 
different domains may be above -1.5 sd of the Dutch norm scores, because people with SCD were 
included in the 4C MCI cohort, but do not satisfy the MCI criteria, also MCI patients were not required 
to score below -1.5 sd on all domains assessed.  
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Disease trajectories and progression 
In the MCI cohort, 225 subjects (71%) were classified as MCI at baseline and 90 
subjects (29%) as SCI, based on the cognitive test results. After 3 follow-ups, 23 
subjects (23/90, 26%) classified as SCI at baseline were reclassified as MCI, 23 
subjects (23/225, 10%) with MCI reverted to SCI, and 74 subjects (10 subjects with 
SCI at baseline and 64 subjects with MCI at baseline) progressed to different types 
of dementia (supplementary table 2). The annual incidence of MCI subjects 
progressing to dementia was 11% (32/278) in the first year, 7% (18/260) in the 
second year and 10% (24/236) in the third year of follow up. In the dementia 
cohort, 58 patients (18%) received a different nosological diagnosis of dementia 
during follow-up. 16 patients (5%) in the MCI cohort and 72 (22%) in the Dementia 
cohort died during follow-up. 
 
What are the main strengths and weaknesses? 
One of the main research questions for the 4C studies was whether the interaction 
with health status would influence the natural disease course of MCI and 
dementia and would contribute to the heterogeneity of clinical outcomes. Thus, 
including participants with comorbidity in the study – rather than excluding them, 
which is regularly done in MCI and dementia research – while assessing the 
disease burden was the essential strength of our studies. 
Prospectively sampling diverse participants with natural disease courses from 
various routine clinical settings (neurology, geriatrics and psychiatry departments) 
who were representative for the MCI and dementia patients regularly seen in 
memory clinics was another strength. Finally, cognitive functioning is a central 
feature of MCI and dementia. In the 4C studies, in addition to global measures of 
cognition, standardized and validated neuropsychological tests were available to 
detail how different cognitive domains changed and to explore the effect of 
comorbidities on cognitive functioning in different domains over time.  !
Although separated into two cohorts by disease phases, the 4C-MCI and 4C-
Dementia cohorts were the same in essence, with comparable research objectives. 
Discerning typical disease trajectories based on long-term observation and 
developing prediction models for disease progression would be beneficial for 
patient care. However, for FTD, DLB or other rarer types of dementia, due to 
limited cases, more efforts should be made to include more patients in future 
studies to increase the power or combining the current samples with other studies. 
 
Attrition was the biggest challenge for the 4C studies, although it is inevitable due 
to the nature of the disease and the aged population. In the MCI cohort, 227 of 315 
(72%) participants completed either the entire follow up (211; 67%) or reached the 
endpoint of death (16; 5%). In the Dementia cohort, 212 of 327 (65%) participants 
completed either the follow up (140; 43%) or reached the endpoint of death (72; 
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22%). In order to minimize the dropout rate and collect as much research data as 
possible, whenever possible home visits by a well-trained researcher to the 
participant’s residence or nursing home were implemented, for those participants 
who were willing to continue participation in the study but unable to visit the 
memory clinics. 
 
Can I get hold of the data? Where can I find out more? 
The 4C research group actively encourages and welcomes external collaborations. 
Data is available for researchers with a specific research question. Interested and 
potential collaborators are invited to contact the study coordinators (Dr. René 
Melis: Rene.Melis@radboudumc.nl or Dr. Inez Ramakers: 
i.ramakers@maastrichtuniversity.nl).  
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SUPPLEMENTARY DATA 
 
Supplementary Table 1 Structural medical review of participant’s health 
conditions 
Body systems Concerned diseases 
Cardiovascular angina, myocardial infarction, angioplasty/stent, coronary bypass 
surgery, carotid stenosis, hypertension, heart failure, others 
Cerebrovascular transient ischemic attack (TIA), cerebrovascular accidents (infarction, 
bleeding), reversible ischemic neurologic deficit (RIND), others 
Endocrinal diabetes mellitus, hypothyroidism, hyperthyroidism, obesity, others 
Psychiatric 
Somatic 
depression, psychosis, delirium, others 
chronic obstructive pulmonary disease (COPD), kidney problems, 
liver problems, others 
 
 
Supplementary Table 2 Incidence of MCI subjects progressing to dementia 
within the study duration 
Study time line 
Number of subjects 
% MCI – dementia In the cohort 
1 year follow-up 32 278 11.5 
2 year follow-up 18 260 6.9 
3 year follow-up 24 236 10.1 
Total 74 315 23.4 
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ABSTRACT 
 
Background 
Specific medical diseases are known to influence cognitive functioning and 
decline. However, most studies focus on a single risk factor and do not take 
multimorbidity into account. Therefore, the aim of this study was to investigate the 
effect of severity of total comorbidity on cognitive decline and conversion to 
dementia in memory clinic visitors. 
 
Methods 
This prospective cohort study is part of the Dutch Clinical Course of Cognition and 
Comorbidity in MCI (4C-MCI) Study and consists of 315 consecutive non-
demented patients who visited the Alzheimer centers of Maastricht, Nijmegen and 
VUmc Amsterdam. Patients were followed annually for three years. Severity of 
comorbidity was rated using the Cumulative Illness Rating Scale for Geriatrics 
(CIRS-G). Random-effects mixed models were performed to investigate the 
influence of comorbidity on cognitive decline for the domains of episodic memory, 
executive functioning, verbal fluency and information processing speed. Time to 
dementia was assessed using Cox proportional hazard models.  
 
Results 
Patients were on average 69.6 years old, 34.8% was male. More severe comorbidity 
was associated with lower performance on information processing speed and 
executive functioning at baseline. Further, patients with moderate/severe 
comorbidity showed a significant decline on information processing speed and 
verbal fluency, while patients with less comorbidity remained generally stable. 
However, severity of comorbidity was not associated with a higher risk of 
conversion to dementia after three years.  
 
Conclusion 
The severity of total comorbidity is associated with lower performance and faster 
decline on mental speed dependent tests, and should thus be taken into account 
when evaluating cognitive performance in clinical practice. However, severity of 
comorbidity is not associated with a higher risk of conversion to dementia. 
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INTRODUCTION 
 
The increasing prevalence of dementia poses a major challenge for society and 
health care systems, and therefore creates an urgent need for early diagnosis to 
initiate timely care and treatment. People with Mild Cognitive Impairment (MCI), 
which is known as the transitional state between normal cognitive functioning and 
dementia, are at increased risk for developing dementia. However, due to 
differences in the underlying cause of the impairment, MCI is a heterogeneous 
concept, with large individual differences in course and prognosis.  
This variation in the natural course of decline in MCI might be affected by medical 
illnesses, which are known to influence cognitive functioning and decline. 
Multiple medical diseases, but especially (cardio)vascular factors have been related 
to cognitive impairment and/or (more rapid) cognitive decline in the cognitively 
healthy population (Aleman et al., 2005, Arntzen et al., 2011, Lipnicki et al., 2013, 
Spauwen et al., 2013, van Boxtel et al., 1997). These (cardio)vascular factors have 
also been related to worse cognitive performance and cognitive decline in people 
with MCI (Ettorre et al., 2012, Siuda et al., 2007, Villeneuve et al., 2009) and were 
associated with an increased risk of developing dementia (Akomolafe et al., 2006, 
Mielke et al., 2007, Solfrizzi et al., 2004).  
Unfortunately, most studies tend to focus on one specific disease or a specific 
cluster of diseases (e.g. cardiovascular factors), thereby ignoring the increased 
burden of multimorbidity that is typically associated with advancing age (Uijen 
and van de Lisdonk, 2008). Few studies have examined the impact of multiple 
comorbid diseases on cognitive functioning. These studies showed that cumulative 
medical illness is related to worse cognitive performance (Morrow et al., 2009) and 
cognitive decline in the elderly population (Patrick et al., 2002). Further, total 
comorbidity burden has also been related to worse cognitive performance and 
cognitive decline in people with dementia (Doraiswamy et al., 2002, Oosterveld et 
al., 2014, Solomon et al., 2011).   
Summarizing, there is evidence that certain medical diseases are associated with 
cognitive decline and conversion to dementia. However, most studies remain 
inconclusive in identifying all medical risk factors and do not take multimorbidity 
into account. Therefore, the aim of this study was to evaluate the effect of the 
severity of total medical comorbidity on cognitive decline and conversion to 
dementia within 3-years in memory clinic visitors.  
 
 
METHODS 
 
Data from the Clinical Course of Cognition and Comorbidity in MCI (4C-MCI) 
study was used. The prospective 4C-MCI study is a longitudinal multicenter study 
into the course of cognitive decline in non-demented memory clinic visitors. 
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Participants for the present study were included from the memory clinics of 
Maastricht University Medical Centre, Radboud university medical centre and VU 
Medical Centre Amsterdam between January 2010 and May 2011. Participants 
were followed annually for three years. The local Medical Ethical Committee of 
each centre approved the study. All participants provided written informed 
consent.  
 
Participants 
The study included 315 patients at baseline who were classified as having either 
objectified cognitive impairment (MCI) or no objectified cognitive impairment 
(SCI), based on neuropsychological test results. Inclusion criteria were: 1) age ≥  55 
years, 2) the presence of subjective cognitive complaints and/or objective 
impairments, in absence of dementia, and 3) a Clinical Dementia Rating (CDR) 
(Morris, 1993) score of ≤  0.5. Exclusion criteria were: 1) the absence of a primary 
caregiver (who has contact with the participant at least once a week), 2) the 
expectation that the participant would not be able to have at least one follow-up, 
and 3) presence of specific neurological disorders that could have caused cognitive 
impairment: Parkinson’s or Huntington’s disease, Normal Pressure 
Hydrocephalus, Korsakoff’s syndrome, and a medical history of brain tumor or 
encephalitis. Participants having any other comorbidities, including 
cerebrovascular or psychiatric disorders were not excluded in this study.  
 
Baseline assessment  
At baseline, all patients underwent a standardized clinical assessment, which 
included a detailed (medical) history of the patient, a psychiatric, neurologic and 
physical examination, assessments of daily functioning, appropriate laboratory 
tests, an extensive neuropsychological assessment (see below) and a magnetic 
resonance imaging (MRI) scan. These assessments were part of the regular patient 
diagnostic procedures of the memory clinics. Baseline diagnosis of MCI was 
defined as a z-score lower than -1.5 SD on any neuropsychological test. All other 
subjects were classified as having SCI. For the current study we extracted data on 
age, gender, level of education, study centre, medical comorbidity, 
neuropsychological test scores at baseline and follow-up, dementia status at 
follow-up and date of dementia diagnosis.  
 
Assessment of medical comorbidity 
All available information on comorbidity from the medical history, data on 
medication use, smoking habits and alcohol usage and information from the 
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physical examination was summarized and scored using the Cumulative Illness 
Rating Scale for geriatrics (CIRS-G) (Miller et al., 1992). Scores between zero (no 
problems) and four (extremely severe problems) were given to 14 categories of 
organ systems (i.e. heart; vascular; hematopoietic; respiratory; eyes, ears, nose, 
throat and larynx; upper gastrointestinal tract; lower gastrointestinal tract; liver; 
renal; genito-urinary; musculoskeletal; neurological, endocrine/metabolic and 
breast; psychiatric). For this study an adapted version of the CIRS-G was used, 
excluding the psychiatric illness category since this category includes psychiatric 
and cognition related comorbidities. By excluding the psychiatric category the 
CIRS-G was used as a measure of pure physical comorbidity, thus avoiding 
overlap with cognitive functioning. The possible total score of this adapted version 
varies from 0 to 52. In addition to the total score, the CIRS-G severity index was 
calculated by dividing the CIRS-G total score by the number of categories 
endorsed. This severity index reflects a more precise estimate of the general 
severity of comorbidity than the CIRS total score, since it allows us to see whether 
the CIRS total score reflects a few serious problems or multiple problems of mild 
severity. The severity index can range between 0 and 4. 
 
Neuropsychological assessment 
The neuropsychological assessment investigated the following cognitive domains: 
episodic memory, information processing speed, executive functioning and verbal 
fluency. Episodic memory was assessed by means of the Dutch adaptation of the 
Verbal Learning Task (VLT) (Lezak et al., 2004, Van der Elst et al., 2005). The score 
at the delayed recall trial was chosen as measure of episodic memory. Information 
processing speed and executive functioning were measured with the Stroop 
Colour Word Test (SCWT) (Hammes, 1973) and Trail Making Test (TMT) (Lezak et 
al., 2004, Schmand et al., 2003). The average of SCWT cards 1 and 2 (SCWT 1 – 2 ) 
was used as a measure of information processing speed, as was TMT part A.  An 
interference index from the SCWT, calculated as Card 3 – [(Card 1 + Card 2) / 2] 
(Van der Elst et al., 2006c), as well as TMT part B were used to measure executive 
functioning. For assessing verbal fluency, a one-minute animal fluency test was 
used (Van der Elst et al., 2006b). All neuropsychological test scores were converted 
to z-scores adjusted for age, sex and education, based on norms for the Dutch 
healthy population (Schmand et al., 2003, Van der Elst et al., 2005, 2006a, b, c). 
 
Follow-up assessment  
Follow-up assessments were conducted annually, for a total of three years. 
Assessments at follow-up were comparable to baseline, except for medical history. 
At follow-up participants and caregivers were asked if there had been any medical 
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changes since baseline (e.g. a new medical diagnosis), if the participant had been 
admitted to the hospital during that year, and if there had been made any 
medication changes. Diagnosis of dementia at follow-up was made according to 
the DSM-IV criteria (American Psychiatric Association, 2000). Alzheimer’s disease 
was diagnosed according to NINCDS-ADRDA criteria (McKhann et al., 1984), 
vascular dementia according to NINCDS-AIREN criteria (Roman et al., 1993), 
Lewy Body dementia according to the McKeith criteria (McKeith et al., 2005) and 
frontotemporal dementia according to the Neary criteria (Neary et al., 1998). 
 
Statistical analyses 
Analyses were performed using STATA version 12 for Mac OS X. Significance was 
set at p < 0.05 in two-sided tests. Baseline differences between diagnostic groups 
were compared using t-tests for continuous variables and chi-square tests for 
categorical variables. 
For medical comorbidity, the CIRS total score and severity index were 
trichotomized ( 0 = no problems; 1 = mild problems; 2 = moderate to severe 
problems) based on tertiles in the distribution of the respective scores, because of 
the right-skewedness in the distribution of the scores. For the same reason the 
scores of the subcategories of the CIRS-G were also trichotomized  (using the same 
coding).  
The influence of severity of total comorbidity (measured by CIRS total score and 
CIRS severity index) on cognitive decline was assessed using random-effects 
(linear mixed) models, thereby accounting for the fact that repeated measurements 
are correlated within individuals. First models with random intercepts were 
specified. Random slopes were included if likelihood ratio testing (LRT) suggested 
that this gave better fit compared to the model with only a random incept. To 
study differences in rate of decline over time between different comorbidity 
groups (0 = no comorbidity, 1 = mild comorbidity, 2 = moderate/severe 
comorbidity), a group-by-time interaction term was added. In addition, we tested 
whether rate of decline over time differed between baseline diagnostics groups (0 
= SCI, 1 = MCI) per comorbidity severity group by adding a diagnosis-by-group-
by-time interaction. For explorative purposes, analyses were repeated using the 
CIRS subcategory scores, to see whether results could be attributed to specific 
comorbidity clusters. The influence of severity of comorbidity on conversion to 
dementia was assessed using cox proportional hazards regression to assess 
differences in hazard ratios (HRs) between comorbidity groups. Observations were 
censored at date of dementia diagnosis or date of last neuropsychological 
assessment. All analyses were corrected for current age, sex, study centre and 
education. 
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RESULTS 
 
Characteristics of the participants at study entry, according to baseline diagnosis 
(MCI/SCI) and for the total group, are presented in table 1. Compared to patients 
with SCI, patients with MCI were older at baseline and scored significantly lower 
on all neuropsychological tests. Further, MCI patients had more severe total 
comorbidity, as indicated by a higher score on both the CIRS total score and the 
CIRS severity index.  
 
Baseline associations 
At baseline, the presence of moderate/severe comorbidity as measured by the 
CIRS total score was associated with significantly lower performance on TMT-A, 
TMT-B and SCWT 1 – 2. The presence of  moderate/severe comorbidity as 
measured with the CIRS severity index was also associated with lower performance 
on the TMT-A, SCWT 1 – 2 and SCWT interference (table 2; figure 1). 
 
 
Table 1 Baseline characteristics  
Variable Overall SCI MCI 
n 315 90 225 
Age, y 69.8 (8.7) 66.9 (8.3) 70.7 (8.3)** 
Sex (% female) 
Education 
  % Low 
  % Middle 
  % High 
MMSE 
34.8 % 
 
39.0 % 
25.2% 
35.8 % 
-1.9 (2.9) 
33.3 % 
 
36.7 % 
26.6% 
36.7 % 
-0.7 (2.0) 
35.5% 
 
40.0 % 
24.5 % 
35.5 % 
-2.4 (3.1)** 
VLT delayed recall 
Fluency 
TMT-A 
TMT-B 
SCWT 1 - 2 
SCWT interference  
CIRS-G total score 
CIRS Severity Index 
Follow-up length, y 
-1.2 (1.3) 
-0.7 (0.8) 
-0.3 (1.4) 
-0.4 (1.3) 
-1.2 (1.7) 
-0.9 (2.4) 
7.0 (4.9) 
1.6 (0.5) 
2.4 (1.1) 
-0.1 (1.0) 
-0.2 (0.7) 
0.4 (0.9) 
0.4 (1.0) 
-0.1 (0.7) 
0.3 (0.8) 
5.9 (4.6) 
1.4 (0.5) 
2.7 (0.8) 
-1.6 (1.2)** 
-0.9 (0.8)** 
-0.6 (1.5)** 
-0.8 (1.3)** 
-1.6 (1.7)** 
-1.4 (2.7)** 
7.5 (4.9)** 
1.6 (0.5)** 
2.2 (1.2) 
Data are presented as mean (SD) unless otherwise specified. Cognitive test scores are presented as z-
scores. MMSE  = Mini Mental State Examination; VLT = Verbal Learning Test; TMT-A = Trail Making 
Test part A; TMT-B = Trail Making Test part B; SCWT 1 – 2 = Stroop Colour Word Test average of cards 
1 and 2; SCWT interference = Stroop Colour Word Test interference index; CIRS-G = Cumulative Ilness 
Rating Scale for Geriatrics. 
* p < 0.05 
**      p < 0.01 
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Table 2 Baseline associations between severity of comorbidity and cognitive 
performance 
Comorbidity 
category 
Neuropsychological 
test 
Baseline 
score 
p-value Interaction effect 
   χ2                                p-value 
CIRS  
total 
score 
None 
Mild 
Moderate 
TMT-B -0.20 (0.15) 
-0.43 (0.13) 
-0.63 (0.16) 
0.17 
<0.01 
<0.01 
 
1.40 
4.12 
 
0.24 
0.04 
 None 
Mild 
Moderate 
TMT-A 
 
-0.06 (0.14) 
-0.28 (0.12) 
-0.62 (0.14) 
0.66 
0.03 
<0.01 
 
1.32 
7.09 
 
0.25 
<0.01 
 None 
Mild 
Moderate 
SCWT 1 – 2  -0.90 (0.18) 
-1.07 (0.16) 
-1.59 (0.19) 
<0.01 
<0.01 
<0.01 
 
0.50 
7.32 
 
0.48 
<0.01 
 None 
Mild 
Moderate 
SCWT interference -1.00 (0.22) 
-0.79 (0.19) 
-0.97 (0.23) 
<0.01 
<0.01 
<0.01 
 
0.50 
0.01 
 
0.48 
0.92 
 None 
Mild 
Moderate 
Fluency -0.62 (0.09) 
-0.65 (0.08) 
-0.83 (0.08) 
<0.01 
<0.01 
<0.01 
 
0.09 
2.43 
 
0.76 
0.12 
 None 
Mild 
Moderate 
VLT delayed -1.33 (0.14) 
-1.01 (0.12) 
-1.07 (0.13) 
<0.01 
<0.01 
<0.01 
 
2.86 
1.72 
 
0.09 
0.19 
CIRS 
Severity 
Index 
None 
Mild 
Moderate 
TMT-B -0.32 (0.13) 
-0.38 (0.13) 
-0.66 (0.15) 
0.01 
<0.01 
<0.01 
 
0.04 
2.49 
 
0.84 
0.11 
 None 
Mild 
Moderate  
TMT-A -0.16 (0.13) 
-0.34 (0.13) 
-0.55 (0.14) 
0.20 
<0.01 
<0.01 
 
1.08  
4.20 
 
0.30 
0.04 
 None 
Mild 
Moderate 
SCWT 1 – 2  -1.00 (0.16) 
-1.11 (0.16) 
-1.53 (0.19) 
<0.01 
<0.01 
<0.01 
 
0.35 
4.82 
 
0.56 
0.03 
 None 
Mild 
Moderate 
SCWT interference -0.67 (0.19) 
-0.91 (0.20) 
-1.29 (0.24) 
<0.01 
<0.01 
<0.01 
 
0.66 
3.89 
 
0.42 
0.04 
 None 
Mild 
Moderate 
SCWT interference -0.67 (0.19) 
-0.91 (0.20) 
-1.29 (0.24) 
<0.01 
<0.01 
<0.01 
 
0.66 
3.89 
 
0.42 
0.04 
 None 
Mild 
Moderate 
Fluency -0.70 (0.08) 
-0.75 (0.08) 
-0.67 (0.09) 
<0.01 
<0.01 
<0.01 
 
0.14 
0.07 
 
0.70 
0.79 
 None 
Mild 
Moderate 
VLT delayed recall  -1.10 (0.12) 
-1.10 (0.12) 
-1.19 (0.14) 
<0.01 
<0.01 
<0.01 
 
0.00 
0.19 
 
0.98 
0.66 
Data are presented as z-cores. VLT delayed = Verbal Learning Test delayed recall; TMT-A = Trail 
Making Test part A; TMT-B = Trail Making Test part B; SCWT 1 – 2 = Stroop Colour Word Test average 
of cards 1 and 2; SCWT interference = Stroop Colour Word Test interference index.  
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Figure 1 Baseline cognitive performance per comorbidity category for CIRS total 
score (upper graph) and CIRS severity index (lower graph) 
 
• significantly different from no comorbidity group 
VLT delayed = Verbal Learning Test delayed recall; TMT-A = Trail Making Test part A; TMT-B = 
Trail Making Test part B; SCWT 1 – 2 = Stroop Colour Word Test average of cards 1 and 2; SCWT 
interference = Stroop Colour Word Test interference index. 
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Cognitive decline  
Random effects models comparing the slope of cognitive decline between subjects 
with no, mild and moderate/severe comorbidity showed a significant group-by-
time interaction effect. Stratified analyses showed that subjects with 
moderate/severe comorbidity as measured by the CIRS severity index declined 
significantly on verbal fluency and TMT-A, while subjects without comorbidity 
and with mild comorbidity remained generally stable (table 3; figure 2). On the 
other cognitive tests, there was no significant decline over time in any of the 
comorbidity groups (table 3). 
 
Next, we studied the effect of baseline diagnostic group (SCI vs. MCI) on decline 
over time per comorbidity group by including a three-way interaction term in the 
analyses. A significant diagnosis-by-group-by-time interaction suggested that rates 
of decline per comorbidity group differed between patients with MCI or SCI only 
for VLT delayed recall, but not for other tests. Stratified analyses specified that SCI 
subjects with moderate/severe comorbidity showed significant decline on the VLT 
delayed recall (beta = -0.43, p-value <0.01) while all other subjects (regardless their 
baseline diagnosis or severity of comorbidity) remained generally stable on the 
VLT delayed recall.  
 
Association with specific comorbidities 
We repeated our analyses using CIRS subcategory scores instead of total 
comorbidity scores to see whether specific clusters of disease were mainly 
associated with lower performance and/or faster decline. Results showed that 
significant associations between severity of comorbidity and cognitive 
performance existed predominantly in the cardiac, respiratory, neurological and 
endocrine domain. Significant results were again only found for TMT-A, TMT-B 
SCWT 1 – 2, and verbal fluency (see supplementary table 1). Further, more severe  
comorbidity in the heart and respiratory domain was associated with faster decline 
on TMT-A (beta = -0.26, p <0.01 and beta = -0.17 p = 0.04 respectively). In the other 
disease clusters there was generally no association between severity of 
comorbidity and cognitive performance or decline (results not shown).  
 
Conversion to dementia 
At three years follow-up, 37 people had dropped out of the study. Drop-outs were 
older at baseline and scored significantly lower on the MMSE, TMT-A, TMT-B and 
SCWT 1 – 2. Further, drop-outs were more often classified as MCI baseline and  
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Table 3 Influence of comorbidities on cognitive decline 
Comorbidity 
category 
  Neuropsychological 
test 
B (SE) p-value Interaction effect 
      χ2                              p-value 
CIRS  
total 
score  
No 
Mild 
Moderate 
TMT-B -0.05 (0.06) 
0.08 (0.05) 
-0.01 (0.06) 
0.37 
0.10 
0.84 
 
3.16 
0.24 
 
0.08 
0.63 
 No 
Mild 
Moderate 
TMT-A 0.03 (0.08) 
0.09 (0.07) 
-0.17 (0.08) 
0.72 
0.16 
0.02 
 
0.42 
3.51 
 
0.52 
0.06 
 No 
Mild 
Moderate 
SCWT 1 – 2  -0.18 (0.10) 
-0.14 (0.09) 
-0.10 (0.11) 
0.08 
0.13 
0.35 
 
0.12 
0.31 
 
0.73 
0.58 
 No  
Mild 
Moderate  
SCWT interference -0.05 (0.16) 
0.05 (0.14) 
-0.18 (0.16) 
 
0.72 
0.27 
 
0.22 
0.32 
 
0.64 
0.57 
 No 
Mild 
Moderate 
Fluency -0.06 (0.05) 
-0.05 (0.04) 
-0.01 (0.04) 
0.18 
0.17 
0.75 
 
0.02 
0.63 
 
0.89 
0.43 
 No  
Mild 
Moderate 
VLT delayed  0.01 (0.06) 
0.01 (0.05) 
0.10 (0.05) 
0.82 
0.79 
0.08 
 
0.00 
1.15 
 
0.99 
0.28 
Severity 
index 
No  
Mild 
Moderate 
TMT-B 0.06 (0.05) 
0.01 (0.05) 
-0.06 (0.07) 
0.22 
0.84 
0.40 
 
0.53 
1.95 
 
0.47 
0.16 
 No 
Mild 
Moderate 
TMT-A 0.05 (0.07) 
0.06 (0.07) 
-0.17 (0.08) 
0.50 
0.39 
0.04 
 
0.02 
4.05 
 
0.88 
0.04 
 No 
Mild 
Moderate  
SCWT 1 – 2  -0.18 (0.09) 
-0.06 (0.09) 
-0.17 (0.12) 
0.05 
0.53 
0.14 
 
0.88 
0.00 
 
0.35 
0.97 
 No 
Mild 
Moderate 
SCTW interference  0.0 (0.14) 
-0.09 (0.15) 
-0.10 (0.18) 
0.99 
0.56 
0.57 
 
0.18 
0.17 
 
0.67 
0.68 
 No 
Mild 
Moderate 
Fluency -0.03 (0.04) 
0.02 (0.04) 
-0.16 (0.05) 
0.60 
0.60 
<0.01 
 
0.52 
4.71 
 
0.47 
0.03 
 No 
Mild 
Moderate 
VLT delayed 0.01 (0.05) 
0.11 (0.05) 
-0.06 (0.06) 
 
0.03 
0.34 
 
1.45 
1.00 
 
0.23 
0.32 
Data are presented as z-scores. VLT delayed = Verbal Learning Test delayed recall; TMT-A = Trail 
Making Test part A; TMT-B = Trail Making Test part B; SCWT 1 – 2 = Stroop Colour Word Test average 
of cards 1 and 2; SCWT interference = Stroop Colour Word Test interference index. 
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had more severe comorbidity as measured by both the CIRS total score and 
severity index. 
Of the remaining 278 subjects at third follow-up, 74 (26.6%) had converted to 
dementia within the three years. Converters were older at baseline and scored 
lower on all neuropsychological tests, except TMT-A and SCWT 1 – 2, compared to 
non-converters. Total severity of comorbidity at baseline did not differ between 
groups. Total severity of comorbidity was not associated with a higher risk of 
conversion to dementia after 3 years, both measured with the severity index (HR = 
1.3; 95% CI: 0.72; 1.78, p = 0.60) and the CIRS total score (HR = 0.90; 95%CI: 0.54; 
1.49, p = 0.67).  
 
 
DISCUSSION 
 
To the best of our knowledge, this study is the first longitudinal multicenter study 
that aimed to evaluate the association between the severity of total medical 
comorbidity and cognitive performance, decline and conversion to dementia in 
memory clinic visitors. We found that the severity of total comorbidity was related 
to worse cognitive performance in executive functioning and information 
processing speed, and that it was also related to faster cognitive decline on verbal 
fluency and information processing speed. On the contrary, severity of total 
comorbidity was not associated with an increased risk of conversion to dementia 
within three years.  
Our results indicate that in particular the cognitive domains of information 
processing speed, executive functioning and verbal fluency are influenced by the 
severity of comorbidity. All tests used to assess these functions (i.e. TMT AB, 
SCWT and verbal fluency) are (partially) based on mental speed. So, our findings 
suggest that participants with more severe comorbidity mainly have problems 
with their speed of processing and executive functioning.  
Our established association between severity of total comorbidity and worse 
baseline cognitive performance corroborates findings of previous cross-sectional 
studies in cognitively healthy elderly (Morrow et al., 2009, Uchiyama et al., 1996), 
people with mild cognitive impairment (Lyketsos et al., 2005) and dementia 
(Doraiswamy et al., 2002, Lyketsos et al., 2005, Oosterveld et al., 2014). Yet, most of 
these studies focused on the effects of comorbidity on global cognitive functioning 
and did not report on domain-specific performances.   
Our results further show that subjects with moderate/severe total comorbidity 
demonstrate faster cognitive decline, again only on mental speed dependent tests 
(i.e. TMT-A and verbal fluency), though severity of comorbidity is not associated 
with a higher risk of conversion to dementia within 3 years. To the best of our  
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Figure 2 Differences in rate of cognitive decline by severity of comorbidity 
(significant results for the CIRS severity index) 
 
 
TMT-A = Trail Making Test part A. 
 
  
knowledge, previous studies did not investigate the relationship between severity 
of total comorbidity and conversion to dementia, though multiple single risk 
factors have been associated with an increased risk of dementia (Barnes and Yaffe, 
2011). The association between total severity of comorbidity and cognitive decline 
has been reported before in cognitively healthy elderly (Patrick et al., 2002) and 
people with dementia (Solomon et al., 2011). Though, the latter study focused only 
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on global cognitive functioning. Interestingly, we did not find a significant 
association between severity of total comorbidity and decline on the SCWT 1 – 2 
(another mental speed based test), while baseline associations with severity of 
comorbidity for this test were quite robust. This could be due to a so-called floor 
effect in performance, since performance of all comorbidity groups on the SCWT 1 
– 2 was already quite low at baseline (1 to 1.5 SD below the population mean). 
Furthermore, we observed an overall stability of performance on most cognitive 
tests for all comorbidity groups. The overall absence of decline over time in this 
ageing population might be due to the heterogeneity associated with an MCI 
sample that includes both converters to dementia and people whose performance 
improves over time. An alternative explanation could be the presence of practice 
and habituation effects, which are well documented for a variety of tests in elderly 
populations (Ferrer et al., 2004, Rabbitt et al., 2001).  
When we explored whether we could identify specific clusters of disease that were 
related to cognitive performance or decline, severity of comorbidity in the cardiac 
and respiratory domain showed significant associations with cognitive 
performance and decline, again on speed-dependent tests. Factors like atrial 
fibrillation and chronic heart failure are known to influence performance in global 
cognitive functioning (Bellomo et al., 2012) and other cognitive domains (Vogels et 
al., 2007) in the elderly. Besides, these diseases are also related to global cognitive 
decline (Almeida et al., 2012, Thacker et al., 2013) and decline on speed measures 
(Thacker et al., 2013). Likewise, the association between pulmonary diseases and 
worse performance in information processing speed has been reported before in 
both clinic-based (Dal Negro et al., 2014, Klein et al., 2010) and general populations 
(Cleutjens et al., 2014), and this effect on cognitive performance seems to increase 
with increasing severity of the disease (Dal Negro et al., 2014, Klein et al., 2010). 
Further, severity of comorbidity in the neurological and endocrine domain was 
related to lower performance on speed dependent tests, though not to cognitive 
decline. Neurological diseases, like stroke and transient ischemic attacks have been 
associated with lower speed-related performance before in clinical populations 
(Middleton et al., 2014, van Rooij et al., 2014). The effect of the endocrine domain 
could likely be attributed to diabetes, which is known to influence cognitive 
performance in speed measures (Ganguli et al., 2013, Spauwen et al., 2013).   
So, although most disease clusters on their own show no significant association 
with cognitive performance or decline, the magnitude of total disease burden is 
related to worse cognitive performance and faster decline. Up till now, studies 
investigating cognitive decline in elderly patients typically address only single risk 
factors, with less attention being paid to multimorbidity and the total severity of 
comorbid disorders. Our study might indicate that a restricted disease-specific 
focus is insufficient in explaining associations between comorbidities and cognitive 
decline and demonstrates the importance of a broad assessment of multiple 
comorbid medical disorders. Furthermore, it provides a basis for shifting from a 
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single disease risk factor approach to a more integrative approach, which also 
better matches the typical increasing disease burden of the elderly population. 
 
Strengths and limitations 
The present study is among the first to evaluate the influence of the severity of 
total comorbidity on cognitive functioning and decline in multiple domains in 
memory clinic visitors. Strengths of the study include the prospective design and 
the enrollment of a relatively large, well-characterized sample. Furthermore, by 
using data that were not restricted to a single center and applying broad inclusion 
criteria in which most comorbidities were not excluded, as is often done in other 
studies, generalizability to the general memory clinic population was maximized. 
Further, we used an extensive neuropsychological assessment to assess cognitive 
performance, which covers the most important cognitive domains.  
However, this study also has some limitations. First, not all patients had 
information on all cognitive tests, for example due to patients getting exhausted 
during the assessment or patients being no longer able to perform specific tests. 
However, by applying random-effects mixed models we are to handle missing 
data effectively by using all available data at a given time point and by integrating 
missing values for slopes of decline with maximum likelihood. Secondly, several 
participants dropped out during follow-up and their characteristics at baseline 
were significantly different from the participants that had follow-up data, which 
might have biased the results for the conversion analyses. Dropouts were older, 
had more health problems and lower cognitive scores at baseline (data not shown), 
which might explain their dropout, as visiting the memory clinic for follow-up is 
likely to be a greater burden in those with more health problems and a higher age. 
More cognitive decline and higher risk of dementia is seen among patients with a 
higher age and more recent diseases (Backman et al., 2003, Kivipelto et al., 2006), so 
dropout of these participants most likely resulted in an underestimation of our 
results. In addition, our follow-up was currently limited to three years, which is a 
relatively short period to investigate effects on cognitive decline. Further, this 
could have led to the relatively small number of people that converted to 
dementia, which might have resulted in (too) limited power for the analyses. In 
addition, some non-converters might have been misclassified at their latest follow-
up assessment, as they will convert to dementia in the future, thereby diluting the 
effect of comorbidity on conversion to dementia. Still, our conversion rate (23.5%% 
over a mean period of 2.4 years) corresponds to the established conversion 
estimates in a systematic review (6.5%/year) (Mitchell and Shiri-Feshki, 2009). 
Furthermore, although we extensively assessed comorbidity and used a structured 
method for scoring the severity, we had to remove the psychiatry category from 
the CIRS-G because of the inclusion of cognitive problems in this category and 
thus avoid circularity in our reasoning. However, by excluding this category we 
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also lost data on other psychiatric comorbidities, like depression or anxiety, that 
are known to be related to cognitive performance (Bunce et al., 2012). 
 
Clinical implications 
Our findings might have implications for current practice in memory clinics. Our 
results show that multimorbidity is important to take into account and also 
underscore the significance of a broad assessment of medical disorders in clinical 
practice, since worse performance on speed dependent tests seems to be influenced 
by the severity of total comorbidity. Furthermore, it is important to realize that 
although patients with more severe total comorbidity show faster cognitive decline 
on several speed dependent tests, they are not at an increased risk to develop 
dementia in a time period of three years.  
 
Conclusions 
The severity of total comorbidity is associated with lower performance and faster 
decline on speed dependent tests, and should thus be taken into account when 
evaluating cognitive performance in clinical practice. However, severity of 
comorbidity is not associated with a higher risk of conversion to dementia within 
three years.  
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SUPPLEMENTARY DATA 
 
 
Supplementary table 1 Significant baseline associations between severity of 
comorbidity within specific disease clusters and cognitive performance 
Comorbidity  
category 
 
 Neuropsychological 
test 
B (SE) p-value Interaction 
effect 
    χ2                            p-value 
Heart No 
Mild 
Moderate 
TMT-A -0.20 (0.05) 
-0.58 (0.26) 
-0.58 (0.15) 
0.04 
0.02 
<0.01 
 
1.90 
4.04 
 
0.17 
0.04 
 No 
Mild 
Moderate  
SCWT 1 – 2  -1.00 (0.12) 
-1.60 (0.33) 
-1.54 (0.21) 
<0.01 
<0.01 
<0.01 
 
2.48 
4.48 
 
0.12 
0.03 
Respiratory No 
Mild 
Moderate 
TMT-B -0.33 (0.10) 
-0.25 (0.19) 
-0.84 (0.17) 
<0.01 
0.18 
<0.01 
 
0.19 
6.05 
 
0.66 
0.01 
Neurological No 
Mild 
Moderate 
TMT-A -0.20 (0.10) 
-0.37 (0.17) 
-0.64 (0.16) 
0.05 
0.03 
<0.01 
 
0.83 
5.37 
 
0.36 
0.02 
 No 
Mild 
Moderate 
SCWT 1 – 2  -0.97 (0.13) 
-1.03 (0.22) 
-1.86 (0.20) 
<0.01 
<0.01 
<0.01 
 
0.05 
12.96 
 
0.83 
<0.01 
Endocrine No 
Mild 
Moderate 
TMT-B -0.31 (0.09) 
-0.63 (0.19) 
-0.77 (0.21) 
<0.01 
<0.01 
<0.01 
 
2.27 
4.15 
 
0.13 
0.04 
 No 
Mild 
Moderate 
TMT-A -0.20 (0.09) 
-0.55 (0.19) 
-0.72 (0.20) 
0.03 
<0.01 
<0.01 
 
2.87 
5.82 
 
0.09 
0.02 
 No 
Mild 
Moderate 
SCWT 1 – 2  -0.98 (0.12) 
-1.64 (0.23) 
-1.61 (0.26) 
0.03 
<0.01 
<0.01 
 
6.78 
4.84 
 
0.01 
0.03 
 No 
Mild 
Moderate 
SCWT 1 – 2  -0.98 (0.12) 
-1.64 (0.23) 
-1.61 (0.26) 
0.03 
<0.01 
<0.01 
 
6.78 
4.84 
 
0.01 
0.03 
 No 
Mild 
Moderate 
Fluency -0.64 (0.06) 
-0.73 (0.11) 
-0.99 (0.12) 
<0.01 
<0.01 
<0.01 
 
0.41 
7.04 
 
0.52 
0.01 
Data are presented as z-scores. TMT-A = Trail Making Test part A; TMT-B = Trail Making Test part B; 
SCWT 1 – 2 = Stroop Colour Word Test average of cards 1 and 2.
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ABSTRACT 
 
Objective 
As diagnostic assessment and treatment options increasingly focus on early stages 
of cognitive decline, more information on Health-related Quality of Life (HRQoL) 
in people searching medical help for cognitive complaints is needed. Therefore, 
this study aimed to investigate the association between HRQoL and comorbid 
disease burden, emotional and cognitive functioning in memory clinic visitors. 
 
Methods 
This study consists of 301 non-demented patients with memory complaints who 
visited one of three Dutch Alzheimer centres. Multiple linear regression analyses, 
corrected for age, gender, study center and education, were used to investigate the 
relation between HRQoL and comorbid disease burden, emotional functioning and 
cognitive functioning. Analyses were performed for the total group and for the 
group with Mild Cognitive Impairment (MCI) and subjective cognitive complaints 
(SCI) separately  
 
Results 
Participant’s mean age was 69.7 years and 64.8% of them were men. The majority 
of the group was classified as having MCI (70%). All three domains were 
significantly associated with HRQoL in the total cohort and the MCI group 
(R2=31%). In the SCI group only emotional functioning was significantly associated 
with HRQoL (R2=46%). Depressive symptoms were most strongly related to 
HRQoL in all groups.  
 
Conclusions  
The HRQoL of memory clinic visitors is largely influenced by their emotional 
functioning, especially by depressive symptoms. Furthermore, HRQoL in MCI is 
also influenced by cognitive functioning and comorbid disease burden, while 
HRQoL in SCI is not. These factors should be taken into account in clinical practice 
and might be promising targets for non-cognitive interventions to improve 
HRQoL. 
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INTRODUCTION 
 
Health-related Quality of Life (HRQoL) is a complex, multidimensional construct 
that refers to the functional effect a medical condition and/or its consequent 
therapy has upon a patient. Most definitions of HRQoL incorporate the domains of 
general health, mental health, physical and social functioning, with important 
concepts such as cognition integrated in these broader categories (Bowling, 2001, 
Ware, 1987). HRQoL has become a topic of interest within dementia research, as it 
has been increasingly acknowledged as a significant outcome.  
Multiple studies have demonstrated decreased HRQoL in people with dementia 
relative to cognitively unimpaired elderly (Missotten, et al. 2008; Ready, et al. 2004).  
However, we know little about HRQoL in the earlier stages of cognitive decline, 
though diagnostic and therapeutic efforts are increasingly focusing on this group. 
Results concerning HRQoL in people with Mild Cognitive Impairment (MCI) are 
inconsistent: some studies showed no reduced HRQoL (Missotten et al., 2008, 
Ready et al., 2004), while others demonstrated decreased HRQoL compared to 
people with unimpaired cognitive functioning (Muangpaisan et al., 2008, Teng et 
al., 2012, Weiss et al., 2012). Further, diminished HRQoL has also been reported in 
people with subjective cognitive complaints (SCI) (Mol et al., 2009).  
According to the above-mentioned definition, emotional well-being, medical 
disease burden and cognitive functioning seem important determinants of HRQoL. 
Indeed, reduced HRQoL in individuals with MCI has been related to the presence 
of neuropsychiatric symptoms and especially depressive symptoms (Teng et al., 
2012, Weiss et al., 2012). However, no associations with cognitive functioning have 
been found (Muangpaisan et al., 2008, Teng et al., 2012), while the relation with 
general health has not been thoroughly investigated in the MCI population.  
In all, current research on HRQoL in people with MCI is limited and shows 
conflicting results, while research on HRQoL in SCI is almost entirely lacking. In 
addition, the contribution of factors influencing HRQoL relative to one another 
and differences in these factors between diagnostic groups have not been 
investigated yet. A better understanding of factors that influence HRQoL in 
memory clinic visitors is important to identify potential targets to ameliorate 
HRQoL, and thus further enhance care for these persons. 
Therefore, the aim of the present study was to investigate which factors are 
associated with HRQoL in memory clinic visitors, both in people with MCI and in 
those with SCI. More specifically, we aimed to investigate the association between 
HRQoL and comorbid disease burden, cognitive and emotional functioning. We 
hypothesized that emotional functioning and comorbid disease burden are 
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associated with HRQoL in all groups, while cognitive functioning is associated 
with HRQoL only in the MCI group.  
 
 
METHODS 
 
Baseline data from the Clinical Course of Cognition and Comorbidity in MCI (4C-
MCI) study were used. The 4C-MCI study is a longitudinal multicenter study into 
the course of cognitive decline in non-demented memory clinic visitors. 
Participants were included from the memory clinics of Maastricht University 
Medical Centre, Radboud university medical center and VUmc Medical Centre 
between January 2010 and May 2011. Participants were followed annually for three 
years. The local Medical Ethical Committee of each centre approved the study. All 
participants provided written informed consent. The authors assert that all 
procedures contributing to this work comply with the ethical standards of the 
relevant national and institutional committees on human experimentation and 
with the Helsinki Declaration of 1975, as revised in 1983. 
 
Participants 
The study included 315 participants at baseline, who were classified as having 
either objectified cognitive impairment (MCI) or no objectified cognitive 
impairment (SCI), based on neuropsychological test results. Inclusion criteria were: 
1) age ≥ 55 years, 2) having subjective cognitive complaints and/or cognitive 
impairments, in absence of dementia, and 3) Clinical Dementia Rating (CDR) 
(Morris, 1993) score ≤  0.5. Exclusion criteria were: 1) absence of a primary 
caregiver, 2) expectation that the participant will not be able to have at least one 
follow-up, based on clinical judgment, and 3) presence of specific neurological 
disorders that could have caused cognitive impairment: Parkinson’s or 
Huntington’s disease, Normal Pressure Hydrocephalus, Korsakoff’s syndrome, a 
medical history of brain tumor or encephalitis. Contrary to common practice in 
MCI studies, participants having any other comorbidities, including 
cerebrovascular and  psychiatric disorders were not excluded.  
 
Baseline assessment 
At baseline, all participants underwent a standardized clinical assessment, which 
included a detailed history of the patient, a psychiatric, neurologic and physical 
examination, assessments of daily functioning, appropriate laboratory tests, an 
extensive neuropsychological assessment and a magnetic resonance imaging (MRI) 
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scan. These assessments were part of the regular patient diagnostic procedures of 
the memory clinics. For the current study we extracted data on age, gender, 
education, quality of life, comorbid disease burden, cognitive and emotional 
functioning.  
 
Health-related Quality of Life 
The EuroQol-5D (EQ-5D) (The EuroQol Group, 1990) including a Visual Analogue 
Scale (VAS) was used to measure (self-rated) HRQoL. Participants rated their 
current health state on a three-point scale in five dimensions (i.e. mobility, self-
care, daily activities, pain/discomfort and anxiety/depression). Scores in each 
dimension ranged from zero (no impairments/complaints) to two (severe 
impairments/complaints), with higher scores indicating worse HRQoL. This 
scoring yields 243 potential combinations of health states across the dimensions. 
Each health state can be allocated a utility score through an algorithm (Dolan, 
1997), indicating its attractiveness based on valuations of the general population. 
Utility scores can vary between -0.59 (worst health) and 1.00 (perfect health). The 
EQ-5D also includes the rating of a VAS score, with values from zero (worst 
possible health state) to 100 (best possible health state).  
 
Comorbid disease burden 
The Cumulative Illness Rating Scale for geriatrics (CIRS-G) (Miller et al., 1992) was 
used to score all available data on medical comorbidities, medication use, smoking 
and drinking habits and information from the physical examination. Scores 
between zero (no problems) and four (extremely severe problems) were given to 
14 categories of organ systems (i.e. cardiac; vascular; hematopoietic; respiratory; 
eyes/ears/nose/throat/larynx; upper gastrointestinal tract; lower gastrointestinal 
tract; liver; renal; genitourinary; musculoskeletal; neurological; 
endocrine/metabolic and breast; psychiatric). For the current analyses, we 
excluded the psychiatric category from the CIRS-G since it contains psychiatric 
and cognition related comorbidities. By excluding this category, the CIRS-G was 
used as a measure of pure medical comorbid disease burden, thus minimizing 
overlap with the cognitive and emotional functioning domain. 
 
Cognitive functioning 
The neuropsychological assessment consisted of the following tests: the Mini 
Mental State Examination (MMSE) (Folstein et al., 1975), the Dutch adaptation of 
the 15-Word Verbal Learning Task (VLT) (Lezak et al., 2004, Van der Elst et al., 
2005), the Stroop Color Word Test (SCWT) (Hammes, 1973), the Letter Digit 
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Substitution Test (LDST) (van der Elst et al., 2006a), the Trail Making Test (TMT) 
(Lezak et al., 2004, Schmand et al., 2003) and the category fluency test (animal 
naming) (Van der Elst et al., 2006b). 
 
Emotional functioning and depressive symptoms 
The Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) was used to assess 
the frequency and severity of 12 neuropsychiatric symptoms (i.e. delusions, 
hallucinations, agitation, depression, anxiety, apathy, irritability, euphoria, 
disinhibition, aberrant motor behavior, nighttime behavior disturbances, and 
appetite/eating disturbances) through a structured interview with the 
participants’ caregiver. For each symptom, severity and frequency scores are 
multiplied to acquire a total symptom score, with higher scores indicating more 
severe problems.  
The Geriatric Depression Scale-15 (GDS-15) (Sheikh and Yesavage, 1986) was used 
to determine the presence and severity of depression by self-rating. The GDS-15 is 
a screening tool in which 15 questions about mood are answered. A score of six or 
more is indicative for possible depression.  
 
Diagnostic procedures 
All neuropsychological test scores were converted to z-scores adjusted for age, sex 
and education, based on norm scores from the Dutch healthy population 
(Schmand et al., 2003, Van der Elst et al., 2005, 2006a, b, c). Adopting a 
psychometric approach, individuals with a z-score lower than -1.5 SD on any 
neuropsychological test were classified as having MCI. All others were classified 
as SCI.  
 
Statistical analyses 
Analyses were performed using SSPS version 20 (Chicago, IL., USA) for Mac OS X.  
Baseline differences between groups (i.e. SCI and MCI group) were analyzed using 
t tests for continuous and χ2 tests for categorical variables.  
For cognitive functioning, extreme z-score values were handled by winsorising 
them, i.e. they were fixed at the lower (-5) or upper (+5) boundary. Extreme values 
were found only for the SCWT (i.e. 1.6% of all scores on Stroop card 2 and 4.7% of 
all scores on the SCWT interference index). For the emotional functioning and 
comorbid disease burden domain, the scores of the subcategories of the CIRS-G 
and of the symptoms of the NPI were dichotomized ( 0 = absence of comorbidity 
or neuropsychiatric symptom; 1 = presence of comorbidity or neuropsychiatric 
symptom). 
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To test for multicollinearity a Spearman’s rank-order correlation was conducted 
between all variables within a predictive domain (i.e. comorbid disease burden, 
cognitive and emotional functioning). Using a cut-off of 0.7, the VLT delayed recall 
score was removed from the analyses, since it correlated high with the VLT 
immediate recall score (r=0.744, p <0.01) and the latter had a larger range of scores, 
which makes it more applicable for multiple linear regression analyses.  
For HRQoL, the VAS score was used as outcome measure, since the utility weight 
scores are predominantly based on the rating of a person’s physical abilities (e.g. 
mobility, pain/discomfort). By using the VAS score, HRQoL was based on the 
pure subjective experience of general health, thus minimizing overlap with the 
comorbid disease burden domain. 
To examine the relationship between each of the above-mentioned domains and 
HRQoL, separate multiple linear regression analyses were performed within each 
predictive domain. Models were built using backward selection (pinclusion < 0.10; pexclusion ≥ 
0.10). Significantly associated variables were subsequently included into a final 
multiple regression model (enter method), combining the results of the three 
domains (significance set at p < 0.05). To give an indication of the predictive power 
of the model, the percentage of explained variance (Nagelkerke’s R2) was 
presented. All regression analyses were corrected for age, gender, study centre and 
education (low, middle, high), and were performed for the total cohort and in the 
MCI and SCI group separately.  
 
 
RESULTS 
 
For the present study, we selected 301 individuals with available EuroQoL-VAS 
scores. Their characteristics at study entry, according to baseline diagnosis and the 
characteristics of the total group, are presented in table 1. Participants were on 
average almost 70 years old and more than half of them were men. 210 participants 
were classified as MCI at baseline, while only 84 participants were classified as 
SCI, 7 participants remained unclassified due to missing data. The mean HRQoL 
score of the entire group was 69.4 (SD = 15.63). Further, almost 40% had a HRQoL 
score higher than 70. HRQoL scores did not differ between participants with MCI 
and SCI. Yet, people with MCI were older, performed worse on all 
neuropsychological tests, and had more often comorbidity in the cardiac and 
eyes/ears/nose domain than those with SCI. However, the levels of 
neuropsychiatric and depressive symptoms were similar in both groups.  
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Table 1 Baseline characteristics of the total group and subgroups 
Variable Overall SCI MCI 
n 301# 84 210 
Age, y 69.7 (8.55) 66.4 (8.00) 70.8 (8.41)** 
Sex (% male) 
Education 
  % Low 
  % Middle 
  % High 
64.8 % 
 
38.4 % 
24.8 % 
35.2 % 
67.9 % 
 
34.5 % 
27.4 % 
38.1 % 
64.3% 
 
39.5 % 
25.7 % 
34.8 % 
Cognitive tests 
  VLT (immediate recall) 
  Fluency 
  TMT-A 
  TMT-B 
  SCWT 1 – 2  
  SCWT interference  
  LDST 
  MMSE 
NPI total score 
NPI items (% with symptoms) 
  Delusions 
  Hallucinations 
  Agitation 
  Depression 
  Anxiety 
  Euphoria 
  Apathy 
  Irritability 
  Disinhibition 
  Aberrant motor behavior 
  Nighttime behavior disturbances 
  Appetite and eating abnormalities 
Self reported depression 
CIRS total score 
CIRS categories (% with comorbidity) 
  Cardiac 
  Vascular 
  Hematopoietic 
  Respiratory 
  Eyes, ears, nose 
  Upper digestive tract 
  Lower digestive tract 
  Liver 
  Kidneys 
  Urogenital 
 
-1.1 (1.22) 
-0.7 (0.85) 
-0.3 (1.31) 
-0.4 (1.34) 
-1.1 (1.42) 
-0.6 (1.72) 
-0.5 (1.12) 
26.9 (2.50) 
14.2 (14.5) 
 
6.3% 
3.7% 
19.3% 
39.5% 
26.2% 
9.0% 
43.5% 
50.2% 
17.6% 
10.3% 
26.6% 
20.6% 
19.6 % 
8.0 (4.96) 
 
36.5% 
61.5% 
16.6% 
38.9% 
42.9% 
22.3% 
23.3% 
14.0% 
12.6% 
35.9% 
 
-0.0 (0.99) 
-0.2 (0.69) 
0.4 (0.93) 
0.4 (1.00) 
-0.1 (0.69) 
0.4 (0.87) 
0.2 (0.83) 
28.0 (1.64) 
13.4 (14.2) 
 
8.3% 
2.4% 
17.9% 
40.5% 
23.8% 
13.1% 
41.7% 
54.8% 
16.7% 
11.9% 
21.4% 
11.9% 
15.5 % 
6.5 (4.46) 
 
25% 
60.7% 
10.7% 
35.7% 
29.8% 
16.7% 
22.6% 
9.5% 
11.9% 
36.9% 
 
-1.5 (1.03)** 
-0.9 (0.82)** 
-0.6 (1.37)** 
-0.8 (1.34)** 
-1.4 (1.41)** 
-1.1 (1.80)** 
-0.8 (1.08)** 
26.5 (2.66)** 
14.2 (14.6) 
 
5.7% 
4.3% 
20.0% 
39.0% 
27.1% 
7.6% 
43.8% 
48.1% 
18.1% 
9.5% 
28.6% 
23.3% 
19.7 % 
8.5 (5.02)** 
 
40%* 
61.0% 
19.0% 
39.5% 
47.1%* 
23.3% 
22.4% 
15.7% 
12.9% 
33.8% 
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Table 1 (continued) 
Variable Overall SCI MCI 
Neuromuscular 
  Neurological 
  Endocrine 
EuroQol 
 VAS score categories 
    0 – 50  
    51 – 70 
    71 – 100  
  VAS total score 
37.5% 
41.9% 
31.6% 
 
 
15.0% 
44.5% 
39.5% 
69.4 (15.6) 
36.9% 
34.5% 
27.4% 
 
 
8.3% 
50.0% 
41.7% 
70.8 (12.7) 
38.1% 
46.2% 
33.3% 
 
 
16.7% 
43.8% 
39.5% 
69.2 (16.3) 
VLT = Verbal Learning Test; TMT-A: TrailMaking Test part A; TMT-B: TrailMaking Test part B; SCWT 
1–2, average of Stroop Color Word Test $ card 1 + 2; SCWT interference index = Stroop Color Word Test 
card 3 divided by the average of Stroop Color Word Test$ card 1 + 2; MMSE: Mini Mental State 
Examination; NPI: NeuroPsychiatric Inventory; CIRS: Cumulative Illness Rating Scale; VAS: Visual 
Analogue Scale;  
Data are presented as mean (SD) unless otherwise specified. Neuropsychological test scores are 
presented as z-scores.  
# 7 patients of the overall group did not have sufficient neuropsychological data to receive a MCI of SCI 
classification.  
* p < 0.05 
** p < 0.01 
 
 
HRQoL in the total group 
Within the cognitive functioning domain, only a slow mental speed (i.e. lower 
score on the LDST) was significantly associated with lower HRQoL. Within the 
comorbid disease burden domain, the presence of comorbidity in the 
eyes/ears/nose, lower gastrointestinal tract and kidney domain was significantly 
associated with lower HRQoL. Regarding emotional functioning, informant and 
self-reported depressive symptoms, nighttime behavior and appetite/eating 
disturbances were significantly associated with lower HRQoL.  
In the final model, that combined the significant predictors from the analyses 
within each domain, all domains remained significantly associated with HRQoL. 
More specifically, lower scores on the LDST (beta = 0.16, p <0.01) and the presence 
of self-reported depressive symptoms (beta = -0.36, p <0.01), appetite/eating 
disturbances (beta = -0.13, p = 0.03), nighttime behavior disturbances (beta = -0.14, 
p = 0.02) and eyes/ears/nose comorbidities (beta = -0.12, p = 0.04) were associated 
with lower HRQoL (table 2). This final model accounted for 31% of the total 
variance. The largest proportion of the variance was explained by emotional 
functioning (R2 = 23%). Cognitive functioning and comorbid disease burden both 
explained 3% of the total variance.  
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When we repeated our analyses using the EuroQoL utility weight as outcome 
measure, results did not essentially change. Only the association between 
comorbid disease burden and HRQoL was now found for comorbidities in the 
respiratory and lower gastrointestinal tract domain instead of the eyes/ears/nose 
domain.  
 
 
Table 2 Final predictive model for HRQoL in the total group, based on  
all significant predictors within each predictive domain (analyses 
corrected for age, education, gender and study centre) 
Predictor Beta p-value 
Nighttime behaviour disturbances -0.14 0.02 
Appetite/Eating disturbances -0.13 0.03 
Self-reported depression -0.36 <0.01 
Eyes/ears/nose -0.12 0.04 
Lower digestive tract -0.10 0.07 
Kidney -0.10 0.07 
LDST 0.16 <0.01 
R2 = 0.31 
 
 
HRQoL in the MCI and SCI group  
We repeated the analyses in the MCI and SCI subgroups separately. In the SCI 
group, cognitive functioning and comorbid disease burden were not related to 
HRQoL. Within the emotional functioning domain, the presence of nighttime 
behavior disturbances (beta = -0.28, p <0.01) and informant and self-reported 
depression (beta = -0.24, p <0.01 and beta = -0.31, p <0.01 respectively) were related 
to lower HRQoL. The presence of agitation, however, was related to higher 
HRQoL (beta = 0.20, p = 0.03 ) (table 3). The total variance explained by the model 
was 46%.  
In the MCI group, comorbid disease burden, emotional and cognitive functioning 
remained significantly related to HRQoL (table 3). Again, a lower score on the 
LDST (beta = 0.22, p <0.01) and the presence of appetite/eating disturbances (beta 
= -0.14, p = 0.04), self-reported depression (beta = -0.41, p <0.01) and 
eyes/ears/nose comorbidities (beta = -0.15, p = 0.03) were associated with lower 
HRQoL. Also, the presence of lower gastrointestinal tract comorbidities was 
associated with lower HRQoL (beta = -0.17, p = 0.01), while this association was 
not significant in the total group. The total variance explained by the model was 
31%, with emotional functioning explaining most of the variance (19%). Cognitive 
functioning and comorbid disease burden both explained 5% of the variance. 
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Table 3 Final predictive model for HRQoL based on all significant predictors 
within each predictive domain, reported for the SCI and MCI group separately 
(analyses corrected for age, education, gender and study centre) 
Group Predictor Beta p-value 
SCI Agitation 0.20 0.03 
 Peer reported depression (NPI) -0.24 <0.01 
 Nighttime behavior disturbances -0.28 <0.01 
 Self-reported depression -0.31 <0.01 
MCI Appetite/Eating disturbances -0.14 0.04 
 Self-reported depression -0.41 <0.01 
 Eyes/ears/nose 
Lower digestive tract 
Kidney 
LDST 
-0.15 
-0.17 
-0.08 
0.22 
0.03 
0.01 
0.27 
<0.01 
R2  SCI = 0.47 
R2  MCI = 0.31 
 
 
DISCUSSION 
 
This study aimed to investigate the effect of comorbid disease burden, cognitive 
and  emotional functioning on HRQoL in memory clinic visitors with SCI and 
MCI. We found that all three domains were significantly related to HRQoL in 
patients with MCI, though most of the variance was explained by emotional 
functioning and especially depressive symptoms. In the SCI group only emotional 
functioning was related to HRQoL.  
HRQoL was affected strongest by the presence of neuropsychiatric symptoms, in 
particular depressive symptoms, in all groups. The association between depressive 
symptoms, and reduced HRQoL in individuals with MCI has been reported in 
other studies (Muangpaisan et al., 2008, Teng et al., 2012, Weiss et al., 2012), and has 
also been found in people with subjective cognitive complaints (Maki et al., 2014). 
This seems to suggest that worries are an important determinant of HRQoL in all 
persons who present themselves at a memory clinic, irrespective of whether or not 
actual cognitive impairment can be demonstrated. In this regard, it is important to 
consider that the clinical diagnosis of SCI or MCI was not yet made at the time of 
assessment of HRQoL and the predictive factors. As a result, persons did not know 
whether their cognitive complaints were verified .  
Further, lower HRQoL was also associated with agitation and nighttime behavior 
disturbances (SCI group) and appetite/eating disturbances (MCI group) in our 
study. The association between lower HRQoL and total NPI scores has been 
investigated previously, however the association with specific neuropsychiatric 
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symptoms has not (Mhaolain et al., 2012, Naglie et al., 2011, Teng et al., 2012). Our 
finding that the presence of agitation was related to increased HRQoL was not in 
line with previous research in patients with dementia (Mjorud et al., 2014, Wetzels 
et al., 2010). A possible explanation for this could be that the level of agitation is 
low in our population (mean score = 1.2), while the severity and thus influence of 
agitation is likely to increase with increasing severity of dementia. Possibly, the 
current low level of agitation may not be experienced as disturbing by the person 
himself and is thus not negatively related to HRQoL. In addition, the NPI is based 
on caregiver reports, which could introduce bias in the ratings of emotional 
functioning of the patient. That is, it may be that predominantly symptoms causing 
more distress for the caregiver, like agitation (Fauth and Gibbons, 2014) are 
recalled. Indeed the NPI items which refer more to concrete behavior (e.g. eating 
and nighttime behavior disturbances) and are less likely to be influenced by the 
caregivers’ perception show the expected association with HRQoL.  
In the present study, cognitive functioning also significantly influenced the 
HRQoL of people with MCI and of the total cohort. This finding is in contrast with 
that of other studies (Mhaolain et al., 2012, Naglie et al., 2011) that found no 
association between cognitive functioning and HRQoL in both MCI and dementia 
samples. However, instead of using only a cognitive screening instrument, our 
study examined the effect of cognitive functioning using a variety of cognitive 
measures which assesses cognition in much more detail. Yet, the study of Teng et 
al., 2012 also failed to find a significant association between cognitive functioning 
and HRQoL in an MCI sample using a more extensive neuropsychological test 
battery. This might be due to the use of cognitive domain scores that combined the 
results of multiple tests, while we used all test scores separately.  
Comorbid disease burden had a significant influence on HRQoL in the MCI group 
and the total group, with eyes/ears/nose comorbidities being associated with 
lower HRQoL in both groups and lower gastrointestinal tract comorbidities being 
associated with lower HRQoL in the MCI group only. Indeed, gastrointestinal 
problems have been related to lower HRQOL in the general population (Halder et 
al., 2004, Irvine et al., 2002). The same association has been found for hearing and 
vision problems in the general elderly (Carabellese et al., 1993, Fischer et al., 2009) 
and nursing home population (Dev et al., 2014). However, the effect of specific 
comorbidities on HRQoL in MCI patients has not been investigated before. It 
should be noted that the severity of comorbidities was mild in our cohort, 
representing a relatively physically healthy sample. Associations might be even 
stronger when people suffer from more severe comorbidities  
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When looking at differences between groups, we found that HRQoL did not differ 
between SCI and MCI patients, as was also reported in previous studies (Missotten 
et al., 2008, Muangpaisan et al., 2008, Ready et al., 2004). However, Barrios et al. 
(2013) did find a lower HRQoL in patients with MCI compared to healthy controls. 
This might be due to differences in study population, since we compared groups 
that both searched medical attention because of worry about cognitive complaints.  
 
Strengths and Limitations 
To the best of our knowledge, the present study was the first that included 
comorbid disease burden, cognitive and emotional functioning simultaneously as 
predictors of HRQoL in memory clinic visitors. This enables comparison of the 
relative importance of these domains for predicting HRQoL. Further, cognitive 
functioning was assessed by an extensive neuropsychological assessment covering 
various domains rather than a short dementia screen, which allows a broader and 
more reliable investigation of the influence of cognition. Another strength of the 
study is the relatively large, well-characterized sample. Furthermore, by using data 
that were not restricted to a single center and applying broad inclusion criteria, 
generalizability to other memory clinic samples was maximized. A limitation of 
the current study might be the use of a non-disease specific HRQoL questionnaire. 
Although this measure is well-established and widely used, one could argue that 
HRQoL questionnaires that have been adapted for use in individuals with 
cognitive impairment, should have been implemented. However, the EuroQoL-5D 
has been reported before as a valid and reliable measure in patients with cognitive 
impairments (Wolfs et al., 2007). An additional limitation could be that the 
measurement of emotional functioning was largely based on informant reports 
(NPI), which might be less reliable than self reports in persons with only limited 
cognitive impairments. This could have diluted the established effects. 
Furthermore, since all measurements in this study were performed at the start of 
the diagnostic trajectory, all individuals had not received a clinical diagnosis yet. 
Possibly, uncertainty about the eventual diagnosis may have been the main reason 
for the large impact of depressive symptoms. However, regardless of whether 
uncertainty is the underlying cause, reduced HRQoL remains important to target 
in these persons. 
 
Clinical Implications 
Our findings might have implications for current practice in memory clinics. It is 
important to realize that the HRQoL of memory clinic visitors, whether they have 
cognitive impairment or not, is influenced mainly by various emotional factors and 
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especially depressive symptoms, but also by sensory impairments. The recognition 
and detection of these factors and possible underlying causes by the clinician 
should be given more importance in current practice. Furthermore, these factors 
might be promising targets for non-cognitive interventions to improve HRQoL in 
these patients.   
 
Conclusions 
In conclusion, the present study shows that the HRQoL of memory clinic visitors is 
mainly influenced by their emotional functioning, and especially by depressive 
symptoms. Furthermore, the HRQoL of MCI subjects is also influenced by 
cognitive functioning and comorbid disease burden. These factors should be taken 
into account in clinical practice and might be promising targets for interventions to 
improve HRQoL.  
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GENERAL DISCUSSION 
 
The transitional state between normal cognitive functioning and dementia is 
usually referred to as Mild Cognitive Impairment (MCI) (Petersen et al., 1999). 
People with MCI are characterized by having cognitive impairments in one or 
multiple cognitive domains, but do not fulfil criteria for dementia. Although they 
have an increased risk to develop dementia, a substantial number of them remains 
cognitively stable or even reverts back to normal cognitive functioning after 
prolonged follow-up (Ganguli et al., 2011, Visser et al., 2006). So, MCI denominates 
a heterogeneous group of people with large individual variation in the level and 
pattern of cognitive impairment, course of decline over time and thus prognosis. 
This heterogeneity is likely due to differences in the underlying causes of the 
impairment, whereby stability or improvement in cognition is unlikely to be 
caused by neurodegenerative pathology.  
Although dementia was long regarded as a monocausal disease, currently it has 
become clear that, especially at older age, a pure form of dementia does not exist 
and multiple factors contribute together to the development of dementia. Yet, 
multimorbidity, which is typically associated with advancing age (Uijen and van 
de Lisdonk, 2008, van den Akker et al., 1998), has received little attention in 
research into early stage cognitive decline thus far.  
Therefore, it is important to investigate the natural course of decline in MCI and 
detect factors that can influence this course. This may help in the identification of 
and distinction between those individuals that show a pattern and rate of decline 
that is typical for emerging underlying neurodegenerative pathology and those 
that do not, which in turns lead to a more accurate prognosis and better care and 
treatment for these patients.  
 
The aim of the first part of this thesis was to investigate the profile and course of 
cognitive decline in Mild Cognitive Impairment. In chapter 2, we examined the 
rates of domain-specific cognitive decline in the pre-dementia phase by means of a 
systematic literature review and meta-analysis. In chapter 3, we studied the 
temporal sequence, pattern and rate of cognitive decline before dementia diagnosis 
in people selected from a memory clinic setting. Further, we described the 
existence of different subtypes of cognitive impairment in a memory clinic-based 
population and their predictive value for conversion to dementia (chapter 4). 
The aim of the second part of this thesis was to investigate the influence of the 
often-overlooked issue of comorbidity on the course of cognitive decline, and also 
on Health-related Quality of Life (HRQoL) in a memory clinic setting. We 
described the study outline of the prospective Clinical Course of Cognition and 
Comorbidity in MCI (4C-MCI) study (chapter 5). This study was set up to 
investigate the abovementioned aims. Further, we assessed the influence of total 
severity of comorbidity on cognitive decline and conversion to dementia in a 
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memory clinic-based population (chapter 6). In addition, we studied the 
association between emotional functioning, cognitive functioning and comorbid 
disease burden and HRQoL in memory clinic visitors (chapter 7).  
In this last chapter, we will summarize and discuss the general findings, elaborate 
on methodological considerations and report on the scientific and clinical 
implications of our findings.  
 
Pattern and rate of cognitive decline in MCI 
The current MCI concept includes amnestic and non-amnestic forms, which can 
involve single or multiple cognitive domains (Petersen and Morris, 2005). This 
concept corresponds to findings that show impairments in the pre-dementia phase 
across multiple cognitive domains, like episodic memory (Backman et al., 2001, 
Chen et al., 2000, Rubin et al., 1998), executive functioning (Albert et al., 2001, Rapp 
and Reischies, 2005), verbal fluency (Fabrigoule et al., 1998, Laukka et al., 2004), 
attention (Linn et al., 1995, Nielsen et al., 1999) and global cognitive functioning 
(Backman and Small, 1998, Fabrigoule et al., 1998). Impairments in some of these 
domains, e.g. episodic memory, have been identified as a strong predictor for 
conversion to dementia (Albert et al., 2001, Twamley et al., 2006), especially 
dementia of the Alzheimer-type. However, the longitudinal course of decline in 
specific domains remains largely undetermined, while a better understanding of 
the pattern, magnitude and temporal sequence of these cognitive deficits is 
important to facilitate early diagnosis, better prognosis and increase insight into 
early pathological brain mechanisms, since changes in the rate of decline might be 
more indicative of incipient dementia than impaired cognitive performance on an 
isolated assessment at baseline.  
 
By means of meta-analysis, we compared the rate of domain-specific decline in six 
distinct cognitive domains before dementia diagnosis, over a relatively long period 
of about 5 years. In addition, we tested whether rates of decline differed between 
future converters (n = 2249) and non-converters (n = 2439) (chapter 2). During the 
period before dementia diagnosis, decline in episodic memory and global 
cognitive functioning was almost two times larger than decline in other cognitive 
domains. In addition, the rate of decline in attention/information processing speed 
(IPS) was relatively small and, more importantly, did not differ between 
converters to dementia and non-converters. Interestingly, our results did not 
essentially change when we included only people who converted to Alzheimer’s 
Disease (AD) dementia compared to the inclusion of people who converted to 
dementia (AD or underlying aetiology not specified). This finding appears 
legitimate, because the majority of this second (aetiology not specified) group 
probably has underlying AD pathology, as AD is the most common cause of 
dementia. The finding that pre-dementia decline is most salient in global cognitive 
functioning and episodic memory is consistent with observations that the earliest 
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pathologic changes in (AD) dementia occur in the medial temporal lobe regions 
(Ridha et al., 2006, Sluimer et al., 2009), which are known to be crucial for episodic 
memory functioning. The lack of discriminative power of attention/IPS might be 
attributed to the effects of normal ageing on attention/IPS performance (Finkel et 
al., 2007, Hoogendam et al., 2014) and matches findings of previous studies into the 
limited predictive value of attention deficits for AD dementia (Albert et al., 2001).  
 
The results found in chapter 2 were mainly based on studies performed in the 
general population. However, these populations of cognitively healthy volunteers 
are not directly comparable to people who present themselves at a memory clinic 
because of cognitive complaints. Yet, the latter group includes subjects that seeks 
help and asks for their prognosis and possible treatment options.   
Therefore, in chapter 3 we studied decline before dementia diagnosis in a memory 
clinic-based population. We examined the pattern, magnitude and temporal 
sequence of decline in various cognitive domains in people who converted to AD 
dementia and compared this to decline in those who did not convert. We found 
that the performance of converters and non-converters differed already seven 
(episodic memory) to three (executive functioning and verbal fluency) years prior 
to AD dementia diagnosis. Again, large differences in decline between groups 
were found for episodic memory, but also for executive functioning, which is in 
line with findings from population-based studies (Chen et al., 2001, Grober et al., 
2008, Johnson et al., 2009). Again, there was no difference in decline in 
attention/(IPS) between groups, which corroborates our findings in chapter 2. Yet, 
when we included data on decline after dementia diagnosis, the trajectories for 
attention/IPS of converters and non-converters did differ. This implies that decline 
in attention is still subtle in the pre-dementia phase and starts widening as 
underlying pathology progresses. Further the absence of decline in attention/IPS 
indicated that the observed decline in executive functioning was merely due to a 
higher order cognitive processing problem instead of being due to an underlying 
mental speed problem.  
 
Our findings from these two chapters might have implications for early detection 
of dementia and indicate that cognitive assessments should not focus solely on 
episodic memory, but should also take measures of executive functioning and 
global cognitive functioning into account. In addition, decline in attention/IPS 
might be regarded as less important since it appears to be not indicative of 
underlying dementia pathology in the early stages of cognitive decline.  
 
In chapter 4, we studied the existence of cognitive subtypes in a memory clinic 
population in order to assess the heterogeneity in clinical presentation (i.e. single- 
vs. multi-domain impairment and amnestic vs. non-amnestic impairment) that is 
often found in people with MCI. Instead of using a theoretical or clinical 
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framework we used a data-driven approach with sophisticated statistics (i.e. latent 
profile analysis) to identify different cognitive subtypes. Our study detected five 
cognitive subtypes: people with low- and high-normal cognition, people with 
primary memory impairments with impairments in long-term consolidation 
(recognition), people with primary memory impairments but without impairments 
in long-term consolidation and people with primary non-memory impairments. 
These different subtypes parallel the current MCI concept. Subtypes displayed 
unique associations with overall dementia risk and dementia aetiology. Lowest 
dementia risk was found in the high-normal cognition subtype, which likely 
represents the “worried-well” patient whose performance is not indicative of any 
underlying neurodegenerative pathology. The highest dementia risk was found in 
people with primarily non-amnestic impairment and they developed most often 
non-AD dementia, which matches previous findings (Petersen and Morris, 2005). 
People with primary amnestic impairment most often developed AD-type 
dementia, regardless of whether they had impaired recognition memory or not. 
Although impaired recognition has been reported before as a predictor of AD-type 
dementia (Didic et al., 2013), our findings state that impaired recognition does not 
discriminate between people with varying dementia risk.  
These findings indicate that it is important to take cognitive variability within a 
memory clinic population into account, because treating people as a single 
population disregards the diverse extent and patterns of cognitive impairment that 
exist within the MCI population and their different associations with dementia risk 
and aetiology. Our results support the use of a three-group classification system: 
normal cognitive functioning, amnestic cognitive impairment and non-amnestic 
cognitive impairment  
 
Multimorbidity 
Advancing age is typically associated with multimorbidity (Uijen and van de 
Lisdonk, 2008, van den Akker et al., 1998), however little is known on whether 
multimorbidity affects cognitive decline. There is some evidence that the 
cumulative medical disease burden is related to worse cognitive functioning in the 
general elderly population (Morrow et al., 2009, Patrick et al., 2002) and in 
demented subjects (Doraiswamy et al., 2002, Oosterveld et al., 2014), hence we 
expected an effect of severity of total comorbidity on cognitive performance over 
time and progression to dementia in our non-demented memory clinic-based 
population.  
Findings of our study indicated that the severity of total comorbidity was related 
to worse cognitive performance on speed related tests already at the time patients 
entered the memory clinic. This corroborates findings of studies in people with 
MCI (Lyketsos et al., 2005) and dementia (Doraiswamy et al., 2002, Oosterveld et al., 
2014), though these studies reported on global cognition instead of specific 
cognitive domains. In addition, severity of comorbidity was also related to 
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cognitive decline over three years, again only on speed dependent tests, which 
corroborates findings in cognitively healthy elderly (Patrick et al., 2002). When 
looking at the influence of specific disease clusters on cognitive decline, mainly 
severity of comorbidity in the cardiac and respiratory domain was associated with 
worse cognitive performance and steeper decline over time. Factors like atrial 
fibrillation and chronic heart failure have been related previously to worse 
cognitive performance and cognitive decline (Almeida et al., 2012, Bellomo et al., 
2012, Thacker et al., 2013), and the same associations have been found for (the 
severity of) pulmonary diseases (Dal Negro et al., 2014, Klein et al., 2010).   
However, severity of total comorbidity was not related to an increased risk of 
conversion to dementia after three years, though multiple single medical diseases 
have been associated with an increased risk of dementia before (Barnes and Yaffe, 
2011). Our finding might be a result of the relatively short follow-up period, which 
limited the number of converters to dementia and thus power of our analyses. In 
addition, it is possible that some non-converters might have been misclassified at 
their latest follow-up assessment because they will convert to dementia in the 
future, thereby diluting the effect. Further, severity of comorbidity mainly affects 
speed and it has been shown before that speed impairments are not an important 
predictor of conversion to dementia.  
Our study showed that multimorbidity has a strong impact on cognitive 
performance and may rather be a cause of cognitive decline than a consequence of 
an underlying neurodegenerative process. Furthermore, our results provide a basis 
for shifting from a single pathology approach to a more integrative approach, 
which also is more representative for the typical increasing disease burden in our 
ageing population. 
 
Health-related Quality of Life 
In absence of curative drug interventions at present, and likely also in the near 
future, the importance of focusing on secondary outcomes, i.e. HRQoL, 
throughout the entire course of dementia is increasingly recognized (Gwyther, 
1997, Logsdon et al., 2002, Ready and Ott, 2003, Walker et al., 1998, Whitehouse and 
Rabins, 1992). HRQoL has been reported to be diminished in dementia (Lapid et 
al., 2011, Missotten et al., 2008, Ready et al., 2004), but has not been extensively 
investigated in MCI and results thus far are inconsistent. It is known that the 
uncertain MCI label may evoke negative reactions like anxiety and loss of self-
confidence, feelings of irritation and anger towards others or abandoning leisure 
activities (Joosten-Weyn Banningh et al., 2008). As a result, MCI could also be 
related to lower HRQoL, which would be an important target for interventions. 
We investigated the association between comorbid disease burden, emotional and 
cognitive functioning and HRQoL to see whether these factors, that are associated 
with HRQoL in dementia (Banerjee et al., 2006, Mhaolain et al., 2012, Sloane et al., 
2005), are also related to HRQoL in memory clinic visitors with MCI and in those 
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with subjective cognitive complaints (SCI).  
Our study showed that most of the variance in HRQoL in memory clinic visitors is 
explained by emotional functioning and especially by depressive symptoms. This 
corresponds to findings of a systematic review into HRQoL in people with 
dementia (Banerjee et al., 2009). In addition, lower HRQoL in people with MCI was 
also related to the presence of comorbidities in the eyes/ears/nose and 
gastrointestinal tract domain. The relation between HRQoL and cognition was 
limited to performance on a processing speed test in MCI. Our study indicated that 
HRQoL in memory clinic visitors is influenced by several potentially modifiable 
factors that are known to be prevalent in this elderly population. These factors 
should be taken into account in this population with cognitive complaints and they 
might be promising targets for non-cognitive interventions to improve HRQoL.  
 
Methodological considerations 
The present thesis reports findings from multiple study designs, including a 
systematic review and meta-analysis, a retrospective cohort study, a prospective 
cohort study and cross-sectional data. 
 
Strengths 
One of the main strengths of our studies was the use of large sample sizes, which 
increased the power of our studies and allowed us to perform sophisticated 
multivariate and random-effects analyses. In addition, our samples were not 
restricted to a single centre and we included both people with MCI and people 
with subjective cognitive complaints. Essentially, and in contrast to what is often 
done in MCI studies, we applied broad inclusion criteria in which most comorbid 
disorders were not excluded, thus avoiding elimination of these potentially 
important contributing factors in advance and maximizing generalization to the 
general elderly population.  
The longitudinal study designs with follow-ups from 3 (chapter 6) up to 10  
(chapter 3) and 14 years (chapter 4) gave us the opportunity to investigate short-
term as well as long-term outcomes of subjects. Further, the relatively long follow-
up period (chapters 3 and 4) allowed us to investigate dementia outcome by 
including a considerable number of converters to dementia with several 
assessment points. In addition, we used an extensive neuropsychological 
assessment in all studies, which covered the most relevant cognitive domains. By 
means of meta-analysis we could increase insight into the annual rate of domain-
specific cognitive decline in the pre-dementia phase by pooling data from previous 
studies and taking into account the sample size of all studies (chapter 2).  
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Limitations 
Our studies also had several limitations. First, people who present themselves at 
highly specialized memory clinics in academic medical centres are likely not 
representative of the general population with cognitive complaints. Further, there 
is the issue of missing data, since not all participants had information on all 
measures through the entire follow-up period, because of which valuable 
information could have been missing. Yet, this is a common and unavoidable 
problem that is intrinsic to clinical research with an elderly population. In 
addition, there is the matter of loss to follow-up that could lead to selection bias. In 
the prospective 4C-MCI study (chapters 5 – 7) participants that dropped out were 
significantly different from the participants that had follow-up data, while in the 
retrospective 4C-MCI study (chapters 3 and 4) we partially relied on routine 
clinical data, which led to absence of information regarding dropouts. However, 
by employing statistical procedures like random-effects linear mixed models we 
made maximum use of all available data for each participant. Yet, given that 
attrition was not completely at random, effects might have been diluted as either 
non-converters with intact cognition in the routine clinical setting (chapters 3 and 
4) or the older, more fragile and more cognitively impaired individuals in a 
research setting (chapter 6) are inclined to get lost to follow-up.  
Furthermore, although our follow-up time was relatively long (especially in 
chapters 3 and 4) it is still possible that some non-converters might have been 
misclassified at their latest follow-up assessment because they will convert to 
dementia in the future, thereby attenuating the effect. This is especially salient in 
the prospective part of the 4C-MCI study which currently only has three years of 
follow-up. A follow-up time of five to ten years seems most appropriate for studies 
into early stage cognitive decline, as this time frame encompasses both the earliest 
decline in cognitive functioning and covers a period that is relevant for questions 
regarding prognosis in the general elderly population (e.g. for how will I remain 
non-demented?). Another important factor to take into account in these 
longitudinal studies is the existence of test-retest or practice effects. When 
neuropsychological tests are applied longitudinally practice effects are 
unavoidable, as the test procedures become more familiar to the participants. We 
indeed observed absence of decline in a part of our ageing study population 
(chapters 3 and 6), which could possibly be attributed to test-retest effects. In 
chapter 3, changes in neuropsychological test performances were compared for 
individuals who did or did not convert to dementia. Given the fact that only non-
converters showed a practice effect, the absence of such an effect might possibly 
also be regarded as an indication of underlying dementia pathology. In chapter 6, 
we compared changes in neuropsychological test performances for people who did 
or did not have a certain risk factor (i.e. severity of comorbidity). Given the 
assumption that practice effects are not dependent on the risk factor of interest, 
test-retest effects most likely did not affect our results substantially. Further, our 
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data did not include neuropathologic confirmation of dementia diagnosis or 
collection of potential diagnostic biomarkers. However, this is presumably an 
adequate reflection of current clinical practice, where biomarkers are 
complementary and only recommended in case of substantial clinical uncertainty 
(Hort et al., 2010). In addition, use and availability of biomarkers is still limited in 
countries outside Europe or the United States.  
 
Recommendations 
Scientific implications 
The results of the research in this thesis have several implications for future studies 
in subjects with MCI. We showed that episodic memory, but also executive 
functioning and global cognitive functioning display early and large decline before 
dementia diagnosis. Future research should investigate the predictive value of 
cognitive decline in these domains over time for conversion to dementia rather 
than focussing on the predictive value of an isolated assessment of cognitive 
performance.  
Another important recommendation for future research is the inclusion of subjects 
with multimorbidity at baseline in studies into prodromal dementia. 
Multimorbidity is common in the elderly population and was related to cognitive 
performance and decline (chapter 6) and HRQoL (chapter 7). By excluding this 
important aspect in diagnostic and therapeutic studies in advance, generalizability 
to the MCI population will be limited, a factor contributing to cognitive decline 
will be overlooked and a substantial number of people at risk for dementia will not 
be detected. Further, as multimorbidity was not related to an increased risk of 
conversion to dementia it does not seem to be a confounder for conversion studies, 
mainly because it affects speed performance, which is not a good predictor of 
conversion to dementia.  
We further recommend that studies into early stage cognitive decline aim to follow 
subjects for five years or more, since AD related decline in episodic memory can 
precede dementia diagnosis by seven years (chapter 3), with other domains 
following several years later. By applying limited follow-up lengths important 
information on cognitive decline in the earliest stages might not be detected. 
Further, the influence of comorbidity on conversion to dementia is likely to be 
more evident after a longer follow-up period, since after three years follow-up 
severity of comorbidity influences only speed related decline but not conversion to 
dementia (chapter 6). In addition, we advocate the use of latent profile analyses 
and multivariate statistics in dementia research, since these statistic techniques 
may reveal more informative patterns of associations than the study of isolated 
cognitive domains. These cognitive patterns can then be used for studying disease 
mechanisms and relations with biomarkers.  
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Clinical implications 
The clinical implications of our findings lie in the establishment of the natural 
course of decline in MCI in memory clinic visitors, the contribution of 
multimorbidity in this population and the determinants of HRQoL we identified.  
We found that episodic memory and global cognitive functioning declined almost 
two times faster than other cognitive domains before dementia diagnosis. The 
findings for episodic memory were corroborated in a memory clinic-based 
population, where decline in episodic memory was the earliest and strongest 
indicator of incipient AD dementia, while also executive functioning showed an 
accelerated rate of decline compared to people that remained non-demented.  
These findings have implications for the use of optimal neuropsychological test 
batteries that aim to detect dementia at an early stage. Although our results 
confirm the importance of episodic memory impairment early in the disease 
process, also decline in executive functioning and global cognitive functioning 
seem early and sensitive indicators of future dementia. Therefore, cognitive 
assessment should not primarily focus on episodic memory, but give equal 
importance to executive functioning and global cognitive functioning using 
sensitive and reliable measures. These domains are also important in the 
identification of different cognitive subtypes within the MCI population. These 
subtypes can be used for establishing specific dementia risks and the suspected 
underlying aetiology.  
Another important consequence of our results is that for detecting early stage 
cognitive decline the main emphasis in a cognitive assessment should not be on 
the attention/IPS domain, since we showed that decline in attention/IPS does not 
differ between converters to dementia and non-converters. It is likely that the 
established decline in attention/IPS in both groups can be attributed to an ageing 
effect in this elderly population (Finkel et al., 2007, Hoogendam et al., 2014) and to 
the presence of comorbidity, which might obscure the effect of eventual 
developing underlying neurodegenerative pathology.  
We further found that performance and decline on speed dependent tests is 
influenced by severity of comorbidity. This implies that medical disorders should 
be intensively assessed in clinical practice in order to assure broad recognition and 
detection of factors that are associated with worse cognitive performance and 
decline. Since (part of) these factors are potentially modifiable, they may be an 
important target for interventions to ameliorate cognitive performance and in the 
long-term prevent cognitive decline and conversion to dementia. This 
multifactorial approach might be a more fruitful and realistic treatment strategy 
than a single molecule approach to, for instance, beta-amyloid removal. Treatment 
of comorbidities may be an explanation for the recently observed decline in 
incidence of dementia (Barnes and Yaffe, 2011, Qiu et al., 2013, Rocca et al., 2011, 
Schrijvers et al., 2012), although this declining incidence might also be due to the 
improved educational level of the population.  
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Our finding that HRQoL in memory clinic visitors is associated with comorbid 
disease burden, but also with worse performance on a speed-related test and 
depressive symptoms, also emphasize the importance of the broad assessment of 
additional non-cognitive factors in clinical practice and underscore the importance 
of a multidisciplinary approach in the diagnostic and treatment possibilities for 
people with MCI.  Special attention should be paid to the detection of depressive 
symptoms, since they turned out to be the most important determinant of HRQoL, 
but have also been related previously to worse cognitive performance (Ganguli et 
al., 2006, Steffens et al., 2006). As depressive symptoms can be ameliorated by a 
diversity of treatments, they appear to be an important target for interventions to 
improve HRQoL.   
 
Conclusions 
In conclusion, this thesis expands our knowledge about the natural course of 
cognitive decline in people with MCI that convert to dementia and those that do 
not. It is important to differentiate at an early stage between progressive and stable 
MCI, as both groups likely benefit from other sorts of advice and interventions.  
A first step in this direction is that we showed that differentiation in cognitive 
performance between stable and progressive MCI is possible already seven years 
prior to dementia diagnosis for episodic memory. Further, besides episodic 
memory also executive functioning and global cognitive functioning show early 
and large decline before dementia diagnosis and are thus important targets for 
early stage dementia detection. In addition, we demonstrated that decline in 
attention/IPS seems less indicative of future dementia. Yet, performance and 
decline in this domain is influenced by severity of comorbidity. However, severity 
of comorbidity seems not related to conversion to dementia in the short-term. In 
absence of curative treatments for dementia, we found that HRQoL of memory 
clinic visitors is affected by several potentially modifiable factors of which 
depressive symptoms appear to be the most important.  
It seems likely that the use of a multifactorial disease model, including cognitive, 
medical, emotional and biological predictors will optimize early recognition of 
dementia and identify new targets for interventions aimed at both preventing 
future cognitive decline and improving current HRQoL.  
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SUMMARY 
 
The increasing number of people with dementia will have large consequences for 
society and health care systems. As a result, there is a growing need for early 
diagnosis of dementia in order to initiate timely care, treatment and support for 
the patient and his/her family.  
The transitional state between normal cognitive functioning and dementia is now 
usually referred to as Mild Cognitive Impairment (MCI). MCI denominates a 
heterogeneous group of people with large individual variation in the level and 
pattern of cognitive impairment, course of decline over time and thus prognosis. 
This variation is likely due to differences in underlying cause of the impairment, 
and it is increasingly recognized that multiple factors contribute together to the 
development of dementia. So, in order to identify and discriminate between 
individuals that progress to dementia and those that do not, it is of major 
importance to investigate the profile of impairment and the natural course of 
cognitive decline in MCI and detect factors that can influence this course.  To 
examine this, the Clinical Course of Cognition and Comorbidity in MCI (4C-MCI) 
study was initiated. In the first part of this thesis we investigated the profile and 
course of cognitive decline in MCI. In the second part, we described the influence 
of the often-overlooked issue of comorbidity on the course of cognitive decline, 
and also on Health-related Quality of Life (HRQoL) in a memory clinic setting.  
 
In chapter 2, we provided a systematic review and meta-analysis on the rate of 
domain-specific cognitive decline in global cognition, episodic memory, executive 
functioning, attention/information processing speed, verbal and visuospatial 
ability in the pre-dementia phase. In addition, we performed domain wise 
comparisons with the rates of decline in non-converters. We included 21 studies, 
representing 2249 pre-dementia subjects and 2439 non-converters. Effect sizes for 
the extent of decline per year were calculated for each cognitive domain. Results 
showed that decline in episodic memory and global cognition was almost twofold 
compared to decline in other domains. In addition, the rate of decline in 
attention/information processing speed was relatively small and, more 
importantly, did not differ between converters to dementia and non-converters.  
Thus, measures for episodic memory and global cognitive functioning seem the 
most promising tools for early detection of dementia.  
 
In chapter 3, we aimed to further investigate the results from the previous chapter 
in a multicentre memory-clinic based population of consecutive non-demented 
patients (n=819). We examined the pattern, magnitude and temporal sequence of 
decline in various cognitive domains in people who converted to AD dementia 
and compared this to decline in those who did not convert. We found that the 
performance of converters and non-converters differed already seven (episodic 
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memory) to three (executive functioning and verbal fluency) years prior to AD 
dementia diagnosis. There was no evidence of decline in attention/information 
processing speed in both groups and thus no difference in trajectory. So, besides 
early episodic memory decline, decline in executive functioning may flag future 
dementia converters and should be given equal weight as memory decline in the 
diagnostic process.  
 
In chapter 4, we investigated the existence of different cognitive subtypes within a 
multicentre memory-clinic based population (n=635) and studied their prognostic 
value for the development of dementia. Using a data-driven approach, we were 
able to distinguish five different subtypes: patients with high-normal cognition; 
patients with low-normal cognition; patients with mainly memory impairment in 
recall; patients with memory impairment in recall and recognition; and patients 
with non-memory impairments. Lowest dementia risk was found in the high-
normal cognition subtype, which likely represents the “worried-well” patients. 
The highest dementia risk was found in the non-memory impairment subtype, 
which developed most often non-AD dementia. People with primarily amnestic 
impairment most often developed AD dementia, regardless of whether they had 
impaired recognition memory or not. Our findings show that is inefficient to treat 
patient’s data as if coming from a single population, and that failure to take 
variability into account may dilute associations that exist between subpopulations.  
 
The study design, measurement instruments and relationship between the 4C-MCI 
and the complementary 4C-Dementia study were described in chapter 5. In the 4C-
MCI study 315 consecutive non-demented patients, who presented themselves 
with cognitive complaints at the memory clinics of three academic centres, were 
followed for three years. Each year we recorded data on: the course of complaints, 
medical comorbidities, frailty, medication use and intoxications, quality of life, 
daily life functioning, neuropsychiatric symptoms and a physical examination and  
extensive neuropsychological assessment.   
 
In chapter 6, the association between the severity of total comorbidity and 
cognitive decline and/or conversion to dementia was investigated using data from 
the 4C-MCI study (n=315). Our results showed that the severity of comorbidity 
was related to lower performance on speed dependent cognitive tests, already at 
the time patients presented themselves at the memory clinic. This was found for 
both the total severity of comorbidity as for specific organ systems (i.e. cardiac, 
respiratory, neurological and endocrine domain). Further severity of total 
comorbidity was also related to faster cognitive decline over a three-year period, 
again on speed dependent tests. However, the severity of total comorbidity was 
not related to an increased risk of conversion to dementia. Our results show that 
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multimorbidity is a significant health problem and underscore the importance of a 
broad assessment of medical disorders in clinical practice.  
 
The research in chapter 7 focused on determinants of Health-related Quality of 
Life (HRQoL) in patients who presented themselves with cognitive complaints at a 
memory clinic (n=301). Our results indicated that most of the variance in HRQoL 
of memory clinic visitors is explained by emotional functioning and especially by 
depressive symptoms. In addition, lower HRQoL in MCI was also related to the 
presence of comorbidities in the eyes/ears/nose and lower gastrointestinal tract 
domain and to worse performance on a processing speed test. Yet, this was not 
found for people with subjective cognitive impairment. So, emotional and physical 
functioning should be taken into account in the memory clinic population and 
these factors might be promising targets for non-cognitive interventions to 
improve HRQoL.  
 
Chapter 8 provided a general discussion of the findings described in this thesis. 
Clinical and research implications of our research were discussed and suggestions 
for future research were debated. Furthermore, this last chapter included a 
summary of the findings, a knowledge valorisation, list of author affiliations, list of 
publications, information about the author, and acknowledgements.   
 
 
 
 
!
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SAMENVATTING 
 
Het groeiende aantal mensen met dementie zal grote gevolgen hebben voor onze 
maatschappij en de gezondheidszorg in het bijzonder. Als gevolg hiervan is er een 
toenemende behoefte naar vroegdiagnostiek bij dementie om zo tijdig zorg, 
behandeling en ondersteuning te kunnen bieden aan de patiënt en zijn/haar 
naasten.  
Tegenwoordig spreekt men vaak over het voorstadium van dementie wanneer er 
sprake is van milde cognitieve problemen (mild cognitive impairment of MCI). De 
groep mensen met MCI is een zeer heterogene groep, die grote individuele 
verschillen laat zien in de mate en het patroon van cognitieve beperkingen, het 
beloop van achteruitgang over tijd en dus ook in prognose. Deze variatie wordt 
waarschijnlijk veroorzaakt door verschillen in de onderliggende oorzaak van de 
cognitieve beperkingen, waarbij het de laatste jaren steeds duidelijker is geworden 
dat dementie een multifactorieel bepaald ziektebeeld is. Het is dan ook van groot 
belang om het natuurlijk beloop van cognitieve achteruitgang in MCI te 
onderzoeken en factoren te ontdekken die het beloop kunnen beïnvloeden, om op 
deze manier een onderscheid te kunnen maken tussen mensen die dementie gaan 
ontwikkelen en mensen die dit niet doen. Om dit te onderzoeken werd de Clinical 
Course of Cognition and Comorbidity in MCI (4C-MCI) studie opgezet.  
In het eerste deel van dit proefschrift hebben we het profiel en natuurlijk beloop 
van cognitieve achteruitgang in MCI onderzocht. In het tweede deel focusten we 
op de tot nog toe vaak genegeerde factor comorbiditeit. Hierbij onderzochten we 
de invloed van comorbiditeiten op het beloop van cognitieve achteruitgang. 
Daarnaast bekeken we de invloed van comorbiditeit op gezondheidsgerelateerde 
kwaliteit van leven in een geheugenpoli setting.   
 
In hoofdstuk 2 beschreven we de resultaten van een systematische review en 
meta-analyse naar de mate van domein-specifieke cognitieve achteruitgang in het 
voorstadium van dementie voor de domeinen: globale cognitieve vermogens,  
episodisch geheugen, uitvoerende controlefuncties, 
aandacht/informatieverwerkingssnelheid, verbale en visuospatiële vaardigheden. 
Daarbij vergeleken we de achteruitgang per domein ook met de achteruitgang in 
mensen die geen dementie ontwikkelden. Er werden 21 studies geïncludeerd met 
daarin 2249 mensen in een voorstadium van dementie en 2439 mensen die niet 
dement werden. Voor de verschillende cognitieve domeinen werden effectgroottes 
voor de mate van achteruitgang per jaar berekend. Resultaten toonden aan dat 
achteruitgang in episodisch geheugen en globale cognitieve vermogens bij 
degenen in het voorstadium van dementie  bijna twee keer zo snel verliep als 
achteruitgang in andere domeinen. Verder viel op dat de mate van achteruitgang 
in aandacht/snelheid relatief klein was en dat er in dit domein ook geen verschil 
in achteruitgang bestond tussen mensen die dementie ontwikkelden en zij die geen 
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dementie ontwikkelden. Voor alle andere domeinen werd echter een duidelijk 
verschil in achteruitgang gezien tussen beide groepen. Hieruit kan geconcludeerd 
worden dat testen voor episodisch geheugen en globale cognitieve vermogens de 
belangrijkste instrumenten zijn voor een vroege detectie van dementie.  
 
In hoofdstuk 3 werden de bevindingen uit het vorig hoofdstuk nader onderzocht 
in een multicenter studie waarin 819 niet-demente patiënten, afkomstig van twee 
geheugenpoli’s, zijn geïncludeerd. We onderzochten het patroon, de snelheid en 
de tijdsvolgorde van achteruitgang in meerdere cognitieve domeinen in patiënten 
die Alzheimer dementie kregen en patiënten die geen dementie ontwikkelden. We 
vonden dat de prestaties van deze twee groepen op een geheugentest reeds zeven 
jaar voor de diagnose dementie werd gesteld van elkaar verschilden. Enkele jaren 
later vertoonden ook de prestaties op woordvlotheid en uitvoerende 
controlefuncties een verschil tussen de twee groepen. Daarbij zagen we grote 
verschillen tussen beide groepen in de snelheid van achteruitgang op met name 
episodisch geheugen en uitvoerende controlefuncties. In beide groepen werd geen 
achteruitgang gevonden in aandacht/snelheid en was er dus ook geen verschil in 
beloop over tijd in dit domein. Hieruit kunnen we concluderen dat naast een 
vroege achteruitgang in geheugen ook achteruitgang in uitvoerende 
controlefuncties een indicator is voor het ontwikkelen van Alzheimer dementie en 
dat beide domeinen van even groot belang zouden moeten zijn in het diagnostisch 
proces.    
 
In hoofdstuk 4 hebben we het bestaan van verschillende cognitieve subtypes 
binnen een multicenter geheugenpolipopulatie (n=635) getest en onderzochten we 
de voorspellende waarde van de verschillende subtypes voor het ontwikkelen van 
dementie. Met behulp van een vooruitstrevende gegevens-gestuurde aanpak, 
waren we in staat vijf verschillende cognitieve subtypes te onderscheiden: mensen 
die presteren op hoognormaal niveau, mensen die presteren op laagnormaal 
niveau, mensen met geheugenstoornissen in het opdiepen, mensen met 
geheugenstoornissen in opdiepen en herkennen en mensen met stoornissen in 
andere functies dan geheugen. De groep die presteerde op hoognormaal niveau 
had het laagste risico op het ontwikkelen van dementie. Het hoogste risico op het 
ontwikkelen voor dementie werd gevonden in het subtype met stoornissen in 
andere functies dan geheugen, deze mensen ontwikkelden het meest frequent 
dementie van een niet-Alzheimer type. Mensen met voornamelijk 
geheugenstoornissen ontwikkelden vooral Alzheimer dementie, ongeacht of ze 
alleen stoornissen hadden in het opdiepen van informatie of stoornissen in zowel 
opdiepen als herkennen. Onze bevindingen tonen aan dat patiënten niet gezien 
moeten worden als één grote groep bestaande uit hetzelfde type en dat bestaande 
associaties tussen subgroepen mogelijk verzwakt worden door geen rekening te 
houden met deze variabiliteit.  
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De studieopzet, gekozen meetinstrumenten en de relatie van de 4C-MCI studie 
met de complementaire 4C-Dementie studie beschreven we in hoofdstuk 5 van dit 
proefschrift. In de 4C-MCI studie werden 315 niet-demente patiënten, die zichzelf 
hadden gemeld met cognitieve klachten op de geheugenpoli van drie academische 
centra, gevolgd gedurende drie jaar. Ieder jaar werd informatie verzameld over: 
het beloop van de cognitieve klachten, medische comorbiditeiten, fysieke 
kwetsbaarheid, medicatiegebruik en intoxicaties, kwaliteit van leven, functioneren 
in het dagelijks leven en neuropsychiatrische symptomen. Ook werd een 
lichamelijk onderzoek en een uitgebreid neuropsychologisch onderzoek 
uitgevoerd. 
 
In hoofdstuk 6 onderzochten we wat de invloed is van de totale ernst van 
medische comorbiditeiten van een patiënt op cognitieve prestaties, cognitieve 
achteruitgang en het risico op het krijgen van dementie in de 4C-MCI studie 
(n=315). Onze bevindingen toonden aan dat de ernst van de comorbiditeiten 
gerelateerd was aan slechtere prestaties op taken waarbij het tempo van werken 
van belang was. Dit effect was al zichtbaar op het moment dat mensen zich 
meldden met klachten. Deze resultaten werden gevonden voor zowel de totale 
ernst van de comorbiditeiten, als voor de ernst binnen specifieke orgaansystemen 
(d.w.z. het cardiale, respiratoire, neurologische en endocriene domein). Verder 
bleek dat de ernst van de comorbiditeiten ook gerelateerd was aan snellere 
cognitieve achteruitgang over een periode van 3 jaar. Dit effect werd wederom 
gevonden voor tempo-gerelateerde taken. Ondanks deze resultaten bleek echter 
dat de ernst van de comorbiditeiten niet geassocieerd was met een verhoogd risico 
op het krijgen van dementie na 3 jaar. Onze resultaten onderstrepen het belang 
van een grondig onderzoek naar medische comorbiditeiten in de klinische praktijk, 
gezien de effecten van multimorbiditeit op cognitie.  
 
In hoofdstuk 7 hebben we onderzocht welke factoren een rol spelen in de kwaliteit 
van leven van patiënten die zich melden met cognitieve klachten op een 
geheugenpoli (n=301). Onze resultaten toonden aan dat het grootste deel van de 
variantie in kwaliteit van leven van geheugenpolipatiënten verklaard wordt door 
hun emotioneel functioneren en in het bijzonder door de aanwezigheid van 
depressieve symptomen. Verder bleek dat een lagere kwaliteit van leven in 
patiënten met MCI geassocieerd was met de aanwezigheid van comorbiditeiten in 
de domeinen ogen/oren/neus en het maagdarmkanaal en met slechtere prestaties 
op een snelheidstaak. Deze resultaten werden echter niet gevonden in de groep 
met alleen subjectieve cognitieve klachten. Concluderend kan worden gesteld dat 
emotioneel en fysiek functioneren belangrijke factoren zijn om te onderzoeken in 
een geheugenpolipopulatie en mogelijk zouden deze factoren veelbelovende 
targets zijn voor niet-cognitieve interventies om kwaliteit van leven in deze groep 
te verbeteren.  
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Hoofdstuk 8 omvat een algemene discussie van onze bevindingen, waarbij ook 
klinische en wetenschappelijke implicaties worden toegelicht en suggesties voor 
toekomstig onderzoek worden gegeven.  Daarnaast bevat dit hoofdstuk een 
Engelse en Nederlandstalige samenvatting van de belangrijkste bevindingen, een 
kennisvalorisatie, een auteurslijst, een publicatielijst, informatie over de auteur en 
een dankwoord. 
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The goal of this valorisation paragraph is to describe how the knowledge resulting 
from the research in this dissertation can be made valuable for clinical and social 
use. This dissertation focuses on the natural course of cognitive decline in people 
with Mild Cognitive Impairment (MCI) and the influence of comorbidity on 
outcomes in this population.  
 
Societal relevance 
Dementia is a growing health problem, since the number of people with dementia 
is thought to dramatically rise due to the ageing population. This development 
poses a major challenge for society, health care systems and also has great 
economical impact. Already in 2011, dementia was the second most expensive 
medical disease in the Netherlands, with disease-associated costs of almost 5 
billion euros. Furthermore, dementia is thought to have the highest disease burden 
of all medical illnesses for the patient, but has also a tremendous impact on the 
caregiver.  
Currently, the transitional state between normal cognitive functioning and 
dementia is usually referred to as Mild Cognitive Impairment (MCI). MCI 
denominates a heterogeneous group of people with large individual variation in 
the level and pattern of cognitive impairment, course of decline over time and thus 
prognosis. Therefore, the uncertain MCI label often leads to negative reactions 
from patients and caregivers and may evoke anxiety, loss of self-confidence, 
feelings of depression etcetera. 
Thus, there are multiple reasons for investigating the course of cognitive decline in 
MCI as has been done in this thesis. First, for patients and caregivers, a more 
accurate prognosis on the risk of developing dementia is important to end the 
uncertainty currently associated with the MCI label and it allows patients and 
caregivers to make arrangements for the future. In addition, when it is possible to 
differentiate between individuals who are likely to develop dementia and those 
who are not, clinicians will be able to initiate timely care, (psychological) treatment 
and support, which will likely reduce health care costs. Further, if pharmacological 
treatment becomes available in the future, these drugs are likely to be most 
effective in the early stages of the disease, which ultimately reduces the total 
disease burden for society and health care and also diminishes costs.  
 
Target audience 
The results described in this dissertation are relevant to various stakeholders who 
are involved in dealing with dementia and it’s consequences.  
First, the results are especially relevant for people with cognitive complaints and 
their families, since they often want to know the course of their cognitive 
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complaints, and whether patients are at increased risk of developing dementia 
and/or becoming care dependent in the near future. 
Clinicians working in memory clinics are also important stakeholders, since they 
are the ones who have to inform patients with cognitive complaints about their 
risk of developing dementia in the future. The results of this thesis will aid them 
improving the accuracy of prognosis by increasing knowledge about which  
neuropsychological tests are important and early indicators of developing 
dementia pathology. As a result, they can better inform patients and their families 
about risks and what specific actions need to be taken. Further, support and 
education can be given at an early stage and when in the future disease-modifying 
treatment is available these patients will be an important target group.  
Commercial organization concerned with neuropsychological test development 
could use the results to improve their products and create more dementia-sensitive 
test batteries. As it appears that especially cognitive decline in episodic memory, 
executive functioning and global cognitive functioning are important indicators of 
developing dementia, extra focus should be placed on the development of 
sensitive, reliable tests that accurately measure small changes in these domains 
over time.  
Decision makers in (government) organizations involved in health care 
regulations, such as the Dutch Centraal Begeleidingsorgaan (CBO), or similar 
entities worldwide, could use the results of this thesis to adapt their 
recommendations about neuropsychological test protocols in dementia 
diagnostics, placing more emphasis on decline in executive functioning and global 
cognitive functioning and less on decline in attention/speed.  
 
Products 
The main products of this dissertation are the implications that our results have for 
routine clinical practice in the assessment of cognitive complaints. In the first 
place, our results have consequences for the use of optimal neuropsychological test 
batteries that aim to detect dementia at an early stage. Our results indicate that 
neuropsychological test protocols should be reshaped, not primarily focussing on 
episodic memory, but giving equal importance to executive functioning and global 
cognitive functioning, using sensitive and reliable measures. In addition, the main 
emphasis should not be on attention/speed, since we showed that decline in this 
domain did not differ between converters to dementia and non-converters. 
Besides, we showed that performance and decline on speed-related tests is 
influenced by the severity of comorbidity. This implicates that a broad assessment 
of additional medical factors, is important in clinical practice, to take into account 
other potential causes for cognitive impairment. Further, since (part of) these 
factors are potentially modifiable, they are also an important target for 
interventions to ameliorate cognitive performance and in the long-term prevent 
cognitive decline and conversion to dementia. The importance of the broad 
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assessment of additional non-cognitive factors in clinical practice is supported by 
our findings that Health-related Quality of Life is associated with comorbid 
disease burden and depressive symptoms. Our general findings thus emphasize 
the importance of a multidisciplinary approach in the diagnostic and treatment 
possibilities for people with MCI.  
 
Innovation 
The results in this dissertation are among the first that are based on a large 
multicentre clinical cohort of people, meaning that patients included in our study 
presented themselves with cognitive complaints at a memory clinic. This 
distinguishes them from cognitively normal subjects from the general population 
who are most often selected for studies into early stage cognitive decline.  
Further, in contrast to what is often done in MCI studies, we explicitly chose to 
apply broad inclusion criteria, in which most comorbid disorders were not 
excluded. By this means, we avoided the elimination of these potentially important 
contributing factors in advance and maximized generalization to the general 
elderly population, which is characterized by an increased disease burden and 
multimorbidity.  
 
Valorisation process 
Before the results of this dissertation are likely to be applied in clinical practice, 
several additional steps are required. First, other clinical studies into early stage 
cognitive decline have to be performed to confirm our results. These studies 
should also include patients with a variety of comorbidities, since they appear to 
influence both cognitive decline and Health-related Quality of Life in memory 
clinic visitors. Further, the inclusion of comorbidities live up to the notion that 
dementia is a multifactorial disease, with diseases and factors not necessarily 
located in the brain enhancing underlying neurodegenerative pathologies. As far 
as we are aware, large-scale studies with comparable broad inclusion criteria like 
ours have not been conducted yet, so new studies have to be set up.  
On the long term, when our results are validated, neuropsychological test 
protocols should be reshaped, putting more emphasis on executive functioning 
and global cognition besides episodic memory and attribute less importance to 
impairments in attention/speed. Tests for these domains are widely available and 
used in clinical practice, so practical issues do not hinder implementation in this 
regard, although new, more reliable and sensitive measures might be developed 
specifically for the purpose of dementia screening. To assure standardization and 
allow comparison between assessments at different facilities in the Netherlands, 
agreements should be made about the exact tests that are recommended to 
measure the indicated domains. To assure generalisation to all hospital and 
memory clinics the CBO should include these recommendations about the test 
protocol in the guidelines for dementia diagnostics and treatment. To make sure 
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that members of the advisory committee of the CBO are aware of the current 
outcomes, it is important to spread the results within the dementia research 
community by publication in international journals and presentations on dementia 
related conferences. Ultimately, when results would be implemented in clinical 
practice, the health care costs associated with dementia could be reduced. First, by 
offering support and education and an early stage, by means of which patients are 
likely to be able to live in their home setting longer, thereby avoiding the costs 
associated with nursing home placement. Second, if disease-modifying medication 
becomes available in the future, these patients are likely to not develop the full-
blown dementia syndrome and so health care costs associated with severe 
dementia are no longer applicable in these cases.  
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Pauline, je startte aanvankelijk als mijn begeleider en hoewel je dat stokje hebt 
overgedragen aan Inez, bleef je als coordinator toch betrokken bij mijn project. 
CHAPTER 8 
 
 
 
200 
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die de inhoud van mijn stukken telkens verbeterd hebben.  
 
4C-MCI was nooit zo goed verlopen zonder de steun en inzet van diverse mensen. 
Allereerst en ontzettend belangrijk: Astrid, bedankt voor het inplannen van al die 
honderden patiënten en de fijne samenwerking. Ik denk dat ik zonder jou na een 
jaar al gillend was weggelopen. 
Tanja & Carla, jullie bedankt voor de inzet bij de mantelzorggesprekken, ook dat 
heeft me heel veel werk uit handen genomen. Ook alle stagiaires, Rens, Suzanne, 
Caroline, Anneloes, Lorraine, Iris, Nele, Eefje, Mijke, Anne, Collin, Laura, Liselot 
en Angela wil ik bedanken voor het vele werk dat jullie verricht hebben. Als ik al 
die NPO’s zelf had moeten afnemen was mijn proefschrift nu nog niet klaar 
geweest. Ook Willemijn, Babette, Isabelle, Lies en Stephanie bedankt voor alle 
ondersteuning bij het zien van patiënten voor de follow-ups. We hebben een hoop 
bijzondere, maar ook hilarische momenten meegemaakt en het was fijn om te 
weten dat ik mijn taken altijd met een gerust hart aan jullie kon overlaten. Suzanne 
Holthuisen, ook jij nog bedankt voor het enthousiasme en de nauwkeurigheid 
waarmee je me destijds hebt ingewerkt. Je was een gezellige kamergenoot en een 
geweldige onderzoeksmedewerker. Helaas had je al snel een andere baan 
gevonden, ik had je nog veel langer willen houden! Claire, jij bedankt voor al je 
hulp met het scoren van de CIRSen, wat een karwei is dat geweest. Na verloop van 
tijd werden we bijna medische experts en leverden diagnoses geen enkel probleem 
meer op, jammer van die plaatjes die we soms op google vonden ;). Ondanks het 
vele werk dat moest gebeuren was het altijd heel gezellig met je.  
Manon, bedankt voor het coördineren van het stukje 4C bij de Riagg. Het verloop 
van het project was niet altijd gemakkelijk, maar uiteindelijk is er toch een mooi 
resultaat uitgekomen. Ook alle andere medewerkers van Riagg Ouderenzorg 
bedankt voor jullie inzet bij dit project.  
 
Ik bedank natuurlijk ook alle onderzoekers in Nijmegen en Amsterdam die bij dit 
project betrokken waren. In het bijzonder wil ik Saskia en Nicole bedanken voor   
hun inspanningen bij de dataverzameling en voor de goede en snelle 
communicatie. Ik heb altijd fijn met jullie samen gewerkt en wie weet komen we 
elkaar in de toekomst nog tegen als psychologen binnen de ouderenzorg. 
 
DANKWOORD 
 
 
 
201 
Lies & Stephje, mijn paranimfjes en Belgische Best Friends. Wie had ooit gedacht 
dat ik hier twee zulke lieve vriendinnetjes zou vinden. Door onze overlappende 
projecten hadden we veel met elkaar te maken en het was al snel duidelijk dat we 
een klik hadden. Zonder jullie was mijn aio-periode vast niet zo leuk geweest. Ik 
dank jullie voor alle mentale support, het aanhoren van mijn klaagzangen, de 
ondersteuning met dataverzameling, het aanleveren (of opeten) van chocolade en 
muffins en alle gezellige momenten die we hebben gehad. Natuurlijk wil ik jullie 
ook bedanken voor het vergroten van mijn vocabulaire, wat er misschien mede 
voor gezorgd heeft dat ik in mijn eerste jaar in Maastricht al werd aangezien voor 
Belg!! Maar ook ik draag voortaan golfjes en stel mijn GPS in om te rijden over de 
autostrade !. Stephje, de koffie-met-lemoncake-traditie gaan we behouden 
komend jaar hoor! Liesje, ook al werk je nu niet meer hier er zullen nog genoeg 
gezellige momenten volgen (met of zonder mannen) met vooral veel lekker eten.  
 
De allerleukste en liefste roomies, Willemijn en Joany, bedankt voor alle wijze 
adviezen en steun. Maar ook voor alle humor, gezelligheid en het luisterend oor 
dat jullie altijd boden als ik weer eens niet stil kon zijn. Willemijn, liefste mede-
Brabo, ik kan zo ontzettend met en om je lachen (remember de kraamvisite met 
hond en mijn uitroep op het station in Amsterdam) en ben blij dat jij tegenover me 
zat. Gelukkig hoeven we het komende jaar nog geen afscheid van elkaar te nemen. 
En ooit wonen we gewoon allebei in Eersel !    
Lieve Joany (aka zjwaanie) als ik tips wil op welk gebied dan ook: huidverzorging, 
koken, powerpoint weet ik dat ik bij jou moet zijn. Bedankt voor alle leuke 
recepten, lieve kleine kadootjes en natuurlijk die geweldige vent van je die mijn 
omslag zo geweldig heeft gemaakt. Je bent een schatje en we gaan snel op doggy 
date!  
Mijn oud-roomie, Deliane. We hebben helaas niet zolang een kamer kunnen delen, 
maar dat maakt niet dat je geen plekje in mijn dankwoord verdient. Je kon me met 
jouw extra jaren ervaring altijd geruststellen als ik me afvroeg hoe promoveren 
ooit ging lukken en herkende de problemen van patiëntgebonden onderzoek maar 
al te goed. Ook jou kom ik vast nog wel eens tegen, misschien in de wetenschap en 
anders gewoon ergens in Brabant! 
 
Sanne, Lizzy, Rosalie & Isabelle, mijn (ex-)treinmaatjes. Heel hard rennen om die 
stomme stoptrein of overstap maar te halen, vloeken wanneer de NS weer eens 
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samen met jullie.  Jullie gezelschap maakte de lange reis telkens toch een stukje 
korter en aangenamer.  
Lizzy, voor jou nog een speciaal bedankje als mijn voormalig mede-
aiovertegenwoordiger. Het was een interessante, maar ook vooral gezellige en 
ontspannen tijd samen. Onze samenwerking was zo vanzelfsprekend, heerlijk als 
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dat zo goed gaat! Ik mis het soms nog wel een beetje, gelukkig kunnen we nu weer 
samen verder met Partner in Balans.  
Nico, wat had ik zonder jou moeten beginnen! Ik heb regelmatig wanhopig aan je 
bureau gestaan met allerlei database- en computerproblemen, verdwenen 
schroefjes en nog erger verdwenen bestanden. Altijd maakte je tijd voor me en wist 
je me weer op weg te helpen. Zonder jou was dit proefschrift er zeker niet geweest! 
 
Els, ook jij bedankt, met name voor je waardevolle ondersteuning in de laatste fase. 
Maar daarnaast ook natuurlijk voor het managen van Frans agenda en het altijd 
weer creëren van een klein gaatje als ik een afspraak wilde verzetten. Ik weet niet 
hoe je het voor elkaar kreeg, maar ik ben je er wel heel dankbaar voor.  
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open sfeer hier op de afdeling, de gezellige tijd en het aangename gezelschap van 
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Dan was er ook nog een leven buiten deze afdeling:  
Lieve Eveline, jij weet als geen ander hoe zwaar het leven als aio kan zijn. Ik vind 
het superknap van je dat je je hart hebt gevolgd en voor jezelf hebt gekozen. 
Daarbij vind ik het zo lief dat je zo mega enthousiast bent over mijn promotie ! 
Fijn dat we zowel de moeilijke als leuke momenten met elkaar kunnen delen en op 
naar een goed feestje!  
 
Lieve Marleen, altijd fijn om even over de mail of app gezamenlijke frustraties over 
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onderzoekswereld soms kan zijn. Enorm geruststellend ook om te weten dat je 
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is het tijd voor jouw promotie, ik heb er al zin in!  
 
Andere vrienden en vriendinnen: Sas, Wouter, Maarten, Eline, Fre, Ilo, Maurice, 
Mari en Max bedankt ook voor jullie interesse! Waar mijn werk nu precies uit 
bestond was misschien niet voor iedereen altijd duidelijk, maar bij deze dus het 
resultaat ;) Naast de interesse wil ik jullie eigenlijk vooral bedanken voor de 
afleiding en gezelligheid die jullie me boden wanneer ik het eens niet over 
wetenschap wilde hebben, voor het bieden van een luisterend oor in goede en 
minder goede tijden, voor de gezellige dagjes weg en etentjes samen en nog veel 
meer.  
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vakanties in Duitsland en de geweldig leuke zoon die jullie op de wereld hebben 
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Papa & mama, van veraf hielden jullie altijd in de gaten waar ik mee bezig was. 
Jullie waren belangstellend, maar boden me ook alle vrijheid om het vooral niet 
over m’n werk te hebben als ik er weer eens klaar mee was. Jullie eigenlijke 
inbreng in dit proefschrift is niet groot, maar jullie inbreng in mijn leven en wie ik 
geworden ben is des te groter. Heel veel dank daarvoor, ik ben trots op hoe jullie 
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jaar bij jouw verdediging op de eerste rij te zitten.  
 
Lieve Lotte/Pobie, zo verschillend maar toch ook weer zo gelijk. We hebben het 
allebei zo druk, maar dat maakt onze band niet minder. Aan 1 woord genoeg als 
we samen zijn en dat zegt eigenlijk alles. Ik ben heel trots op hoe jij het allemaal 
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er altijd voor me bent als ik je nodig heb!  
 
Als laatste en liefste: Alex. We hebben ook de afgelopen vier jaren weer veel 
meegemaakt; leuke, maar helaas ook veel minder leuke dingen. De laatste 
maanden toen ik moest afronden waren niet altijd gezellig voor je. Je opluchting 
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